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Abstract

IMPACTS OF BLACK BOX WARNING, NATIONAL COVERAGE DETERMINATION,
AND RISK EVALUATION AND MITIGATION STRATEGIES ON THE INPATIENT
ON-LABEL AND OFF-LABEL USE OF ERYTHROPOIESIS-STIMULATING AGENTS

By Arpamas Seetasith, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013

Director: DAVID A. HOLDFORD, R.Ph., M.S., Ph.D., FAPhA
Professor and Vice Chair of Graduate Education
Department of Pharmacotherapy and Outcomes Science

Background: FDA black box warning, Risk Evaluation and Mitigation Strategies (REMS), and
CMS national coverage determination (NCD) aim to reduce inappropriate use of erythropoiesisstimulating agents (ESAs) that are widely used in anemic patients. Previous studies have not
linked specific safety interventions to changes in ESA utilization patterns in the inpatient settings
nor assessed such interventions on off-label use of the drugs. Ineffectiveness of the intervention
and lag time between such interventions and the observed change in clinical practice could lead
to serious clinical outcomes. In addition, such interventions may unintentionally reduce on-label
and some off-label use of ESAs considered “appropriate” in patients who could otherwise
benefit.
Objectives: The primary aim of the study is to quantify the impacts of the (1) addition of black
box warning, (2) implementation of NCD, and (3) institution of REMS on ESA on-label and offxvi

label utilization patterns of adult inpatients. Demographic, clinical condition, physician, and
hospital characteristics of ESAs users by their use category are also described in detail.
Methods: Electronic health records in Cerner Database from January 1, 2005 to June 30, 2011
were used. The use of the two erythropoietic drugs: epoetin alfa and darbepoetin alfa were
categorized into three groups using ICD-9-CM diagnoses and procedures codes and patients’
medication information. The three categories were (1) on-label use (approved by the FDA); (2)
off-label use supported (use for the indications not approved by the FDA, but there is strong
clinical evidence to support its use); and (3) off-label use unsupported (use for the indications not
approved by the FDA and lacking clinical evidence). The immediate and trend impacts of the
interventions on the proportion of ESAs prescribed for each usage category between 2005 and
2011 were assessed using an interrupted time series technique. The likelihood of receiving ESAs
among patients with on-label, off-label supported, off-label unsupported indications was assessed
using a generalized estimating equation approach with binary logistic regression technique,
clustering for hospitals and controlling for potential confounders such as patient characteristics,
patient clinical conditions, physician specialty, and hospital characteristics.
Results: During the study period, there were 111,363 encounters of ESA use. These encounters
represented 86,763 patients admitted to Cerner health system between January 1, 2005 and June
30, 2011. Of these patients, 66,121 were prescribed epoetin alfa only (76.2%); 20,088
darbepoetin alfa only (23.2%); and 554 were prescribed both epoetin alfa and darbepoetin alfa
(0.6%). Forty-nine percent of the patients used ESAs for the on-label indications, 8.6% for offlabel supported indications, and 42.7% for the off-label unsupported indications. The main uses
of ESAs in our sample were for CKD (ONS, 41.1%) and chronic anemia (OFU, 31.8%). From
2005 to 2010, the proportion of visits with ESA ONS and OFS use decreased 53.2% and 81.9%,
xvii

while ESA OFU increased 112.6%. Results from binary logistic regression using GEE model
showed overall decreasing trends in ESA use for the on-label and off-label supported indications,
but not off-label unsupported indications. REMS had no impact on the odds of receiving ESAs
among patients with on-label and off-label conditions. Black box warning reduced the odds of
being prescribed with epoetin alfa in patients with off-label unsupported conditions by 40%. It
was also associated with 4% and 15% per month reduction in the odds of using darbepoetin alfa
in patients with off-label supported and unsupported conditions. Lastly, there was a significant
decline in all categories of ESA use the month after Medicare national coverage determination
was implemented. The impact of NCD ranged from a 20% reduction in the odds of off-label
supported use to a 37% reduction in on-label use. Age, gender, race, source of payment,
admission type, clinical complexity, discharge disposition, and hospital size were significant
associated with ESA use on-label and off-label.
Conclusion: This study was the first to determine the impact of safety interventions on ESA onlabel and off-label utilization patterns in the inpatient settings using the Cerner database. We
demonstrated lag between the interventions and observed change in clinical practice, and the
relative impacts of three types of safety interventions on on-label and off-label ESA use in the
hospital settings. The indirect impact of the reimbursement change was the potential unintended
consequence of reducing the likelihood of receiving ESAs for a patient with indicated conditions
who could have otherwise benefited from the drugs.
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CHAPTER 1
Introduction
Overview of the document

This dissertation was designed to assess the relative impacts of three events, the revision
of product label to include a black box warning, restrictive reimbursement policy from the
Center for Medicare and Medicaid Services for the National Coverage Determination (NCD),
and implementation of the Risk Evaluation and Mitigation Strategies (REMS) program, on the
on-label and off-label use of erythropoiesis-stimulating agents (ESAs) in the inpatient settings in
the United States between January 2005 and December 2011.
This introductory chapter provides an overview of the study, background information
necessary for the understanding of study significance, conceptual frameworks, objectives, and
clinical and political implications of this study. The second chapter provides extensive
background of related topics including potential confounding factors and systematically reviews
existing literature. Methodology and database used in this study are described in Chapter 3,
followed by results in Chapter 4. Discussions and comments are concluded in Chapter 5.

1

Background

Anemia is a condition characterized by low hemoglobin (Hb) level or red blood cell
volume. According to the World Health Organization criteria, anemia is marked by the level of
hemoglobin less than 12 g/dL for women and <13 g/dL for men. This decrease in oxygencarrying capacity of the circulation system results in symptoms such as fatigue, faintness, chest
pain or shortness of breath which may affect one’s ability to perform activities of daily living and
also quality of life (QoL).1 Anemia is second to tuberculosis as the world’s most prevalent health
condition; it was estimated that anemia affects 1.62 billion people, one-quarter of the world
population.2 Numerous underlying pathologies that lead to anemia have been identified. Causes
of anemia range from blood loss, nutrition deficiency (iron, vitamin B12, and folic acid)
morphologic abnormality of hemoglobin or red blood cells (beta-thalassemia and sickle cell
anemia), and other chronic diseases such as inflammation, malignancy and chronic kidney
disease (CKD).2
Anemia is common in patients with chronic kidney disease and a frequent side effect in
cancer patients being treated with chemotherapy. Approximately half of patients with cancer3, 4
or CKD5 suffer from anemia at some point in their disease course. Severe anemia is linked to
increased risks of comorbidities in the elderly such as falls, dementia, depression, and heart
failure.6 Severe anemia often requires blood transfusion, an event which carries its own risks.
These risks include transmission of infectious agents, acute lung injury, and development of
alloantibodies which reduce a patient’s ability to receive organ transplant.7 Acquisition and
storage of blood for transfusion requires special procedures and is costly. Apparently, anemia is
economically burdensome to health care payers. It has been estimated that anemic patients have
a two-fold greater average annualized medical cost of that for non-anemic patients.8
2

The production of red blood cells, termed erythropoiesis, is regulated by the supply and
demand for oxygen in the body. In response to low tissue oxygen level, peritubular fibroblasts of
the kidney increase their production of endogenous erythropoietin which in turn acts on the
erythroid progenitors in the bone marrow to stimulate late differentiation and maturation of red
blood cells. Erythropoiesis-stimulating agents (ESAs) are a class of biological medications
approved as an alternative to blood transfusions, the traditional treatment of anemia.
Recombinant human erythropoietin possesses the same biological effects as endogenous
erythropoietin. Three drugs in this class are marketed for use in the United States: epoetin alfa
(Procrit®, Johnson & Johnson’s Ortho Biotech Unit and Epogen®, Amgen), darbepoetin alfa
(Aranesp®, Amgen), and methoxy polyethylene glycol-epoetin beta (Mircera®, Roche).
Epoetin alfa, the first human recombinant ESA was first approved in 1989 for anemia
associated with chronic kidney failure.9 The drug was later approved to treat chemotherapyinduced anemia, treat zidovudine-related anemia in HIV infected patients, and use as a
prophylaxis of allogeneic blood transfusion in non-cardiovascular surgeries. Following in 2001,
darbepoetin alfa was introduced into the market for treating anemia associated with chronic
kidney failure and later for chemotherapy-induced anemia.10 With an addition of Nglycosylation at the two sites of epoetin alfa, darbepoetin possesses a three-fold longer half-life
for erythropoietin receptors relative to erythropoietin alfa11, implying greater potency and
extended dosing interval that may improve patient compliance and better control anemia. Two
other ESAs not available in the US are methoxy polyethylene glycol-epoetin beta, Mircera12 and
epoetin beta, NeoRecormon® (Roche).
The use of erythropoietins as an alternative to red blood cell transfusion therapy
represents a major advancement in anemia treatment and has been the mainstay of therapy in
3

anemia associated with chronic kidney failure since its approval. Global sales of erythropoietin
products dramatically increased 95% from 2004 to $12.3 billion in 2005. In that same year,
procrit and epogen, each with $3.0 billion US sales, ranked among the top 10 drug products in
the United States according to sales.13 Since the initial entry of ESAs onto the market, the drugs
have found their place in the treatment of anemia outside their initial approved uses. This broad
array of use includes anemia of chronic heart failure, rheumatoid arthritis, and beta thalassemia.
The use of ESAs off-label, the term which refers to the prescribing of medications in a manner
different from that approved by the FDA, is common.14 It was estimated that more than half of
ESAs prescribed between 2001 and 2004 were for off-label purposes.15 Among those off-label
prescriptions for ESAs, three-quarters were for indications supported by scientific evidence.15
Benefits of ESAs in anemia treatment have been extensively elaborated. Correction of
anemia with ESAs translates to a relief of its common symptoms like fatigue, improving one’s
physical ability and quality of life. The approval of epoetin alfa and darbepoetin, the two ESAs
widely used in the United States by the FDA was based mainly by the evidence of reduced needs
for blood transfusion in anemic patients. The use of ESAs is thus a promising anemia treatment
alternative to blood transfusion. Benefits of ESAs extend beyond a simple reduction in
transfusion requirements. ESA therapy in less severe CKD patients has been shown to delay time
to dialysis.16 In addition; a meta-analysis of 60 studies found that anemia is an independent risk
factor of death in cancer patients17 and thus correcting it could improve survival.
Despite their clinical benefits, ESAs have been associated with increased risks of adverse
events such as cardiovascular complications, hypertension, and red cell aplasia. In 1998, the
Normal Hematocrit Cardiac Trial (NHCT), the first large randomized controlled trial (RCT)
aimed at determining the outcomes of treating anemia with epoetin alfa in patients with cardiac
4

disease who were undergoing hemodialysis was published. Patients who were randomized to
receive high dose epoetin alfa to maintain high hematocrit level of 42 percent had 1.3 times
higher risk of death or nonfatal myocardial infarction compared to those in the group targeted to
lower hematocrit level of 30 percent though this finding was merely a near statistically
significant one.18 A tipping point in ESA therapy started in November 2006 when two RCTs,
the correction of hemoglobin and outcomes in renal insufficiency (CHIOR) and cardiovascular
risk reduction by early anemia treatment with epoetin beta (CREATE), were published. CHIOR,
the largest trial, showed that CKD patients treated with epoetin alfa dosed to a higher target
hemoglobin concentration of 13.5 g/dL were at a significantly increased risk for serious
cardiovascular events including thrombosis, congestive heart failure, and stroke compared to the
treated patients whose hemoglobin was targeted at 11.3 g/dL.19 Results from another large trial
published at the same time showed no benefit or harm of early correction of anemia with epoetin
beta in reducing the risk of cardiovascular events in anemic patients with CKD.20
Safety concerns of ESA use among patients with cancer were raised with the publication
of the two pharmaceutical company-sponsored phase III randomized clinical trials. Patients
randomized to receive erythropoietin in the Breast Cancer Erythropoietin Survival Trial (BEST)
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and the Advanced Head-and-Neck Cancer Treated with Radiotherapy (ENHANCE) 22 showed

significant worsening of overall survival and an increase in venous thromboembolic events. A
meta-analysis of 57 clinical trials evaluating the use of ESAs in certain types of cancer published
in 2006 also pointed toward their negative effects on survival.23 Similarly, the most recent
Danish Head and Neck Cancer Study (DAHANCA 10), terminated early in October 2007,
reported in their interim analysis that darbepoetin alfa had shown a low likelihood in improving
patient outcomes.24 Cancer progression acceleration was observed in several studies include the
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ENHANCE trial of head and neck cancer, BEST trial of breast cancer, and EPO-CAN 20 of nonsmall-cell lung cancer.25 An exception was found in one study of 600 previously untreated
patients with extensive-stage small-cell lung cancer where significant difference in progressionfree survival was not found.26 While the mechanisms by which ESAs enhance tumor
progression is unclear, it is plausible that the drug stimulates erythropoietin receptors commonly
expressed in tumor cells, promoting tumor growth. The results from 154 subjects in the
ENHANCE trial support this hypothesis; ESAs were found to be harmful in two thirds of
patients with erythropoietin receptor-positive tumors but beneficial in those with receptornegative tumors.27
As evidence pointed toward potential harm associated with the use of high dose ESAs,
the FDA issued a series of public health advisories.28 On November 16, 2006, the FDA issued a
public health advisory alerting ESA prescribers to the results from CHIOR trial, emphasizing on
maintaining the recommended target hemoglobin range of 10 to12 g/dL in all patients.29 A
combined effort came from Amgen, the manufacturer of epoetin alfa and darbepoetin alfa,
sending out a series of dear doctor letters alerting physicians of the FDA updates. In January 26,
2007, Dear Healthcare Professional Letters were sent to highlight the results from recent clinical
trials and recommend caution in the off-label use of darbepoetin alfa in cancer patients. The
letter specifically warned against the use of ESAs in non-chemotherapy cancer patients and its
increased risk of death in this population.30 These warnings were expected to alert prescribers of
risks associated with the use of ESAs at high doses and their use in non-indicated populations.
Two similar public health advisories were issued in March and November 2007.
Finally, ESA labeling was revised to include a black box warning on March 9, 2007 to
address these concerns. The warning advised prescribers to use the lowest ESA dose possible
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that gradually increases hemoglobin to sufficient levels to avoid blood transfusion.31 An update
of the black box warning on March 7, 200832, 33 added the findings from two additional clinical
studies, Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) in patients with breast
cancer, and the National Cancer Institute Gynecologic Oncology Group (COG-19) in patients
with cervical cancer. These trials showed increased mortality and shortened time to tumor
progression in cancers patients treated with Aranesp compared to those who did not receive
ESAs.34, 35
To supplement the black box warnings, the FDA required on March 24, 2010 that all
ESA drugs be prescribed under the Risk Evaluation and Mitigation Strategies (REMS)
program.36, 37 This REMS program requires physicians prescribing ESAs to cancer patients to
complete and receive documentation of certification of the online ESA APPRISE Oncology
Program Training. To complete such training, physicians must acknowledge that they understand
the treatment recommendations and the specific risks associated with the use of ESAs. Also, the
program requires prescribers to counsel their patients regarding risks and benefits of ESAs prior
to dispensing the medications. More importantly, physicians not enrolled in the ESA APPRISE
Oncology program are prohibited from prescribing ESAs for use in cancer patients. The
implementation of the ESA REMS program is designed to bring about high awareness of the
warnings issued and risks associated with them and increase physician compliance with ESA
guidelines. The impact of REMS ESA inpatient prescribing remains unknown.
Recombinant erythropoietin was first approved for Medicare outpatient reimbursement in
June 198938 when it was reimbursed for up to 80% of the allowed charge.39 Since that time,
ESA reimbursement in Medicare beneficiaries has been through many changes. In January
1991, the Medicare payment policy for ESA treatment of dialysis patients changed from a fixed
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payment to a payment based on the doses of ESA administered40 to increase the use of ESAs in
ESRD patients and to improve Hb levels. In September 1997, the Hematocrit Measurement
Audit (HMA) policy was implemented to halt reimbursement of ESAs if patient Hb level was
greater than 12 g/dL41 as recommended by the NKF-DOQI clinical practice guidelines.42 With
the rise in ESA utilization, ESAs became Medicare’s largest pharmaceutical expense, at
approximately $20 billion in 2004.43 In April 2006, payments for ESA dosing was capped at
500,000 IU/ month for dialysis patients and a 25% dose reduction was mandated for patients
whose hemoglobin level exceeded 13 g/dL in the prior month.44
National Coverage Determination (NCD) is a nationwide policy initiated by CMS to
ensure that services and treatments provided to their beneficiaries are reasonable and necessary.45
NCD identifies the nationally covered indications for which Medicare will reimburse. On July
30, 2007, NCD restricted payment for ESAs in cancer-related anemia. Nationally covered
indications include ESA treatment for anemia secondary to myelosuppressive anti-cancer
chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia.
However, CMS no longer pays for the use of ESAs in anemia due to radiotherapy; anemia of
cancer not related to concurrent chemotherapy including anemia of bone marrow fibrosis;
anemia resulted from the treatment of myelogenous leukemia, chronic myelogenous leukemia, or
erythroid cancers; prophylactic use of chemotherapy-associated anemia; or use to reduce tumor
hypoxia (which can inhibit radiotherapy and oxygen-dependent chemotherapy effectiveness).
Reimbursement is not provided for patients with uncontrolled hypertension even when used to
treat of anemia associated with chemotherapy. Additionally, under NCD, Medicare does not
reimburse ESA use in anemia due to folate, vitamin B12, and iron deficiencies; anemia of
hemolysis; anemia of bleeding; and its use in patients with erythropoietin-type resistance due to
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neutralizing antibodies.46 In addition to indication restrictions, CMS restricted the use of ESAs
exclusively to patients whose hemoglobin level is lower than 10 g/dL prior to ESA initiation or
maintenance as such drugs “lacks adequate data to establish proof of no harm.”47
Recommendations on dosing, dosage escalation and reduction, discontinuation, and treatment
duration were also specified in the NCD.48 However, NCD restrictions conflicted with FDAapproved labeling and professional society guidelines on ESA initiation, dosage escalation,
dosage reduction, and definition of response, creating confusion among health care providers.49
According to the letters written on behalf of professional societies to CMS, the decision was
“inconsistent with available scientific evidence and national guideline on ESA use” and CMS
was urged to reconsider “in order to avoid further confusion and harm to Medicare
beneficiaries.”50 Despite criticisms from several professional associations that the decision could
lead to greater chances for patients subjected to blood transfusion and endanger cancer patients,
the NCD was officially implemented on April 7, 2008.
NCD restrictions are not meant to impact ESA use for inpatient care because ESAs are
included into the Diagnoses-Related Group (DRG) prospective payment system. Under the
DRG system, reimbursement is given for a patient's condition, not the drugs used to treat that
condition. Thus, the change in the coverage determination would not affect the payment of ESAs
in the hospital setting. However, physicians who work in hospitals often work in outpatient
settings where ESA coverage restrictions apply. Thus, the policy change may indirectly change
prescribing in both setting. Moreover, the restriction may influence prescribing patterns for nonMedicare payer types because physicians typically treat more than just Medicare patients. As a
result, NCD policies may impact off-label use of ESAs outside of their intended purpose. It is of
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our interest to determine the impact of Medicare national coverage determination on ESA use in
the inpatient settings where the determination does not directly apply.
In summary, a timeline of significant events associated with ESA utilization since its
approval is presented in Figure 1.1. These include approval indications for ESA treatment,
publications of scientific evidence from larger clinical trials, and interventions from
manufacturers and government regulatory agencies.
Epoetin alfa:
Pre-surgical prophylaxis
of allogeneic blood
transfusion

Epoetin alfa:
HIV
AZT-related anemia

Epoetin alfa:
Chronic Renal
Failure -related
anemia

1989

Pre-ESA Era

Darbepoetin alfa:
Chronic Renal
Failure -related
anemia

1991

1993

1995

1999

1997

2001

1998
NHCT (CKD)

Blood transfusion,
IV Iron therapy,
Androgen therapy

Darbepoetin alfa:
Chemotherapyrelated anemia

Epoetin alfa:
Chemotherapyrelated anemia
March:
1 st Black box warning
July:
Medicare NCD became effective

March:
REMS

November:
Public health advisories

2003
2003
ENHANCE (cancer)

2004
2005
BEST (cancer)

2005

2006

2006
CHOIR (CKD),
CREATE (CKD)

2007

2008

2009

2010

2011

2007
DAHANCA 10 (cancer)

April:
Medicare NCD implemented
March & November:
Black box warning updated

Figure 1.1 Timeline for ESA treatment, scientific evidence from clinical trials, and interventions from
government regulatory agencies between 1989 and 2010 (adapted from Arbuckle et. al. 2008)
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Conceptual Framework

This study is based on the diffusion of innovation of health care framework and an
evidence-based medicine framework. Diffusion of innovation refers to “the process by which an
innovation is communicated through certain channels over time among the members of a social
system.” 51 According to Everett Roger’s Diffusion of Innovation model, the spread of
innovations follows a sigmoid pattern (the S-shaped curve), describing three stages of adoption:
the early slow phase characterized with only the first few individual adopting the innovation, a
rapid middle phase, and a slow third phase. The model also illustrates five categories of adopters
characterized by their relative rates of adoption of innovations: innovators, early adopters, early
majority, late majority, and laggards.51, 52 Rates of diffusion of innovation vary by various
factors. The main factor includes perceptions of the innovations viewed by stakeholders, which
predict between 49% and 87% of the variance in the rates of spread of a change. These
perceptions include (1) the perceived benefit of the change; (2) compatibility of the innovation
with the current values, belief, and needs of the individuals as well as their past history; (3)
complexity of the proposed innovation; (4) trialability of the innovation without total
commitment or minimal investment; and (5) the extent to which potential adopters observe the
adoption by others (observability).51
The process by which information is disseminated is similar to the diffusion of
innovation. Whether a prescriber will adjust their prescribing pattern to new information
depends on several factors such as physician characteristics and the nature of the intervention of
which knowledge is disseminated itself. Since high doses of ESAs given to cancer patients or
for its use for unsupported purposes could lead to serious adverse events including death, the
stakes are significant for reducing the time lag between the interventions aiming at reducing
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inappropriate use of ESAs in clinical practice. It is therefore our interest to assess the relative
impacts of the FDA black box warning, and FDA REMS, and National Coverage Determination
on the rate of change in prescribing patterns.
A systematic classification of indications for the three erythropoietic drugs into three
drug use categories will be based on an evidence-based medicine (EBM) framework which
provides objective evidence about the effectiveness of interventions through the use of research
methods that minimize the risks of bias, such as randomized controlled trials. Evidence
synthesized in such manner is considered best to inform treatment decisions.53

Objectives

The proposed study aims to quantify the impacts of FDA interventions (adding a black
box warning to drug labeling and the addition of a REMS program) and Medicare reimbursement
restrictions established by the NCD on the on- and off-label use of ESAs among adult inpatients.
The secondary objective is to investigate factors associated with the odds of being prescribed
ESAs, controlling for the interventions and other confounding factors.

Study Implications
Correction of anemia is necessary as it has been shown to improve patients’ health status
and quality of life.54 Approximately 90% of hemodialysis patients in the US received an ESA55
to avoid blood transfusion. The adoption of ESAs in clinical practice of anemia has alleviated
some of the complications associated with blood transfusion and the issues of constrain blood
limited supply. However, concerns regarding serious risks of ESAs have led regulatory
authorities to intervene with both regulatory communications and reimbursement changes.
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These interventions can lead to have positive outcomes (reasonable and necessary drug use) or
negative outcomes (reduced on-label use considered “appropriate” to patients who could
otherwise benefit). This study will quantify impacts of the communications from four sources: a
public health advisory, an FDA black box warning on ESA labeling, ESA APPRISE Oncology
program under REMS, and a reimbursement restriction under CMS National Coverage
Determination for ESAs. We hope to demonstrate their relative immediate and trend impacts on
ESA prescribing among patients admitted to the U.S. hospitals.
Previous studies that investigated the impacts of FDA risk communications on ESA use
did not link specific interventions to the level change in ESA use nor that for the off-label
indications for patients treated in the inpatient settings. The knowledge of relative impacts of
the interventions would help policymakers make informed decision when designing risk
communications and healthcare policies intending to shape prescribing patterns in the future.
To our knowledge, no study has assessed the linkage between FDA risk communication
including public health advisory, black box warning issuance, and REMS implementation, or the
CMS National Coverage Determination on the prescribing patterns of erythropoiesis-stimulating
agents in the inpatient settings. More importantly, the impacts of such interventions on the offlabel use of ESAs have never been investigated. Our proposed study quantified the immediate
and trend impacts of both on on-label and off-label ESA prescribing and assess factors associated
with ESA prescribing patterns in the inpatient settings between 2005 and 2011.
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CHAPTER 2
Literature Review
This chapter has been divided into four parts: 1) an overview of ESA treatment of anemia
for the on-label and off-label indications as classified by the evidence-based medicine
framework; 2) regulatory risk communications and health policies shaping prescribing patterns;
3) potential confounding factors associated with prescribing patterns and methods to control for
confounding; and 4) a systematic review of existing studies. This chapter concludes with a
summary of literature gaps, research questions, research hypotheses, and specific aims
formulated as a result of the literature evaluation.

Erythropoiesis-stimulating agent treatment of anemia overview

This section is further subdivided into two parts. The first part provides an overview of
an official compendium, Thomson Micromedex Drugdex®, the system adopted in this study to
describe the classification of ESA use by indications. The second part reviews treatment
regimens, guidelines, and supporting evidence for the all ESA indications listed in DRUGDEX.
Empirical studies of ESA off-label use in the United States are also summarized at this end of
this section.
1. Classification System
Official compendia refer to nationally recognized sources of drug information including
the US Pharmacopoeia (USP), National Formulary, or any supplements to them. DRUGDEX
system (Thomson Micromedex, Greenwood Village, CO) is recognized as a pharmaceutical
compendium that provides reliable evidence-based evaluation for the on-label and off-label uses
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of prescription drugs listed in the USP Dispensing Information.56 Information on strength of
scientific evidence supplied by DRUGDEX can be used to assess the level of medical evidence
supporting the use of ESAs in an off-label manner.
The three dimensions of drug use evaluated by DRUGDEX are efficacy, strength of
recommendation, and strength of evidence. Strength of recommendation is categorized into 4
classes: Class I, IIa, IIb, III, and in-determinant. Similar to that, strength of evidence as
supported by clinical studies is presented in 4 levels: Category A, B, C, and no evidence. Lastly,
drug efficacy is subcategorizes into 4 groups: effective, evidence favors efficacy, evidence is
inclusive, and ineffective. The details of recommendation levels, strength of evidence scale and
efficacy ratings defined by DRUGDEX are listed in Table 2.1, 2.2, and 2.3, respectively.
Table 2.1 Strength of Recommendations specified by DRUGDEX
Level
Class I

Decision to recommend
Recommended

Class IIa

Class III

Recommended,
In most cases
Recommended,
In some cases
Not Recommended

Class In-determinant

Evidence Inconclusive

Class IIb

Definition
The given test or treatment has been proven to be
useful, and should be performed or administered.
The given test, or treatment is generally considered
to be useful, and is indicated in most cases.
The given test, or treatment may be useful, and is
indicated in some, but not most, cases.
The given test, or treatment is not useful, and
should be avoided.
-
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Table 2.2 Strength of Evidence for use of a drug specified by DRUGDEX
Level
Category A

Category B

Category C
No Evidence

Definition
Evidence is based on data derived from: Meta-analyses of randomized controlled
trials with homogeneity with regard to the directions and degrees of results between
individual studies. Multiple, well-done randomized clinical trials involving large
numbers of patients.
Evidence is based on data derived from: Meta-analyses of randomized controlled
trials with conflicting conclusions with regard to the directions and degrees of results
between individual studies. Randomized controlled trials that involved small
numbers of patients or had significant methodological flaws (e.g., bias, drop-out
rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, casecontrol studies, observational studies).
Evidence is based on data derived from: Expert opinion or consensus, case reports
or case series.
-

Table 2.3 Efficacy ratings of a drug specified by DRUGDEX
Efficacy rating
Effective
Evidence favors
efficacy
Evidence is
inconclusive
Ineffective

Definition
Evidence and/or expert opinion suggests that a given drug treatment for a specific
indication is effective
Evidence and/or expert opinion is conflicting as to whether a given drug treatment for
a specific indication is effective, but the weight of evidence and/or expert opinion
favors efficacy.
Evidence and/or expert opinion is conflicting as to whether a given drug treatment for
a specific indication is effective, but the weight of evidence and/or expert opinion
argues against efficacy.
Evidence and/or expert opinion suggests that a given drug treatment for a specific
indication is ineffective.
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2. ESA use in anemia treatment
A review of clinical literature for all ESA indications listed in DRUGDEX is provided in
the following section. The review is based on clinical trials that support the FDA approval of
such indications or scientific evidence reported in DRUGDEX. Clinical guidelines and
recommendations, if available, are also provided. This review of anemia treatment is limited to
adults only, as this population aligns with the study inclusion criteria. A summary of
DRUGDEX evaluation of scientific evidence ratings of such use of epoetin alfa and darbepoetin
alfa is provided in Table 2.4 and 2.5, respectively.
2.1 FDA-approved Indications
Approved indications of ESAs are drug specific. Epoetin alfa, the first erythropoietin in
the market was approved for use in anemia of chronic kidney disease, chemotherapy induced
anemia, zidovudine-related anemia in HIV infected patients, and prophylaxis of allogeneic blood
transfusion in non-cardiovascular surgeries. The second generation ESA, darbepoetin alfa is
approved for two indications: anemia of chronic kidney disease and chemotherapy induced
anemia.
Anemia of Chronic Kidney Failure: epoetin alfa and darbepoetin alfa
Epoetin alfa has been shown to stimulate erythropoiesis and hence normalize Hb level in
chronic kidney failure patients regardless of their dialysis requirement.57 A meta-analysis of
sixteen studies of 982 end-stage renal disease patients receiving epoetin alfa reported 87%
effectiveness of the treatment defined as at least a 0.06 increase in hematocrit or a 2 g/dL
increase in hemoglobin.58 In a subsequent study, erythropoietin was proven to have no negative
effect on blood pressure and be effective in correcting Hb values in adult with cardiac disease
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and hemodialysis-dependent ESRD patients.59 Similar improvement in Hb level was observed
in non-dialysis patients. In a large multi-center, open-label, single-arm, non-randomized trial,
epoetin alfa dosed subcutaneously once weekly at 10,000 IU for 16 weeks significantly led to an
increase in the mean Hb level of 2.7 g/dL.60 Likewise, darbepoetin alfa, when given at 0.45
mcg/kg once a week was proven to be as effective as 50 IU/kg epoetin alfa two to three times
weekly in correcting anemia in epoetin-naïve dialysis and renal insufficiency patients.61, 62 The
drug was also able to maintain stable Hb concentration in CKD patients when given at an
extended dosing interval once monthly.63, 64 Despite its efficacy, both erythropoietic drugs dosed
to high target Hb level was shown to be associated with greater risk of all-cause mortality
compared to that of lower Hb group in a meta-analysis of nine randomized controlled trials of
5,143 patients with chronic kidney disease.65
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF
KDOQI) published guidelines for the management of anemia in CKD patients in 2006. After the
2007 update of the target Hb concentration, no further change in the guidelines was made. In
dialysis and nondialysis patients with CKD receiving ESA therapy, a target Hb level between
11.0 g/dL and 12.0 g/dL is recommended. The KDOQI guidelines also emphasize the
importance of not exceeding the target HB level beyond 13 g/dL.66 Of note, this Hb target
recommendation does not align with the darbepoetin alfa current labeling, revised in 2011, which
suggests physicians to initiate ESA therapy only when Hb level falls below 10 g/dL. As for the
dose, an ESA starting dose often depends upon the initial and target Hb level of a patient67
though a starting dose of epoetin alfa at 50 to 100 units/kg three times weekly is
recommended.9,10 In general, because of a longer half-life of darbepoetin alfa compared to
epoetin alfa, darbepoetin alfa is recommended to be administered once weekly in patients who
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are receiving epoetin alfa 2 to 3 times weekly and once every 2 weeks in once-weekly epoetin
alfa patients.68 It is important to halt the therapy once Hb level exceeds 10 g/dL for nondialysis
and 11 g/dL for dialysis patients.10 On the other hand, if a patient’s Hb level has not increased
by more than 1 g/dL after 4 weeks of the initiation of the therapy, ESA dose may be increased by
25%.10
Chemotherapy-Induced Anemia (CIA): epoetin alfa and darbepoetin alfa
Several trials demonstrated efficacy of epoetin alfa and darbepoetin alfa in improving Hb
levels and reducing the need for blood transfusion.9,10 Epoetin alfa dosed subcutaneously at
40,000 IU once weekly led to a mean increase of 1.8 g/dL with a mean final Hb level of 11.3
g/dL in patients receiving chemotherapy for nonmyeloid malignancies after the maximum of 16
treatment weeks.69 Results from a large community-based study also found a similar increase in
Hb level of 2 g/dL and a progressive decline in the percentage of patients requiring transfusion
during ESA treatment.70 Similarly, darbepoetin alfa, both dosed weekly or at an extendeddosing regimen every 3 weeks was more effective than placebo in increasing Hb values of
anemic cancer patients receiving chemotherapy.71-74 Based on their clinical efficacy, epoetin
alfa and darbepoetin alfa are used widely for the treatment of chemotherapy-induced anemia in
nonmyeloid cancer patients.
Three major guidelines are currently being used today in the ESA treatment of
chemotherapy-induced anemia: the American Society of Clinical Oncology and the American
Society of Hematology (ASCO/ASH), the European Organisation for Research and Treatment of
Cancer (EORTC), and the National Comprehensive Cancer Network (NCCN).75 In 2002 ASCO
and ASH published their clinical practice guidelines for epoetin alfa using medical literature
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published between 1985 and 1999. The guideline suggests the use of epoetin alfa in CIA
patients with Hb level < 10g/dL at 150U/kg, three times a week. Epoetin alfa dose should be
escalated to 300 U/kg three times a week if a patient fails to respond after 4 weeks. The target
Hb level is recommended at 12 g/dL, with the dose of epoetin alfa adjusted to maintain a
patient’s Hb at this level. Another reputable source of ESA treatment recommendation is the
2004 EORTC guidelines which include evidence of both epoetin alfa and darbepoetin alfa
between 1996 and 2003. The EORTC guidelines recommend clinicians to initiate ESA treatment
at Hb level of 9 to 11 g/dL, on the basis of anemia symptoms while targeting a patient’s Hb level
at 12 to 13 g/dL. Lastly, NCCN, an alliance of 19 major cancer centers in the United States,
developed several guidelines in cancer treatment including supportive care.6 Updated in 2011
the NCCN clinical practice guidelines suggest physicians to consider ESA treatment of anemia
in cancer patients with chronic kidney disease, patients undergoing palliative treatment, and
patients on myelosuppressive chemotherapy without identifiable cause of anemia.76 ESAs
should not be prescribed for a treatment of anemia in cancer patients under myelosuppressive
chemotherapy with curative intent such as early stage breast cancer, Hodgkin lymphoma, nonHodgkin’s lymphoma, testicular cancer, and early stage non-small cell lung cancer.
Additionally, co-administration of iron supplement is not required but should be considered with
regard to a patient’s functional iron deficiency status.
Anemia in zidovudine-treated HIV-infected Patients: epoetin alfa only
Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), is one of the most
commonly used antiviral drugs for HIV infection. Despite its effectiveness, the prevalence of
zidovudine-induced anemia is high (5.42-9.62%).77-79 Epoetin alfa is the only erythropoietic
drug approved for treating anemia in zidovudine-treated HIV-infected patients; results from four
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placebo-controlled trials suggest that it could significantly increase hematocrit and reduced blood
transfusion requirements in the treatment group compared to the placebo group.80-83
Nonetheless, correcting anemia related to zidovudine use in HIV-infected patients with epoetin
alfa is encouraged only in patients receiving zidovudine ≤ 4200 mg/week with endogenous
erythropoietin level less than 500 mUnits/mL. This is because patients with endogenous
erythropoietin level greater than that appear to be nonresponsive to epoetin alfa therapy. To treat
anemia due to adverse reaction of zidovudine, epoetin alfa is recommended at 100 units per kg
body weight, three times weekly.
Prophylaxis of allogeneic blood transfusion in non-cardiovascular surgeries: epoetin alfa only
Epoetin alfa was approved for use as a prophylactic of allogeneic blood transfusion in
patients with Hb level greater than but not exceeding 13 g/dL undergoing elective noncardiovascular surgeries that are at risk of perioperative blood loss, but are not willing to donate
autologous blood. In patients scheduled for major, elective orthopedic hip or knee surgery who
were expected to require ≥ 2 units of blood, epoetin alfa dosed subcutaneously at 300 units/kg 10
days before surgery, on the day of surgery, and for 4 days after surgery, significantly reduced the
need for blood transfusion compared to the placebo group, only when pretreatment Hb level was
greater than 10 but not more than 13 g/dL.84
2.2 FDA-Unapproved Indication
Several off-label uses of ESAs are documented in DRUGDEX. These indications
include the treatment anemia in cancer patients not currently on active chemotherapy, anemia of
congestive heart failure, prematurity, puerperium, multiple myeloma, myelodysplastic syndrome,
myelofibrosis, rheumatoid arthritis, beta thalassemia, anemia due to radiation, and anemia in
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hepatitis C patients being treated with a combination of ribavirin and interferon alfa, and their
use for blood unit collection for transfusion. The following section review uses of ESAs for the
unapproved indications and studies supporting their uses.
Anemia of congestive heart failure
Anemia, a common complication of congestive heart failure (CHF), often leads to poorer
cardiovascular outcomes and higher mortality.85 The prevalence of anemia in CHF is estimated
to be as high as 55 percent.86 An uncontrolled study of ESAs therapy in anemic patients with
CHF found that subcutaneous erythropoietin at an average dose of 5,227 units/week is associated
with decreased hospitalization and improvement in several cardiovascular aspects including an
increase in left ventricular ejection fraction and decline in the New York Heart Association
(NYHA) class.87 DRUGDEX recommends epoetin alfa to be used in some cases of CHF
according to the moderate strength of evidence and efficacy report that favors efficacy for this
indication.
Anemia due to radiation
Anemia is widespread in cancer patients undergoing local radiotherapy. An anemia
prevalence study using Hb level < 12 g/dL as a cut-off point found that anemic patients increased
from 41% at presentation to 54% by the end of radiation.88 The majority of patients with almost
all tumor types have developed anemia and the prevalence of anemia is found to be extremely
high in patients with uterine-cervical tumor (75% and increased to 79% after radiation). Epoetin
alfa dosed at 200 units/kg/day for 5 consecutive days for up to 7 weeks during radiotherapy was
found to significantly increase Hb level in anemic patients with lung, uterine-cervical, prostate,
or breast cancer during a randomized, open-label trial of 48 patients.89 As a result, DRUGDEX
22

recommends epoetin alfa to be used in certain cases of radiotherapy according to the moderate
strength of evidence and efficacy report that favors efficacy for this indication.
Anemia during Puerperium
Iron deficiency during pregnancy and acute blood loss at delivery constitutes a main
cause of postpartum anemia.90 The prevalence postpartum anemia is high in developing
countries and was found to be as high as 80%.91 In a randomized, placebo-controlled trial in
which a mother lost an average of 806 mL of blood during delivery, a combination of IV
erythropoietin at 300 units/kg/day and IV iron sucrose 200 mg/day given daily for 4 days after
the delivery showed to be more effective than placebo or IV iron alone in correcting postpartum
anemia.92 DRUGDEX therefore recommends epoetin alfa to be used in certain cases of
puerperium anemia according to the moderate strength of evidence and efficacy report that
favors its efficacy.
Anemia of ribavirin and interferon alfa use for treatment of Hepatitis C
Anemia is a common adverse effect observed in 10%-30% of hepatitis C patients
receiving ribavirin and interferon alfa combination therapy.93 This is due to the bone marrow
suppression property of interferon and potential red blood cell hemolytic action of ribavirin.
Criteria for initiating ESA therapy for hepatitis C treatment-related anemia have been provided
based on medical evidence and clinical expert opinion. Physicians may consider using
subcutaneous injection of 40,000 IU epoetin alfa weekly (or darbepoetin alfa at 200 mcg weekly,
though response is reported to be slower), together with ribavirin dose reduction, to increase Hb
level of patients on ribavirin-interferon alfa combination therapy with Hb < 10 g/dL or < 11g/dL
but with symptoms of anemia. ESAs and/or ribavirin dosing should be adjusted based on a
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patient’s Hb level and his response to ESA therapy. Base on the moderate strength of evidence
and favorable efficacy reports for this indication, DRUGDEX recommends epoetin alfa to be
used in some cases of anemia associated with ribavirin and interferon alfa treatment of HCVinfected patients.
Anemia of multiple myeloma
The cause of anemia observed in more than two thirds of patients with multiple myeloma
(MM) is multi-factorial, ranging from the cancer itself, chemotherapy treatment, or deficiency of
endogenous erythropoietin.94 Several studies reported benefits of ESAs in myeloma-associated
anemia. A meta-analysis of 39 studies reported 40% effectiveness of erythropoietin in the
treatment of anemia of multiple myeloma.95 Another study shows that 85% of 13 multiple
myeloma patients with baseline Hb less than 11.3 g/dL experienced an increase in Hb level of at
least 2 g/dL after 5 weeks and a complete resolution of anemia symptoms after receiving 150
units/kg ESAs three times weekly.96 Recently, consensus guidelines for the management of
anemia with ESAs in multiple myeloma were developed by the collaboration of MM specialists
known as the International Myeloma Working Group. Once other causes of anemia is ruled out,
ESA therapy can be initiated in MM patients with HB level ≤ 10 g/dL and in those with higher
Hb values but with symptoms of anemia. The guidelines recommend starting epoetin alfa at 40
IU once weekly or 10 IU three times weekly, or darbepoetin alfa 150 mcg once weekly or 500
mcg every 3 weeks. Dose increment is allowable if a patient does not respond but the therapy in
non-responding patients should be discontinued within 6-8 weeks.97 DRUGDEX recommends
epoetin alfa to be used in some cases of multiple myeloma according to the moderate strength of
evidence and efficacy report that favors efficacy for this indication.
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Anemia of myelodysplastic syndrome
Anemia is the most common comorbid condition of myelodysplastic syndrome (MDS), a
group of diseases characterized by the malfunction of bone marrow. An MDS patient
experiences anemia because of the damaged bone marrow becoming unable to producing
sufficient blood cells and approximately 50% of MDS high-risk patients progress to having acute
leukemia within 5 years. Risk factors of MDS include certain kinds of cancer treatment such as
mechlorethamine and procarbazine, genetic mutation, and smoking. Stem cell transplant is the
only curative for MSD but patients are more commonly treated with chemotherapy and/or
growth factors including ESAs.98 Despite significant improvement in Hb level observed in
several clinical trials, results show similar rates of overall survival and progression to acute
myeloid leukemia99, and conflicting evidence of transfusion requirement and quality of life
associated with ESA treatment.100 Given as a monotherapy, epoetin alfa subcutaneous treatment
of 150 IU/kg three times weekly or 40,000 IU once weekly for 24-26 weeks was found to be
associated with 37-68 % erythroid response defined as an increase in Hb or reduction in
transfusion requirement in low-risk MDS patients.101-103 Positive response was also observed
with a combination therapy of ESAs and granulocyte colony-stimulating factor (G-CSF).96, 97
Likewise, the benefit of darbepoetin alfa is also evidenced in a clinical trial of anemic patients
with low-risk MDS.104 As the results of several trials pointed toward favorable erythroid
response to erythropoietin in this population, the American Society of clinical
Oncology/American Society of Hematology Clinical Practice Guidelines recommend the use of
ESAs in low-risk MDS patients whose Hb values approaches 10 g/dL to avoid blood transfusion.
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In line with ASCO/ASH guidelines, DRUGDEX recommends epoetin alfa to be used in

25

some cases of myelodysplastic syndrome due to the moderate strength of evidence and efficacy
report that favors efficacy for this indication.
Anemia of myelofibrosis
Myelofibrosis refers to the condition by which bone marrow tissues are replaced with
fibrous tissue, hindering blood cell productions and resulting in anemia.106 Profound anemia
associated with myelofibrosis is usually treated with transfusion therapy but several small, openlabel studies of 7-20 patients suggest the condition occasionally responds to ESAs.107-111
Epoetin alfa given subcutaneously at 10,000 IU three times weekly was found to be welltolerated and effective in reducing transfusion requirement and increasing Hb level in
myelofibrosis patients with myeloid metaplasia112 and chronic idiopathic myelofibrosis (CIMF).
113

Due to the small sample size of the trials, DRUGDEX recommends epoetin alfa to be used in

some cases of myelofibrosis according to the moderate strength of evidence and efficacy report
that favors efficacy for this indication.
Anemia of rheumatoid arthritis
Anemia prevalence in rheumatoid arthritis (RA) is high. A systematic literature review
of anemia in RA reveals that between 33% and 60% of RA patients experience mild anemia.114
More than 60% of anemia cases in RA are classified under anemia of chronic disease in which
the increased production of inflammatory cytokines characterized rheumatoid arthritis reduces
the response of bone marrow to erythropoietin.115 A report of two patients with anemia of
rheumatoid arthritis showed that erythropoietin dosed at 100 units/kg administered three times
weekly for 8 weeks resulted in positive hematologic response but with no change in RA
outcomes over a five-month period. 116 According to similar results from other studies,
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DRUGDEX recommends epoetin alfa to be used in some cases of RA. The strength of evidence
is moderate and favors efficacy for its use in this indication.
Beta Thalassemia
Beta thalassemia is a genetic disorder of beta globin protein that makes up red blood
cells. The disease is most common in persons with Mediterranean, Asian, or African origins.
Defects in hemoglobin lead to destruction of red blood cells and hence anemia symptoms that
can be corrected with blood transfusion.117 Results from an open-label clinical trial of 10
patients with beta thalassemia suggest potential use of epoetin alfa for this indication.
Subcutaneous administration of epoetin alfa at 150 units/kg three times weekly for at least 12
weeks successfully reduced the median blood transfusion units though no significant change in
Hb level was found.118 In addition, a combination of ESAs (200 units/kg/day) and iron (300
mg/day) therapy from week 30 of pregnancy to week 4 of delivery may alleviate the requirement
for blood transfusion in pregnant women with beta thalassemia though a larger clinical trial is
needed to warrant such findings.119 DRUGDEX recommends epoetin alfa to be used in some
cases of beta thalassemia according to the moderate strength of evidence and efficacy report that
favors efficacy for this indication.
Blood unit collection of autotransfusion
As noted earlier, epoetin alfa was approved for use as a prophylactic of allogeneic blood
transfusion only in patients who are not willing to donate autologous blood before undergoing
elective surgeries. If a patient is willing to donate, erythropoietin may be used off-label to
increase capacity donation. DRUGDEX recommends epoetin alfa to be used in some cases of
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transfusion prior to elective surgery according to the moderate strength of evidence and efficacy
report that favors efficacy for this indication.
Anemia in traumatic, postsurgical patients
The use of erythropoietic drugs as an alternative to blood transfusion is potentially
beneficial in a case where a patient of traumatic or surgical blood loss denies blood products due
to his religious belief.120 It was evident from many case reports and case series that epoetin alfa
could successfully reverse life-threatening anemia due to trauma, burns, and surgical procedures
in Jehovah’s Witness patients refusing blood transfusion.121-123 For example, erythropoietin
given IV or SC at 300 IU/kg daily until a patient achieved a suitable response, then reduced to
150 U/kg every other day has resulted in 5% increases in Hb level.124 DRUGDEX recommends
epoetin alfa to be used in some cases despite inconclusive evidence of efficacy and only
moderate strength of evidence present to support the use of ESAs in the treatment of anemia in
traumatic, postsurgical patients.
Anemia in critical illness
The use of ESAs to treat anemia in critically ill patients shows positive effects in term
increasing hematocrit values and reducing the need for blood transfusion. In two randomized,
double-blind, placebo-controlled trials of 1,302 and 86 adult ICU patients, weekly subcutaneous
administration of 40,000 IU epoetin alfa shows to increase Hb level and reduce the need for
blood transfusion125, 126 and no significant difference in mortality or adverse events was found
between the treatment and placebo groups in two trials. Another small study of 36 patients also
shows significant between-group differences of Hb values after five doses of subcutaneous
erythropoietin at 300 units/kg was given every other day to anemic patients in the intensive care
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unit.127 In contrast, results from a large multi-center randomized double-blind placebocontrolled clinical trial indicate that erythropoietin is ineffective in reducing the need for blood
transfusion in this specific group of patients and its use was in fact was associated with greater
risk of thrombotic vascular events.128 The use of erythropoietin in anemia of some critical
illness cases is recommended in some cases by DRUGDEX (Class IIb) despite the inconclusive
evidence of efficacy and moderate strength of evidence.
Anemia of malignancy - not due to chemotherapy
Causes of cancer-related anemia are multifaceted, ranging from the direct effect of the
neoplasm to the products of the cancer. Almost all of cancer patients suffer from anemia over
the course of the disease.3, 4 Improvements in hematologic profile are demonstrated in various
cancer trials though the treatment has failed to benefit quality of life or cancer outcome.129, 130 In
fact, the use of ESAs was associated with increased mortality. 131 Epoetin alfa dosed
subcutaneously at 40,000 IU once weekly for 12 weeks was found to be associated with lower
median survival in the treatment arm that remains significant after adjusting for baseline
characteristics (68 versus 131 days).128 Similar to epoetin alfa, darbepoetin alfa successfully
increases Hb level of cancer patients not on active chemotherapy in spite of conflicting evidence
on transfusion requirement and quality of life improvement132-135 but is also associated with an
increased incidence of cardiovascular and thromboembolic events though no difference in
serious or fatal adverse events was observed. As a result, the ASCO/ASH guidelines caution
against the use of ESAs in cancer patients not currently receiving chemotherapy102 and
DRUGDEX does not recommend the use of ESAs in anemia of malignancy not due to
chemotherapy in any cases due to its negative effect on survival despite the moderate strength of
evidence and evidence that favors efficacy.
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Anemia of Porphyria cutanea tarda
Porphyria cutanea tarda (PCT) is the most common type of porphyria, 136 a rare disorder
of liver enzyme uroporphyrinogen decarboxylase deficiency which is diagnosed in
approximately 1 in 10,000 individuals.137 Inefficiency of the enzyme causes porphyrin to
accumulated in the liver, transported to the skin, and resulted in skin damage. About 20% of
PCT diagnosed is hereditary, resulting from a genetic mutation, while majority of causes may be
due to use of alcohol, estrogens, smoking, chronic hepatitis C, or HIV infection.138 A reduction
of serum iron through a removal of blood termed phlebotomy is a preferred treatment of PCT. In
patients with advance kidney disease, PCT can be extremely severe and a combined ESA therapy
and phlebotomy may be beneficial. Two case reports pointed out that ESAs can help manage
anemia of porphyria cutanea tarda and hepatoerythrpoietic porphyria. A remission was achieved
in a woman with porphyria cutanea tarda after undergoing ESA therapy at 150 units/kg for 4
months.139 Similarly, subcutaneous administration of erythropoietin at 600 units/kg/week for 1
year partially corrected severe anemia in a 68-year-old male with chronic hepatoerythropoietic
porphyria.140 DRUGDEX recommends epoetin alfa to be used in some cases of anemia of
porphyria cutanea tarda though the strength of evidence is low and efficacy evidence is still
inconclusive.
Athletic performance enhancement
Abusive use of ESAs in sport is well-recognized. An alternative to blood transfusion,
erythropoietin is used to increase the number of red blood cells, oxygen uptake, and hence
player’s endurance. Risks of erythropoietin use in athletic performance enhancement were
widely reported141 resulting in the prohibition of its use by the International Olympic Committee
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and other sport authorities.142 Similarly, the use of erythropoietin for this indication is not
recommended by DRUGDEX because of an inconclusive evidence of efficacy.
Iron-overloaded – Transfusion
Iron overload, an excessive state of tissue iron, may result from repeated blood
transfusion or over-absorption of iron from the gastrointestinal tract. Deposition of iron in
various organs leads to dysfunctionality of the heart, endocrine system and death.143 A
combination of 150 units/kg erythropoietin therapy and phlebotomy in 5 transfusion-dependent
hemodialysis patients was found associated with a reduction mean serum ferritin at the end of the
18-week study period.144 DRUGDEX therefore recommends the use of epoetin alfa as an
alternative to deferoxemine therapy in some cases of transfusional iron overload. Evidence of
ESA use for this indication favors efficacy though the strength of evidence is low.
Sexual Dysfunction
Erythropoietin may enhance sexual function in male patients undergoing dialysis by
directly affecting the endocrine or by increasing patient Hb level and blood viscosity.
Improvement in sexual function was reported in 4 of 7 males undergoing hemodialysis after
initiating ESA therapy. Moreover, 5 of 9 dialysis female patients reported a restoration of
menstruation during the treatment.145 Because of inconclusive evidence on efficacy and low
strength of evidence, DRUGDEX recommend the use of ESAs for the treatment of sexual
dysfunction only in selected cases.
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Table 2.4 Use of Epoetin alfa and DRUGDEX ratings
FDA Approval

Yes

No

Therapeutic use

Anemia - Chronic renal failure
Anemia - Due to chemotherapy Neoplastic diseases, Non-myeloid,
metastatic
Anemia - Zidovudine adverse reaction
Surgical procedure - Transfusion of
blood product, Allogeneic; Prophylaxis
Anemia - Congestive heart failure
Anemia - Due to radiation
Anemia - During the puerperium
Anemia - Hepatitis C, In patients
being treated with a combination of
ribavirin and interferon alfa or ribavirin
and peginterferon alfa
Anemia - Multiple myeloma
Anemia - Myelodysplastic syndrome
Anemia – Myelofibrosis
Anemia – Prematurity
(pediatric)
Anemia - Rheumatoid arthritis
Beta Thalassemia
Blood unit collection for
autotransfusion
Anemia - Traumatic or postsurgical
Anemia - Critical illness
Anemia - Not due to chemotherapy Neoplastic disease
Epidermolysis bullosa (pediatric)
Anemia - Porphyria cutanea tarda
Athletic performance enhancement
Cancer
Iron overload – Transfusion
Sexual dysfunction

Level of Evidence
Strength of
Strength of
Recommendation
Evidence
IIa
B
IIa
B

Efficacy
Rating
Effective
Effective

IIa
IIa

B
B

Favors efficacy
Effective

IIb
IIb
IIb
IIb

B
B
B
B

Favors efficacy
Favors efficacy
Favors efficacy
Favors efficacy

IIb
IIb
IIb
IIb

B
B
B
B

Favors efficacy
Favors efficacy
Favors efficacy
Favors efficacy

IIb
IIb
IIb

B
B
B

Favors efficacy
Favors efficacy
Favors efficacy

IIb
IIb
III

B
B
B

Inconclusive
Inconclusive
Favors efficacy

IIb
IIb
III
III
IIb
IIb

C
C
B
B
C
C

Inconclusive
Inconclusive
Inconclusive
Inconclusive
Favors efficacy
Inconclusive
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Table 2. 5 Use of Darbepoetin alfa and DRUGDEX ratings
FDA Approval

Yes

No

Therapeutic use

Anemia - Chronic renal failure
Anemia - Due to
chemotherapy - Neoplastic
diseases, Non-myeloid,
metastatic
Anemia - Not due to
chemotherapy - Neoplastic
disease
Anemia - Myelodysplastic
syndrome

Level of Evidence
Strength of
Strength of
Recommendation
Evidence
IIa
A
IIa
B

Efficacy
Rating
Effective
Effective

III

B

Inconclusive

IIb

B

Favors efficacy

Table 2. 6 Use of ESAs for conditions not supported by scientific evidence and DRUGDEX ratings
Therapeutic use

Anemia due to trauma, postsurgical,
and critical illness
Anemia in neoplastic disease not due to
chemotherapy
Anemia in porphyria cutanea tarda
Sexual dysfunction
Sickle cell anemia

Strength of
Recommendation
IIb

Level of Evidence
Strength of
Evidence
B

Efficacy
Rating
Inconclusive

III

B

Favors efficacy

IIb
IIb
IIb

C
C
C

Inconclusive
Inconclusive
Inconclusive
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Empirical studies of ESA Off-label Use

The use of erythropoiesis-stimulating agents in the hospital settings is extensive and
involving multiple hospital units and various indications. A study reports that over a 6-month
study period, 120 physicians in a large medical center prescribed approximately 17 million units
of erythropoietin, translating into a direct drug cost of $172,390.146 Hemodialysis and renal
indications were found to be the most common indications of ESA use though oncologists
accounted for the highest units of ESA use. Off-label prescribing of ESAs is prevalent in
inpatient settings. The same study found that 49% of ESAs prescribed for 248 inpatients
between February and June 2000 were for off-label indications. Off-label indications of ESAs
included bone marrow transplantation and hematologic malignancy (13%), neonatal care (10%),
and their use in neurosurgical procedure (8.2%).
Similar patterns of ESA prescribing were observed in a study entailing nearly half a
million ESA users in 515 hospitals nationwide.15 Chronic kidney disease and cancer were the
most common reason for ESA use in the hospitals between January 2002 and June 2004. During
this period, inpatient off-label prescribing of ESAs was found to be 52%. Interestingly, onequarters of such off-label use were prescribed for the indications not supported by strong
scientific evidence including cardiovascular (3.7%) and pulmonary (3.8%) disorders. This study
offers further insight into inpatient off-label prescribing of ESAs patterns. For example, offlabel prescribing was more common in teaching hospitals compared to the community ones;
surgeons were more likely to prescribed ESA off-label compared to specialists and generalists.
Regional variations and patient characteristics such as age, gender, race, insurance status, and
hospital length of stay were also found to be associated with off-label prescribing of ESAs.
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Efforts of regulatory risk communications and health policies to influence prescribing
patterns

The first part of this section describes risk communication approaches undertaken by the
FDA to ensure safety use of a medication while the final part summarizes a systematic review of
the impact of FDA drug risk communications on health care utilization and health behaviors.
The United States Food and Drug Administration (FDA) takes responsibility in
protecting public health, one of which by ensuring that the drug products are safe and
effective.147 At the same time, there is pressure on the FDA’s Center for Drug Evaluation and
Research (CDER) to put the new drug onto the market as quickly as possible causing the period
of premarketing surveillance period of adverse events to be significantly reduced.148 As a result,
the burden of drug safety monitoring relies heavily upon post-marketing surveillance. The
primary mechanism for post-marketing surveillance is FDA's MEDWATCH program, which
relies on health professionals to spontaneously and voluntarily report drug adverse events. Based
upon MEDWATCH adverse event reports, the FDA’s CDER and its an advisory committee
analyzes drug risk and communicates them to patients and providers. The FDA channels of risk
communication of medical products include safety alerts or public health advisories, Dear
Healthcare Professional Letters, labeling revisions including black box warnings, and
implementation of Risk Evaluation and Mitigation Strategies (REMS).149
Safety alert or public health advisory is often the FDA's first step in communicating drug
risks to the public. When the evidence of risk accumulates the addition of a black box warning
on the drug labeling is often warranted. Sometimes a black box warning occurs soon after a
public advisory. An ESA public health advisory was first issued to the general public in
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November 2006, highlighting the increased cardiovascular risk associated with epoetin alfa use
in CKD patients not on dialysis. This was quickly followed by a black box warning in March
2007. Following that, a second public health advisory was issued which emphasized the black
box warning and highlighted additional risks of death in cancer-ESA treatment and blood clot in
major surgery. A third advisory was issued in November 2007 which warned that ESAs may
shorten time to survival in cancer patients and emphasized maintaining Hb levels at 10-12 g/dL
in CKD patients.
Black box warning is a frequently used risk communication tool of the FDA. The name
“black box” refers to a prominent section outlined by a black border on the labeling of a drug, of
which clinical or animal toxicity data indicate the use of serious adverse reactions.150 The
warning highlights risks associated with and warns prescribers against the use of the drug for
certain indications and/or in some population. The use of black box warning, the strongest safety
warning issued by the FDA, 151 is limited to “the most serious warnings necessary to ensure the
continued safe use of the product.” The popularity of black box warnings has been noted in a
study that found approximately 8.2% of the 548 new drugs approved between 1975 and 1999 had
at least one black box warning.152 Among all drugs listed in the 1995 Physicians Desk
Reference (PDR), 206 carried a black box warning.153 The most frequent warning found was for
the identification of use in high-risk patients, followed by information on dosing and drug
interaction, and the need for special training or use in special settings. Nearly 14% of all
labeling revisions between 2005 and 2008 were due to black box warnings.154 In March 2007, a
black box warning was added to the label of epoetin alfa and darbepoetin alfa to reflect increased
risks associated with ESAs use in cancer and CKD patients reported in many large clinical trials.
The boxed warning was later updated in March 2008 to include results from recent trials.
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In addition to the public advisories and black box warnings, the FDA also
communicates with prescribers using a Dear Health Care Professional letter (DHCP), or Dear
Doctor/Dear Health Care Provider letter. DHCP letter is a paper or electronic mailing from the
manufacturer, distributor of drugs or biologics, or the FDA to health care providers about the
new information concerning a drug. DHCP letters can be of three types: “important drug
warning letter”, “important prescribing information letter”, and “important correction of drug
information letter.” The “important drug warning letter” alerts health care providers of the safety
issue hazardous to patient health such as life-threatening adverse reactions or a subpopulation in
which the drug is contraindicated. The “important prescribing information letter” indicates
changes in the prescribing information other than those in important drug warning letter type.
Such important prescribing information includes a change in the indication, dosage, and route of
administration intended to minimize risk or optimize effectiveness of the drug. The “important
correction of drug information letter” emphasizes corrections of misleading information in
prescription drug advertisements or other forms of promotion. A DHCP letter may either be
requested by the FDA or initiated by drug manufacturers according to one of the reasons noted
above but is normally done by the manufacturer. Information on DHCP letters can typically be
found on the MedWatch website. In the case of ESAs, an important drug warning DHCP letter
was sent by Amgen, a manufacturer of erythropoietin, in January 2007 to alert physicians of
results from major clinical trials regarding risks associated with ESAs use. The letter
specifically warned against the use of ESAs in non-chemotherapy cancer patients and the
potential for increased risk of death in this population. In addition, physicians were
recommended to use the lowest does of erythropoietin possible to maintain patient Hb at the
level sufficient to avoid blood transfusion.
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Under the FDA Amendment Act of 2007, the risk evaluation and mitigation strategies
(REMS) surveillance system was developed. The FDA is now empowered with the authority to
order manufacturer of a drug to provide REMS. The scope of REMS varies by drugs and the
risks they carry. For example, REMS of a drug with relatively low risk may require nothing but
an addition of package insert. However, because of the apparent risk associated with ESA use in
cancer treatment, REMS for ESAs requires physicians prescribing ESA drugs to cancer patients
to complete and receive documentation of certification of the online ESA APPRISE Oncology
Program Training. Physicians must be enrolled in the ESA APPRISE Oncology program in
order to be able to prescribe ESAs for use in patients with cancer.
Before the implementation of Risk Evaluation and Mitigation Strategies programs, no
formal system exists to document physician adherence to FDA warnings; adherence to the
warning is purely voluntary. One study found that 0.7% of prescriptions violate at least one
aspect of the warning, though less than 1% actually resulted in adverse drug events.155
Moreover, a national survey found the physician knowledge of the FDA-approved indications
and evidence base for prescription drugs to be low. 156 The problem of risk communication has
not been resolved with the REMS program.
Dusetzina et al. systematically reviewed the impact of FDA drug risk communications on
health care utilization and health behaviors from the studies published between January 1990 and
November 2010 listed in MEDLINE and Web of Sciences.157 Among 16 therapeutic classes
investigated in the forty-nine studies included in the review, antidepressants were the most
common therapeutic class (31%) assessed for the impact of risk interventions, followed by
glitazones (13%), cisapride (8%), terfenadine (8%), long-acting β2- agonist (6%), droperidol
(6%), and antipsychotics (6%). Black box warnings were the most frequent risk communication
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tool (51%), followed by public health advisory or safety alert (47%) and dear healthcare provider
letters (29%). None of the studies included in this review investigated the impact of FDA risk
communication on prescribing patterns of ESAs.
Nearly all studies of drug risk communications investigate their effect on changes in the
level of targeted drug utilization. Drug risk communications fell into four recommendation
types: 1) increase patient monitoring; 2) avoid co-prescribing of drugs that may have adverse
interaction; 3) avoid use of a drug among subpopulations; and 4) provide general caution of a
drug product. Of note, recommendations regarding increased clinical monitoring appeared to
have little or no effect on clinical practice. In addition, the effect of the recommendations failed
to be sustained in the short term, although physicians appeared to decrease inappropriate
prescribing over time. The effect of risk communication also appeared to vary considerably by
therapeutic classes. Lastly, spillover effects of the regulatory risk communication messages to
non-target user population were assessed in a few studies. A drop in antidepressant use was
observed in adult populations even though the communications only warned against its use in
youth.158
This study seeks to add to the literature in the following ways. This will be the first to
assess the impact of safety warnings and funding changes on the use of erythropoietin. It will be
one of the few studies that look at the impact of REMS on any type of drug on patient-level
changes in utilization. It is also the first to examine the relative impact of safety warnings and
funding decisions on on-label and off-label drug use of any type when examined at the patient
level.
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The following section extensively review potential confounders needed to be considered
in the analysis of patient-level data. Lastly, systematic literature review of public interventions
on ESA utilization that leads to the formulation of research question concludes the final section
of this chapter.

Potential confounding factors associated with prescribing patterns

The diffusion of innovation of health care framework clearly defines factors influencing
the decision to adopt an innovation including perceived benefit of the change, compatibility of
the innovation with the current values, belief, and needs of the individuals, complexity of the
proposed innovation, trialability of the innovation, and the extent to which potential adopters
observe the adoption by others. In parallel to the diffusion of innovation theory, influencing
factors of prescribing have been extensively studied. Prescribing decisions are a complex and
intertwining process where changes in physician’s prescribing patterns are a variety of factors.
Such influencing factors may be categorized into 3 groups: patient, physician, and external
factors. 159
1. Patient Factors
Patient clinical conditions (admission type, severity of illness, length of hospital stay)
Patient clinical conditions are major influencing factors of treatment patterns. The
relationship holds true for ESA use in specific; the likelihood of the off-label use of ESAs
showed a positive relationship with patient’s length of hospital stay.15 Similar results were found
in oncology where a drug use report indicated that the use of drugs for off-label purposes is more
prevalent in patients with advance cancer stages compared to the initial stages.160 Admission
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status, severity of illness calculated using a combined comorbidity score, and length of hospital
stay available in electronic medical records can serve as proxies for patient clinical conditions in
this study.
Patient characteristics (age, race, gender)
Off-label prescribing is a concern as the drugs tested in adult participants may not work
as safely or effectively in the elderly and children because of differences in body composition
and pharmacokinetics.161, 162 In addition, treatment patterns in the older elderly patients may
differ from the younger ones. Physician could be more reluctant to prescribe a drug with some
risks to older patients who are frailer and the goals of therapy may shift from increasing
longevity to improving quality of life. Also, as an individual draw closer to death, health care
utilization increases and thus adjusting for patient age in the analyses is essential.163
Racial disparities in ambulatory care and pharmacotherapy are well-documented.
African-American and other minorities were less likely to be prescribed with medications for
certain chronic disease conditions such as diabetes and mental disorders compared to their White
counterparts.164, 165 Even though the association between patient race and off-label prescribing
has rarely been assessed, it is crucial to control for potential confounding effect of patient race on
ESA prescribing in this study.
Despite evidence suggesting that women are greater users of health care resources than
men, gender disparities in the treatment of life-threatening diseases were apparent in the medical
literature.166 Researchers have rigorously examined gender as a predictor of the extent of
therapeutic intervention provision in various health conditions. For example, gender differences
were found to be correlated with the likelihood of receiving dialysis or a kidney transplant
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among patients with kidney diseases.167-169 It is therefore important to include patient gender
into the model to avoid its potential confounding effects on ESAs prescribing.
Primary Payer of Health Insurance
Health insurance has been long identified as enabling factor of healthcare encounter.170
A study found that physicians also incorporate patient’s health insurance in their prescribing
decision where participating physicians reported to change their therapeutic treatment due to
insurance issues in approximately 16% of the sampled visits.171 Additionally, this change is
most likely to occur when the patients was uninsured. The impact of health insurance on
prescribing patterns in the inpatient settings is largely unknown and deserved further
investigation.
2. Physician Factors
Physician specialty
Existing literature have identified that specialists and generalists may be different in their
treatment intensity. Research has found, for example, that endocrinologists and cardiologists
may have been more resource-intensive than generalists in the treatment of diabetes.172 Another
Canadian study also found that early prescribers of celecoxib, a specific cox-2 inhibitor
analgesic, were more likely than majority of prescribers to be general practitioners.173 A
possible explanation of such differences may lie in the extent of medical journal use or training.
As the literature suggests possible differences in prescribing patterns between physician
specialties, it is important to include information on physician specialty in the model.
Information on physician specialty is readily available in Cerner data.
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3. Hospital Specific Factors
Hospital characteristics (bed size, teaching status, geographic region)
Hospital characteristics including size, teaching status, and geographic region may
influence prescribing patterns. Larger hospitals are better equipped with prescribing decision
support system that leads to quality prescribing. A study of new drug adoption found that Dutch
general practitioners who used a prescribing decision support system were less likely to prescribe
angiotensin II receptor blockers (ARBs), an expensive anti-hypertensive medication, compared
to those who worked in single-handed practices or in rural areas where decision support system
is less likely to exist.174 In addition, knowledge dissemination may happen at a faster rate in a
larger hospital where thought leaders reside. One study found that key opinion leader physicians
and those who are socially well connected with their peers will also be one of first to react
compared to “patient-oriented” physicians.175 Though a study of ESA off-label prescribing
found no association between hospital bed size and ESA off-label prescribing, it is still important
to control for hospital size in this study. Hospital size in this study is measured through the
number of beds in a hospital and categorized into 5 groups: <99, 100-199, 200-299, 300-499,
500 or more beds, based on a categorization of the American Hospital Association (AHA).176
Small area variation (SAV) is evident in medical practices. For clinical conditions where
alternative treatments are available or in the absence of well-defined guidelines, practice styles
vary across physicians depending on their preferences. Economists believe that SAV mainly
stems from physician’s uncertainty and lack of knowledge as a result of inadequate diffusion of
medical information.177, 178 Regional variations were seen in off-label prescribing of ESAs such
that hospitals in the northeast and western portions of the country being more likely to prescribe

43

ESAs for off-label unsupported indications than other regions. Information on geographical
region is available in our database and will be categorized into Northeast, South, Midwest, and
West.
Teaching status of the hospital may be associated with prescribing patterns. Diffusion of
innovation and the uptake of technologies usually occur faster in a larger practice179, 180 and it is
possible that physicians who work in a group practice and those in teaching hospitals would be
more likely to follow the warning compared to those in solo practice and nonteaching hospitals.
Previous study has identified that off-label use of ESAs occurred more in teaching hospitals than
nonteaching hospitals.15
To conclude, it is evident from the literature that patient characteristics and their clinical
conditions, primary payer of health insurance, physician and hospital characteristics, to a certain
extent affect one’s decision to prescribe for on-label and off-label purposes. Outside influences
including safety issues speculate around the prescribing environment could likewise influence
prescribing patterns. Since effects of safety interventions on the ESA prescribing can be masked
by these characteristics, it is essential to include them in the analytical model.
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Systematic literature review

The systematic review of existing literature is subdivided into four parts: methods,
results, discussion, and conclusion. The objectives of this literature search was to summarize
existing knowledge on FDA and Medicare actions on ESA use patterns, namely the proportion of
patients treated, dose, and duration of ESA treatment. Findings from this review are used to
identify gaps in the literature and formulate research questions, research hypotheses, and specific
aims that are described at the end of this chapter.

Methods

Three databases were used for this search: MEDLINE, CINAHL, and Web-of-Sciences.
First, MEDLINE was searched via PubMed for relevant studies from a combination search of 3
search strings that comprised of MeSH terms and keywords. CINAHL database via EBSCO host
and Web-of-Science were searched using a combination search of similar keywords to identify
additional articles. Reference lists of selected studies and relevant review articles were also
searched. To keep such search at a manageable level, keyword search was applied to title and
abstract [tiab] in PubMed. Web-of-Science search was limited to topic field and studies based in
the United States only while no search field was specified in CINAHL.
Inclusion criteria are English language articles studies that analyzed empirical data on the
impact of interventions of interest on ESA use patterns. This review excluded letters to editors,
commentaries, news articles, and meeting abstracts. Review articles were included only for
reference mining. The search was limited to English language articles published between 2007
and May 2012. The year 2007 was chosen because the scope of this study focuses interventions
that took place only between 2006 and 2010. To be included in this review, a study must have
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investigated at least one of the following outcomes during the period of study: proportion of
patients treated with ESAs, ESA dose, and treatment duration. Abstracts produced from initial
search strategies were reviewed for possible inclusion and exclusion. The corresponding full
articles of qualifying abstracts were then retrieved through Virginia Commonwealth University
and inclusion and exclusion criteria were then confirmed. Search strings used in for PubMed
search are described below. For Web-of-Science and CINAHL, MeSH terms were substituted
with exact or similar keywords.
String #1:
“Erythropoiesis-Stimulating Agents” [MeSH] OR “Erythropoietin” [MeSH] OR
“Erythropoiesis” [MeSH] OR “ESA” [tiab] OR “Erythropoietic” [tiab]
String #2:
“safety” [tiab] OR “warning” [tiab] OR “black box” [tiab] OR “public health” [tiab] OR
“advisory” [tiab] OR “alert” [tiab] OR “dear doctor” [tiab] OR “dear healthcare professional”
[tiab] OR “dear healthcare provider” [tiab] OR “letter” [tiab] OR “risk communication” [tiab]
OR “risk evaluation and mitigation strategies” [tiab] OR “REMS” [tiab] OR “drug labeling”
[MeSH] OR “Food and Drug Administration” [tiab] OR “FDA”[tiab] OR “regulatory” [tiab] OR
“United States Food and Drug Administration” [MeSH] OR “National Coverage Determination”
[tiab] OR “NCD” [tiab] OR “reimbursement” [tiab] OR “restrict” [tiab] OR “payment” [tiab] OR
“policy” [tiab] OR Medicare [MeSH] OR “United States Centers for Medicare and Medicaid
Services” [MeSH]
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String #3:
“Physician's Practice Patterns" [MeSH] OR "Drug Prescriptions" [MeSH] OR "Drug Utilization"
[MeSH] OR “prescribing” [tiab] OR “impact” [tiab] OR “effect” [tiab] OR “change” [tiab] OR
“outcome” [tiab] OR “consequence” [tiab] OR “results” [tiab] OR “trend” [tiab]

Results

PubMed search (string #1 AND string #2 AND string #3) identified 477 articles
published between 2007 and 2012, ninety-five of which were review articles. After applying
exclusion criteria, abstracts were selected for full text assessment for eligibility. Eight original
research article of a qualitative analysis of empirical data was identified. Reference mining of
original studies and review articles did not yield additional relevant study. Likewise, no
additional eligible studies were found from CINAHL (247 studies) and Web-of-Science (339
studies) search. Thus, a total of eight studies are used for this review.
Studies of impact of regulatory safety warnings and reimbursement restriction through
the national coverage determination cover a variety of outcomes. The primary outcomes
commonly identified are the proportion of patients treated with ESAs, dose, treatment duration,
Hb level, and requirement for blood transfusion. Two studies assessed the change in ESA use in
CKD patients while the other six studies investigated such change in cancer patients. Study
methods, results, and conclusion are summarized in Table 2.7 and 2.8.
An increasing trend in mean ESA dose was observed among hemodialysis patients
internationally between1996 and 2008.181 MaFarlane and his colleagues analyzed the trend in
ESA use and their Hb levels among patients treated in selected dialysis units in 12 countries (US,
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Canada, France, Germany, Italy Spain, Belgium, Sweden, the UK, Australia, New Zealand, and
Japan) using data from a three-phase large prospective observation study, Dialysis Outcomes and
Practice Pattern Study (DOPPS). The study found an increasing trend in mean ESA doses
between the DOPPS study phases (1996-2001, 2002-2004, and 2005-2008) in all participating
countries but Belgium. An increase in Hb levels was observed in all countries but Sweden.
Contradicting results were reported among CKD patients not on dialysis in the United
States between 2005 and 2009.182 ESA use in this population treated in free-standing US
nephrology clinics decline from 60% to 46% during this period with the largest drop in 2007 and
2008 (the study did not test for statistical significance in this difference). A significant decline in
the proportion of patients with Hb level > 12 g/dL and an increase in the proportion of patients
with Hb within 10-12 g/dL range were observed in 2007. This change was parallel with a
decline in ESA dose that began in early 2007 (a 21% drop throughout the 4 years period).
Nonetheless, the drop in ESA dose and Hb level was not statistically significant after adjusting
for patient case-mix.
A consistent decline in ESA use in cancer treatment was noted in all studies. Vadhan-Raj
et al. assessed usage patterns of ESAs and transfusion among patients on active treatment at a
cancer center between January 2006 and December 2008 to determine whether changes in the
level of ESA use correspond with changes in the safety concerns and reimbursement strategy
during the study period.183 Active treatment was defined as inpatient admission, emergency
center visit, blood transfusion, surgery, chemotherapy, radiation therapy, and other therapy for
cancer. Compared with 2006, the proportion of patients receiving ESAs decreased by 26% in
2007, and by 61% in 2008. A non-significant increasing trend of 8% in the proportion of
patients receiving transfusions was observed during the investigational period. A significant
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reduction in Hb values at ESA initiation was also found among ESA-naïve patients such that the
proportion of patients first receiving ESAs at Hb level ≤ 10 g/dL increased from 60.6% in 2006
to 88.9% in 2008. Additionally, the proportion of ESA-naïve patients receiving transfusion
before any ESA use increased from 26.4% in 2006 to 40.7% in 2008. Moreover, the study used
piecewise linear models to detect changes in the numbers of patients treated at the center, ESA
units dispensed, blood units transfused, mean Hb values on the day of transfusion and at the
initiation of ESAs, proportions of ESA use among transfused patients, and proportions of ESAreceiving patients undergoing transfusion. A significant reduction in ESA units dispensed was
observed at 9.8 months (October 2006) and ESA units dispensed reduced by 77% during the
three years study period. In the same period, no significant changes in the number of patients
treated at the center, RBC units transfused, or mean Hb values on the day of transfusion were
found. The greatest reduction in ESA use was in the hematologic services (28%) though this
decrease was observed across all services. Finally, after adjusting for patient and clinical
characteristics, the authors found that though ESA use decreased, transfusion did not increase
significantly. Despite a large number of outcomes studied the study did not investigated
differences in such outcomes between patients on and off-chemotherapy.
The impact of the reimbursement change on the level ESA utilization in cancer patients
receiving chemotherapy in multiple oncology clinics was first observed in a study by Hess et
al.184 ESAs were used in 41.3% of all episode of chemotherapy care before the implementation
of national coverage determination (NCD). In the post-NCD period, only 30.4% of the
chemotherapy episodes were associated with ESA use, translating into 26.4% reduction in ESA
use. Concurrently, a significant increase in the episodes with blood transfusion was observed
(17% relative reduction) while the mean minimum Hb values during the episodes were
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significantly lower after NCD (10.7 g/dL vs. 10.9 g/dL). The impact of NCD seemed to be
different between the two groups of patients such that more prominent changes in ESA use,
blood transfusion, and Hb values were found in patients older than 65 years old (29.1% relative
reduction in ESA use and a 31% increase in blood transfusion). In contrast, though ESA use
decreased significantly by 24% among those younger than 65 years old, no significant increase
in blood transfusion was found.
A study by Henry and his colleagues determined the impact of NCD on utilization of
ESAs among Medicare patients with colorectal, lung, and breast cancer patients on concomitant
chemotherapy.185 Information of patients with chemotherapy-induced anemia (Hb values < 11
g/dL while receiving chemotherapy or within 60 days of the last chemotherapy dose) from 49
community oncology clinics with was derived from electronic medical records to assess blood
transfusion (proportion of patients receiving transfusion and transfusion units), ESA use, time,
and dosing, Hb values, and hospitalization. The proportion of CIA patients receiving ESAs
decreased in the post-NCD compared to the pre-NCD period (56% vs. 88%). Duration of ESA
use decreased significantly from 48 days to 32 days and doses reduced from 4.6 to 2.9 units.
Adjusting for patient demographics, clinical characteristics, tumor types, and chemotherapy
treatment, the likelihood of receiving transfusion was found to be 41% greater after NCD.
Parallel with this increase, a significant rise in the proportion of patients with Hb < 10 g/dL,
mean number of transfusion per patient and mean number of units transfused was found postNCD period. Nonetheless, no significant differences in the rate of hospitalization between the
two periods were observed. In spite of reporting a crude reduction in the proportion of cancer
patients receiving ESAs after the implementation of NCD, the study did not assess the likelihood
of receiving ESAs, adjusting for covariate.
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Hemoglobin trends and anemia treatment among chemotherapy-treated patients with
cancer between 2006 and 2009 were assessed by Feinberg and colleagues.186 Overall, the
proportion of chemotherapy episodes in community oncology clinics in which ESA was
prescribed decreased significantly from 45.4% to in 2006 to 11.5% in 2009. This change aligned
with an increase in chemotherapy episodes with no anemia treatment (44.6% to 77.8%), episodes
with transfusion services only (3.4% to 8.73%), and a decrease in episodes with both transfusion
and ESA treatment (6.6% to 2.0%). For episodes with ESA treatment, patients showed
decreased in mean Hb values. The study implied that over time, initiation of ESAs after
chemotherapy was delayed (from 29.4 days in 2006 to 39.0 days in 2009) and patients seemed to
be initiated with any anemia treatments at a lower Hb values.
Arneson et al. assessed the impact of NCD on ESA and transfusion use in chemotherapytreated Medicare beneficiaries with cancer using a nationally representative Medicare claims
data between 2005 and 2007.187 The proportion of ESA use among patients aged 66 or older
who had lung, breast, or colorectal cancer, or lymphomas, and initiated chemotherapy in the
outpatient settings decreased significantly from 35.0% pre-NCD to 15.2% in post-NCD period,
adjusting for patient demographic and clinical variables. Though an increasing trend was found
in the proportion of patients receiving transfusion or transfusion event rate, a statistical
difference could not be detected pre- and post-NCD implementation (9.3% vs 10.4% of patients
and 19.0 to 21.8 transfusion events per 100 patient-quarters). The findings were similar across
the four types of cancer.
Lastly, appropriateness of ESA use at National Cancer Centre in Singapore was assessed
by Chan and Chan.188 The release of safety advisories appeared to be associated with
appropriate ESA prescribing measured through Hb initiation level and target level achieved, but
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ESA treatment duration remained unchanged. Furthermore, a smaller proportion of patients
required more blood transfusion after ESA therapy was observed after the warnings compared to
the pre-warning period. Nonetheless, the study did not statistically compare the proportion of
patients using ESA before and after the release of safety advisories considered useful to answer
our research questions.

Discussion and Conclusion

ESA use in all patients except those receiving hemodialysis decreased after 2006.
Among the six studies of ESA use in cancer patients, a consistent reduction in use was observed
over time. The greatest decline in use (number, dose, duration of therapy) occurred between late
2006 and early 2007, corresponding to the release of negative results from clinical trials, black
box warning, and restriction in Medicare reimbursement. Though impact of NCD was most
prominent among Medicare beneficiaries, studies observed a spillover effect in the younger
population. Consistent with safety warnings, patient Hb levels at the initiation of ESA treatment
seemed to lower over time. The reduction in ESA prescribing was associated with increases in
the use of transfusion services in many, but not all studies. No study examined the impact of
safety warnings on off-label prescribing of ESAs.

52

Table 2.7 Results of systematic literature review: summary of study methods
Author, pub year

Study Design

Study Sample

Data Source
Time period
Chronic Kidney Disease
DOPPS
1996-2008
database

McFarlane et al.,
2010

Descriptive

Regidor et al.,
2010

Pre-post
comparison

Hemodialysis
patients in 12
countries
CKD non-dialysis
patients at freestanding nephrology
clinics
N = 15,836

Vadhan-Raj et al.,
2010

Time-series

Hess et al., 2010

Pre-post
comparison

Cancer patients on
active treatment at
one cancer center
N = 83,399
Cancer patients with
chemotherapyinduced anemia at
52 oncology clinics
N Pre-NCD = 4,784
N Post-NCD = 5,605

Electronic
medical
records

Cancer
Electronic
medical
records
Electronic
medical
records

Intervention

Unit of Analysis

None

Patient

Mar 05-Jul 09

All possible
between the study
period

Patient

Jan 06-Dec 08

All possible
between the study
(black box warning
and NCD)
NCD

Patient

Jun 06-Mar 08

Episode of
chemotherapy care
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Author, pub year

Study Design

Study Sample

Henry et al., 2011

Pre-post
comparison

Adult Medicare
patients with
colorectal, lung, or
breast cancer who
were treated at
community oncology
clinics and
developed
chemotherapyinduced anemia

Feinber et al.,
2012

Pre-post
comparison

N = 800 pre-NCD
(Jan 00 – Jul 07)
N = 994 post-NCD
(Aug 07 – Jan 09)
Cancer patients at an
oncology private
practice
N =4,021 patients
(4,864 episodes of
chemotherapy care)

Data Source
Cancer
Electronic
medical
records

Time period

Intervention

Unit of Analysis

January 2000 –
January 2009

NCD

Patient

Electronic
medical
records

Jan 06-Aug 09

All possible
between the study
period with focus
on NCD

Episode of
chemotherapy care
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Arneson et al.,
2012

Pre-post
comparison

66 years old
Medicare
beneficiaries who
had lung, breast,
colorectal cancer, or
lymphomas, and
initiated
chemotherapy in
outpatient settings

Medicare 5%
sample

September
2006November
2007

NCD

Patient

Data Source
Cancer
Pharmacy
electronic
dispensing
records

Time period

Intervention

Unit of Analysis

January 2005 –
December
2009

FDA safety
warnings

Patient

N = 1,897 pre-NCD
N = 1,877 post-NCD

Author, pub year

Study Design

Study Sample

Chan, 2010

Pre-post
comparison

Patients who
received at least one
dose of ESAs at a
cancer center in
Singapore
N = 91pre-NCD
N = 48 post-NCD
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Table 2. 8 Results of systematic literature review: summary of study results
Author,
pub year
McFarlane et al.,
2010

Regidor et al.,
2010

Outcomes Measure

Trend in mean Hb level
and ESA dose

Proportion of patients
treated with ESAs
ESA dosing in
mcg/month and mean
Hb level

Statistical
Approach

Results

Chronic Kidney Disease
Linear regression
Mean Hb level and percentage
analysis adjusting
of patients with Hb level ≥ 12
for clustering by
g/dL, in the US increased
facility
significantly.

Mantel-Haenszel
chi-square test
and ANOVA for
biavariate
analysis
Multiple linear
regression of
trends in ESA
dosing and Hb
level over the
study period

Mean ESA doses increased
from 15,959 U/week in DOPPS
Phase I to 21,386 U/week in
DOPPS Phase III (p < 0.001).
Percentage of patients with a
mean ESA dose greater than
35,000 U/week also increased
significantly.
ESA use declined from 60% in
2005 to 46% in 2009 with largest
decline (20.5%) between 2007
and 2008
Mean dose declined from 176 to
136 mcg/month with the largest
decline observed at the
beginning of 2007. Mean Hb
level declined significantly.

Conclusion

Limitations/Gaps
in literature

ESA use in the
kidney disease in
the US increased
despite safety
warning and
reimbursement
change

Crude estimates of
outcomes change
that are loosely tied
to an intervention
since the study
compares Hb level
and ESA dose
between phases of
DOPPS.

A decline in ESA
use between 2005
and 2008 was
observed and may
be associated with
safety warnings,
change in clinical
practice guidelines,
and reimbursement
restriction

Did not test for
statistical difference
in ESA use between
years
Did not adjust for
patient
characteristics
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Author,
pub year

Outcomes Measure

Statistical
Approach

Vadhan-Raj et
al., 2010

Proportion of patients
receiving chemotherapy,
ESAs, or transfusion

Chi-square test
for proportion

Change point during 36month period and
differences in slopes
before and after change
point for:
- ESA use: total ESA
unit dispensed and
total number of
patients treated during
the period
- Transfusion: Total
number of transfusion,
proportion of ESAreceiving patient
requiring a
transfusion, proportion
of transfused patients
receiving ESAs
- Hb profile: mean Hb
level on the day of
transfusion (implies
transfusion threshold),
mean Hb at initiation
of ESAs in ESA-naïve
patients (implies
threshold for initiating

Piecewise linear
model to assess
change points
Wald test to
assess change in
slope
Multiple logistic
regression

Results
Cancer
ESA use
Compared to 2006, number of
patients who received ESAs
decreased by 26% in 2007, 61%
in 2008.
Total number of standardized
ESA units dispensed decreased
by 29% in 2007, and by 80% in
2008. Change point occurred at
9.8 months (October 2006),
slope before = 31.58 ESA
units/month, slope after = -91.38
units/month (p<0.0001).

Conclusion

Limitations/Gaps
in literature

Safety concerns and
reimbursement
change were
associated with a
decrease in ESA
use among cancer
patients, both
receiving and
receiving
concomitant
chemotherapy.

-

Blood transfusion
Total number of transfusion
increased by 2% in 2007, by 8%
by 2008. Number of patients
received transfusion increased
by 6% in 2007, 8% by 2008 (p =
0.003). However, no statistically
significant change point was
detected.
Subgroup analysis of those
receiving chemotherapy
Proportion of patients receiving
ESAs decreased from 26.5% in
2006 to 9.4% in 2008, p <
0.0001). No change in the
proportion of patient receiving
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ESAs)

transfusion was observed.

Change in ESA use and
transfusion use over
time, adjusting for
patient demographic and
clinical characteristics.

Hess et al., 2010

Proportion of patients
administered with ESAs
Proportion of patients
required blood
transfusion
Frequency of
myelosuppressive
chemotherapy treatment

Hb value at transfusion
No change was found in Hb
values at transfusion and in
proportion of patients with Hb
level < 10 g/dL on day of
transfusion

Chi-square tests
and t-tests

Hb value at initiation of ESAs
Proportion of patients who
started ESAs at Hb ≤ 10 g/dL
increased from 60.6% in 2006 to
88.9% in 2008 (P < 0.0001).
All patients: 26.4% relative
decrease (p < 0.001)
Aged ≥65: 29.1% relative
decrease (p < 0.001)
Blood transfusion increased
significantly (17.1% for all
patients and 31.3% in elderly)

NCD reimbursement
restriction was
associated with the
reduction in ESA
use among cancer
patients treated at
oncology clinics

The study did not
adjust for patient
characteristics when
testing for the
difference in ESA
use.
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Author,
pub year

Outcomes Measure

Statistical
Approach

Henry et al.,
2011

Proportion of patients
receiving transfusion
during chemotherapyinduced anemia episode

Bivariate analysis
comparing prepost outcomes of
interest

Mean number of units of
blood transfused

Logistic
regression to
evaluate the
likelihood of
receiving a
transfusion and
negative binomial
regression to
estimate the
number of units
transfused

Patient hematologic
status (mean Hb)
Frequency and duration
of ESA use
Hospitalization

Results
Cancer
Proportion of patients receiving
ESAs before and during CIA
episode decreased significantly
pre-post NCD (88% vs 56%, p <
0.0001). ESA doses and
duration of treatment decrease
significantly (48 vs. 32 days and
4.6 vs. 2.9 doses, p < 0.0001).
NCD is associated with lower Hb
level, 41% increase in the odds
of receiving a transfusion, and
53% increase in blood
utilization.

Conclusion

Limitations/Gaps
in literature

NCD was
associated with
decreased
frequency and
duration of ESA
treatment in cancer
patients receiving
chemotherapy, a
modest increase in
blood transfusion,
and a decreased Hb
level, but was not
associated with an
increase in
hospitalization.

The study did not
look at the likelihood
of receiving ESAs
before and after
NCD.

No significant difference in the
rate of hospitalization was
found.
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Author,
pub year

Outcomes Measure

Statistical
Approach

Feinberg et al.,
2012

Number of episodic
cohorts (stratified by Hb
at anemia treatment
initiation < 10 g/dL) with:
1. No anemia
treatment
2. ESA use only
3. Transfusion only
4. ESA+transfusion

Bivariate analysis
using chi-square
(number of
episodic cohorts)
and t-test (mean
Hb values, time
from
chemotherapy to
Hb < 10 g/dL and
to treatment
initiation)

Mean Hb values,
stratified by episodic
cohorts at:
1.
Initiation of
anemia treatment
2.
Up to 6 weeks
before treatment
3.
Up to 6 weeks
after anemia
treatment

Comparing yearly
number of
episodic
outcomes, using
2006 as
comparator

Results
Cancer
Chemotherapy episodes with
ESA treatment decreased
significantly from 45.42% in
2006 to 11.47% in 2009, with
significant all year-to-year trends
(p < 0.05).
Mean Hb values at initiation of
ESA-anemia treatment
decreased from 10.8 g/dL in
2006 to 8.9 g/dL in 2009 (p <
0.001).
Average number of days
between chemotherapy and
anemia treatment initiation with
ESAs increased each year from
21.2 days in 2006 to 39.0 days
in 2009 (p < 0.001)

Conclusion

Limitations/Gaps
in literature

Between 2006 and
2009, there was a
decreased use of
ESAs, delayed in
ESA-anemia
treatment, and a
decrease in Hb level
at time of treatment
initiation among
cancer patients
receiving
chemotherapy at a
private oncology
clinic.

The study did not
adjust for patient
characteristics when
testing for the
difference in ESA
use.

Average number of days
from chemotherapy
initiation to Hb < 10 g/dL
and average number of
days from Hb < 10 g/dL
to anemia treatment
initiation
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Author,
pub year

Outcomes Measure

Statistical
Approach

Arneson et al.,
2012

Proportion of patient with
ESA use

Logistic
regression
comparing prepost proportion
and poisson
regression
comparing prepost event rates

Proportion of patients
requiring ≥ 1 blood
transfusion and
transfusion event rates

Chan 2010

“Appropriateness” of
ESA prescribing
measured through Hb
initiation and targeted
levels, ESA dose
adjustment, treatment of
duration and presence of
concomitant iron
supplement
“Appropriateness” of
ESA efficacy and toxicity
monitoring measured
through the number of
blood transfusion
needed before and after
ESA therapy and other
indicators

Chi-square tests
and t-tests

Results
Cancer
ESA use in Medicare cancer
patients receiving chemotherapy
decrease from 35.0% to 15.2%.
After adjusting for covariates,
NCD was associated with 67%
reduction in the odds of ESA
use (OR = 0.33, p < 0.0001)
No significant change in the
adjusted transfusion use and
transfusion event rates was
found
Mean Hb level at treatment
initiation was significantly lower
(8.52 g/dL vs. 8.95 g/dL, p =
0.032), but the duration of
treatment remained unchanged
(17 days vs. 20 days, p = 0.844).
A significantly smaller proportion
of patients requiring more blood
transfusion after ESA therapy
was observed (44.8% vs. 7.1%,
p = 0.016).

Conclusion

Limitations/Gaps
in literature

NCD was
associated with a
reduction in ESA
use among
Medicare cancer
patients receiving
chemotherapy, but
was not associated
with transfusion use

-

Safety guidelines
were associated
with lower Hb level
at the time of
treatment initiation
and fewer blood
transfusions after
ESA treatment
among patients with
cancer in
Singapore. No
change in duration
of ESA treatment
was seen.

The study did not
test for a
significance
difference in the
proportion of
patients receiving
ESAs pre- and postwarning period and
did not adjust for
covariates for other
statistical testing.
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Gaps in the Literature

Existing literature has provided concrete evidence of changes in ESA prescribing in the
outpatient settings from 2005 to 2009. However, the literature is lacking on prescribing patterns
of ESAs among hospitalized patients since 2004. Among studies exploring changes in ESA
outpatient utilization over time, none of them has attempted to link specific safety interventions
to prescribing patterns of ESA. In addition, the effect of REMS, the FDA’s most recent risk
communication tool implemented in 2010, on ESA use has never been assessed. Finally, the
relative impacts of various safety interventions on the on-label and off-label use of ESAs has not
been explored.
This study contributes to the literature in the following ways. First, it provides update on
the on-label and off-label use of ESAs in the inpatient settings - last studied in 2004. Second, it
quantifies relative immediate and trend impacts of various regulatory interventions on inpatient
ESA use between November 2006 and November 2010. The study further compares impacts of
such interventions across the. Third, this study explores how these interventions might influence
three types of ESA prescribing (on-label, off-label supported, and off-label unsupported
indications) differently. Finally, the study determines factors associated with the likelihood of
receiving ESAs in the inpatient settings between 2005 and 2011.
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Research Questions, Specific Aims, and Hypotheses

Descriptive Study: Specific Aim 1
No hypotheses were formulated for the descriptive study.

Research Question 1a

Do differences in demographic characteristics, clinical conditions, insurance status,
hospital characteristics, and physician characteristics exist between users of epoetin alfa and that
of darbepoetin alfa?
Specific Aim 1a
To compare demographic characteristics, clinical conditions, insurance status, hospital
characteristics, and physician characteristics between epoetin alfa users and darbepoetin alfa
users.

Research Question 1b

Do differences in demographic characteristics, clinical conditions, insurance status,
hospital characteristics, and physician exist among ESA users of on-label, off-label supported,
and off-label unsupported indications in the inpatient settings?
Specific Aim 1b
To compare demographic characteristics, clinical conditions, insurance status, hospital
characteristics, and physician characteristics among ESA users of on-label, off-label supported,
and off-label unsupported indications in the inpatient settings.
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Inferential Study: Specific Aim 2 and 3
Specific Aim 2: Impact of Black box warning, NCD, and REMS on the proportions of visits with
on-label, off-label supported, and off-label unsupported ESA use

Research Question 2

What are the immediate and trend impacts of 1) black box warning, 2) national coverage
determination, and 3) REMS on utilization patterns of ESAs and for the on-label, off-label
supported, and off-label unsupported indications?
Specific Aim 2
To quantify the immediate and trend impacts of black box warning, NCD, and REMS on
the proportion of visits where a patient was prescribed ESAs for on-label, off-label supported,
and off-label unsupported indications
Hypothesis for Question 2
Each of the interventions is associated with a significant change in the immediate and
trend of the proportion of ESA use in the three use categories.
H0-2-a : There exists no significant immediate and trend change in the proportion of visits
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label
unsupported indications in the hospital settings after the issuance of black box warning
H0-2-b : There exists no significant immediate and trend change in the proportion of visits
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label
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unsupported indications in the hospital settings after the implementation of national coverage
determination.
H0-2-c : There exists no significant immediate and trend change in the proportion of visits
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label
unsupported indications in the hospital settings after the implementation of REMS.
Specific Aim 3: Impact of Black box warning, NCD, and REMS on the odds of a patient being
prescribed ESAs for the on-label, off-label supported, and off-label unsupported indications

Research Question 3a

What are the immediate and trend impacts of 1) black box warning, 2) national coverage
determination, and 3) REMS on the odds of receiving ESA among patients with a) on-label and
b) off-label supported indications, adjusting for patient & hospital characteristics? This question
is formulated to find out whether the three interventions have an unintended effect on ESA use in
the hospital settings. Specifically, we would like to know if there is a decrease in the likelihood
of receiving ESAs among patients who could benefit from the on-label and off-label supported
indications of ESAs after the interventions.
Hypothesis for Question 3a
Each of the interventions is associated with significant unintended change in the
immediate and trend in the odds of receiving ESAs in patients with the on-label and off-label
unsupported indications, adjusting for individual patient characteristics, hospital characteristics,
and physician specialty.
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H0-3a-a: There exists no significant immediate and trend change in the odds of receiving
ESAs in patients with the on-label or off-label supported indications in the hospital settings after
the issuance of black box warning.
H0-3a-b : There exists no significant immediate and trend change in the odds of receiving
ESAs in patients with the on-label or off-label supported indications in the hospital settings after
the implementation of NCD.
H0-3a-b : There exists no significant immediate and trend change in the odds of receiving
ESAs in patients with the on-label or off-label supported indications in the hospital settings after
the implementation of REMS.
Specific Aim 3a
To quantify the immediate and trend unintended impacts of black box warning, NCD,
and REMS on the odds of receiving ESAs among the following patients in the hospital settings,
adjusting for individual patient characteristics, hospital characteristics, and physician specialty:
1. Those with diagnoses related to the on-label indications of ESA use in the absence of
observable contraindications.
2. Those with diagnoses related to the off-label supported indications of ESA use in the
absence of observable contraindications.
3. Those with diagnoses related to the documented off-label unsupported indications of ESA
use in the absence of observable contraindications.
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Specific Aim 3b: Association between patient characteristics, clinical conditions, hospital
characteristics, and admitting physician medical specialties on the odds of being prescribed
ESAs for the on-label, off-label supported, and off-label unsupported indications

Research Question 3b

What are the associations between patient demographic and clinical characteristics,
hospital characteristics, or physician specialty and the odds of receiving ESAs between January
2005 and June 2011 among patients with a) on-label and b) off-label supported indications, and
c) documented off-label unsupported indications, other things constant?
Hypotheses for Question 3b
We hypothesize that patient demographic, clinical characteristics, hospital characteristics,
and ordering physician specialties are associated with the odds of receiving ESAs among patients
with a) on-label, b) off-label supported indications, and c) documented off-label unsupported
indications.
Patient characteristics (age, race, gender, primary payer of health insurance)
H0-3b-a : There exists no significant association between patient’s age and the odds of
receiving ESAs in the hospital settings among the three patient populations.
H0-3b-b : There exists no significant association between patient’s race and the odds of
receiving ESAs in the hospital settings among the three patient populations.
H0-3b-c : There exists no significant association between patient’s gender and the odds of
receiving ESAs in the hospital settings among the three patient populations.
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H0-3b-d : There exists no significant association between patient’s primary payer of health
insurance and the odds of receiving ESAs in the hospital settings among the three patient
populations.
Patient clinical conditions (admission status, severity of illness, discharge disposition)
H0-3b-e : There exists no significant association between patient’s admission status and the
odds of receiving ESAs in the hospital settings among the three patient populations.
H0-3b-f: There exists no significant association between patient’s severity of illness and the
odds of receiving ESAs in the hospital settings among the three patient populations.
H0-3b-g : There exists no significant association between patient’s place of discharge and
the odds of receiving ESAs in the hospital settings among the three patient populations.
Hospital characteristics (teaching status, bed size, geographic region)
H0-3b-h : There exists no significant association between teaching status and the odds of
receiving ESAs in the hospital settings among the three patient populations.
H0-3b-i : There exists no significant association between hospital size and the odds of
receiving ESAs in the hospital settings among the three patient populations.
H0-3b-j : There exists no significant association between geographic region and the odds of
receiving ESAs in the hospital settings among the three patient populations.
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Physician specialty
H0-3b-m: There exists no significant association between physician specialties and the odds
of receiving ESAs in the hospital settings among the three patient populations.
Specific Aim 3b
To determine if association exist between patient characteristics, clinical conditions,
physician specialty, and hospital characteristics and odds of receiving ESAs among patients with
a) on-label, b) off-label supported indications, and c) documented off-label unsupported
indications.
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CHAPTER 3
Methodology
This chapter describes the study methodology used to assess the relative effect of safety
regulations on the inpatient on-label and off-label ESA use between January 1, 2005 and June
30, 2011. The chapter is divided into five parts including 1) information regarding the data and
subject selection, 2) classification of ESA use, 3) variable measurements, 4) statistical analysis
and testing of hypotheses, and 5) data privacy.

Study Design and Data Collection

This was a retrospective time-series study of patients within a multi-hospital database.
The data for this retrospective cohort study came from Cerner Millennium and was provided
through the Center for Clinical and Translational Research (CCTR) at Virginia Commonwealth
University.a The Cerner HealthFacts® database provides de-identified, HIPAA-compliant,
longitudinal collection of patient information generated from the Cerner® electronic medical
record (EMR) from over one hundred community and academic hospitals in the United States.
The data
The Cerner HealthFacts® database contained detailed information on inpatient care such
as procedure and diagnoses-specific data (in International Classification of Diseases, 9

th

Revision, Clinical Modification (ICD-9-CM) format) from discharge abstract summaries and
a

The project described was supported by CTSA award No. UL1TR000058 from the National Center for Advancing

Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent
official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.
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inpatient medication orders. Database elements also included patient (age, gender, race,
admission date, discharge date and length of stay), hospital (bed size, geographic region), drug
(medication started dates), and ordering physician (medical specialty) information.

Study Population

Eligible visits/patients were adult individuals who were admitted to Cerner hospitals with
predefined diagnoses codes (on-label, off-label supported, or known off-label unsupported) or
received at least one order of erythropoietin during the period of January 1, 2005 and June 30,
2011.

Inclusion and Exclusion Criteria
This study included all visits of adult patients (≥ 18 years of age) who were admitted to
Cerner hospitals and received erythropoietin (epoetin alfa or darbepoetin alfa) at least once
during their stay. Visits with no recorded information on ICD-9-CM diagnoses codes were
excluded. In addition, all visits of adult patients with predefined ICD-9-CM for on-label and offlabel indications of ESAs were included in the analysis. Visits without any drug records were
excluded from the analyses. Children and adolescence were excluded from all analyses as the
indications and level of evidence supporting use of ESAs were different by age within the
pediatric population themselves and also between the two populations. A list of pre-specified
ICD-9-CM codes used to define on-label, off-label supported, and documented off-label
unsupported uses are described in Table 3.1 – 3.4 and detail use categorization is described in the
later part.
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Classification of ESA use

Use of ESAs was classified into three categories using ICD-9-CM diagnoses codes,
procedures codes, and/or their medication use, into (1) on-label use, ONS (approved by the
FDA); (2) off-label use supported, OFS (use for the indications not approved by the FDA, but
there is strong clinical evidence to support its use); and (3) off-label use unsupported, OFU (use
for the indications not approved by the FDA and lacking clinical evidence). The DRUGDEX
system is described in detail in Section 1 of Chapter 2.
First, the list of all FDA-approved indications provided in the drug’s package inserts was
compared with the FDA-approved indication listed by DRUGDEX. Conditions that matched
with the indications stated in the drug’s package insert and confirmed by DRUGDEX were
identified as on-label (ONS). Discrepancies existing between the two sources were resolved by
consulting with the clinical expert, Dr. Donald F. Brophy, Pharm.D., M.Sc., FCCP, FASN,
BCPS. ICD-9-CM diagnoses codes, ICD-9-CM procedures codes, and certain use of
medications related to the conditions were used to identify patients with ONS conditions. The
ONS conditions for epoetin alfa and darbepoetin alfa included anemia of chronic kidney disease,
chemotherapy-induced anemia, zidovudine-induced anemia, and an indication of a patient
undergoing a major, non-cardiovascular surgery that may result in loss of significant amount of
blood.
The categorization of a specific off-label indication using the strength of evidence, level
of recommendation, and treatment effectiveness provided by DRUGDEX were proposed by
Walton et al. 189 In their study, off-label use was categorized into three groups: evidence-based
off-label use, uncertain evidence for off-label use, and inadequate evidence for off-label use.
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However, to avoid classifying off-label as uncertain, we categorized off-label use into two
groups: supported and unsupported, as suggested by other off-label studies.15, 190 A use of a drug
for a condition was off-label supported (OFS) if its use in such condition was recommended by
the compendium (Class I-IIb) and/or supported by published clinical evidence (Category A, B).
On the other hand, the use was classified as off-label unsupported (OFU) if it was for a condition
not recommended by DRUGDEX (Class III or In-determinant) and minimal evidence regarding
such use was present (Category C or No evidence).56 An indication receiving an efficacy rating
of “effective” and “evidence favors efficacy” was classified as off-label supported use while that
with “inconclusive evidence” and “ineffective” was labeled off-label unsupported.56 Should
conflicts between these three drug evaluation dimensions arise; a conservative approach was
taken; an indication was categorized into the group that the least favorable level of evidence
indicates. For example, if a use falls under Class IIb, Category C, with an evidence that favors
efficacy, it was classified as off-label unsupported, not off-label supported, based on its strength
of evidence (Category C).
In a similar fashion to ONS, ICD-9-CM diagnoses codes, ICD-9-CM procedures codes,
and certain use of medications related to the conditions were use to identify visits of a patient
with OFS conditions. Examples of OFS conditions for ESAs were non-chronic kidney diseases,
anemia due to adverse effect of ribavirin and interferon alfa in hepatitis C patients, congestive
heart failure, and rheumatoid arthritis.
Listed OFU use included treatment of anemia in cancer patients not undergoing
concurrent chemotherapy, anemia in traumatic patients, porphyria cutanea tarda, and sickle cell
anemia. Additional unsupported off-label uses of ESAs were identified from the published offlabel literature.15 Examples of such use included the treatment of anemia of chronic diseases,
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hemorrhage, and cardiac surgery. The algorithmic categorization used in this study is described
in Figure 3.1 and complete list of ICD-9-CM diagnoses/procedure codes and drug orders used to
identify the ONS, OFS, and OFU cohorts can be found in Table A.1, A.2, and A.3, respectively.

Does the condition match any of the indications listed in package inserts?
NO

Off-label use

Is there a strong evidence supporting such use?
YES

YES
On-label use (ONS)
Appropriate Use

- Class I, IIa, or IIb
- Category A or B
- Effective or Evidence
favors efficacy
Off-label use, supported (OFS)
Appropriate Use

NO
- Class III or In-determinant
- Category C or No evidence
- Evidence inconclusive or
Ineffective
Off-label use, unsupported (OFU)
Potentially Inappropriate Use

Figure 3.1 Schematic algorithm of categorizing ESA use

Despite the fact that darbepoetin alfa was only approved for the treatment of chronic
kidney disease and chemotherapy-induced anemia, hospitals may choose to include solely
darbepoetin alfa in their formulary and the drug can be used solely in place of epoetin alfa be
used on-label and off-label. As a result, this study did not distinguish the two erythropoietins for
on-label or off-label indications.
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Table 3.1 ICD-9-CM procedures and diagnoses codes used to identify on-label use of ESAs
Therapeutic use of
epoetin alfa

1. Anemia of
chronic renal failure

2. Anemia due to
chemotherapy in
patients with
metastatic, nonmyeloid
malignancies

3. Anemia due to

Selection criteria
ICD-9-CM descriptions
(ICD-9-CM diagnoses &
procedure codes and drug
use)
On-label indications (ONS)
285.21
Anemia in chronic kidney disease
585
Chronic kidney disease (CKD)
403
Hypertensive kidney disease
404
Hypertensive heart and kidney disease
753.0
Congenital anomalies of urinary system - Renal
agenesis and dysgenesis
753.3
Other specified anomalies of kidney
996.73
Other complications of internal (biological)
(synthetic) prosthetic device, implant, and graft Due to renal dialysis device, implant, and graft
996.81
Complications of kidney transplant
V42
Kidney transplant
V45.1
Renal dialysis status
V45.73
Acquired absence of kidney
V56.0
Aftercare involving extracorporeal dialysis
V56.1
Fitting and adjustment of extracorporeal dialysis
catheter
V56.2
Fitting and adjustment of peritoneal dialysis
catheter
V56.3
Encounter for adequacy testing for hemodialysis
or peritoneal dialysis
V 56.8
Aftercare involving other dialysis
38.95
Venous catheterization for renal dialysis
39.27
Ateriovenostomy for renal dialysis
39.95
Hemodialysis
54.98
Peritoneal dialysis
285.22 combined with any of Anemia in neoplastic disease
the following codes or
chemotherapeutic agents
(see chemotherapeutic
agents list)
V58.1
Encounter for antineoplastic chemotherapy and
immunotherapy
E933.1
Antineoplastic and immunosuppressive drugs
causing adverse effects in therapeutic use
V66.2
Convalescence following chemotherapy
V67.2
Follow-up examination following chemotherapy
00.10
Implantation Of Chemotherapeutic Agent
99.25
Injection Or Infusion Of Cancer
Chemotherapeutic Substance
042
Human immunodeficiency virus (HIV) disease
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zidovudine adverse
reaction

4. Prophylaxis of
blood transfusion
before and during
surgical procedure

Any order of zidovudine

Zidovudine, abacavir/lamivudine/zidovudine, or
lamivudine-zidovudine
E931.7
Antiviral drugs causing adverse effects in
therapeutic use
Any of the following V codes or major surgical procedure codes (see Table X in
Appendix) with codes for injury, cardiac dx/surgeries, or procedural bleeding (see
lists of injury diagnoses and procedural bleeding codes in Table 3.3)
V54.0
V54.9
V58.4
V58.7
V66.0

Aftercare involving internal fixation device
Unspecified orthopedic aftercare
Other aftercare following surgery
Aftercare following surgery to specified body
systems not elsewhere classified
Convalescence following surgery

Generic names of chemotherapy agents used as inclusion criteria of on-label use of ESAs
were specified below:
Arsenic trioxide, azacitidine, bleomycin, busulfan, capecitabine, carboplatin, carmustine,
cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin,
daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil,
gemcitabine, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan,
mercaptopurine, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel,
pemetrexed, procarbazine, streptozocin, teniposide, thioguanine, thitepa, topotecan,
vinblastine, vincristine, and vinorelbine191
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Table 3.2 ICD-9-CM procedures and diagnoses codes used to identify off-label supported use of ESAs
Therapeutic use of
epoetin alfa

1. Non-chronic
kidney disease

2. Anemia in patients
with hepatitis C
being treated with a
combination of
ribavirin and
interferon alfa or
ribavirin and
peginterferon alfa
3. Anemia due to
congestive heart
failure
4. Anemia due to
radiation

Selection criteria
ICD-9-CM descriptions
(ICD-9-CM diagnoses &
procedure codes and drug
use)
Off-label Supported indications (OFS)
581
Nephrotic syndrome
582
Chronic glomerulonephritis
583
Nephritis and nephropathy not specified as acute
or chronic
584
Acute kidney failure
586
Renal failure unspecified
587
Renal sclerosis unspecified
588.89
Other specified disorders resulting from impaired
renal function
593.0
Nephroptosis
593.1
Hypertrophy of kidney
593.2
Cyst of kidney acquired
593.6
Postural proteinuria
593.8
Other specified disorders of kidney and ureter
593.9
Unspecified disorder of kidney and ureter
753.1
Cystic kidney disease
794.4
Nonspecific abnormal results of function study of
kidney
070.41
Acute hepatitis c with hepatic coma
070.44
Chronic hepatitis c with hepatic coma
070.51
Acute hepatitis c without hepatic coma
070.54
Chronic hepatitis c without hepatic coma
070.70
Unspecified viral hepatitis c without hepatic coma
070.71
Unspecified viral hepatitis c with hepatic coma
Any order of ribavirin and
interferon alfa-2a, interferon alfa-2b, interferon
interferon alfa
alfacon-1, interferon alfa-n1, interferon alfa-n3,
interferon alfa-2b-ribavirin, or ribavirin
398.91
Rheumatic heart failure (congestive)
402.91
Unspecified hypertensive heart disease with
heart failure
428
Heart failure
V58.0
Encounter for radiotherapy
V66.1
Convalescence following radiotherapy
V67.1
Follow-up examination following radiotherapy
990
Effects of radiation unspecified
E879.2
Radiological procedure and radiotherapy as the
cause of abnormal reaction of patient or of later
complication without misadventure at time of
procedure
E926.3
Exposure to x-rays and other electromagnetic
ionizing radiation
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5. Anemia during
the puerperium

E926.5
92.2
641

238.72

Exposure to radioactive isotopes
Therapeutic Radiology And Nuclear Medicine
Antepartum hemorrhage abruptio placentae and
placenta previa
Other complications of pregnancy not elsewhere
classified
Other current conditions in the mother classifiable
elsewhere but complicating pregnancy childbirth
or the puerperium
Trauma to perineum and vulva during delivery
Postpartum hemorrhage
Other and unspecified complications of the
puerperium not elsewhere classified
Late effect of complication of pregnancy childbirth
the puerperium
Forceps, Vacuum, And Breech Delivery
Other Procedures Inducing Or Assisting Delivery
Cesarean Section And Removal Of Fetus
Other Obstetric Operations
Multiple myeloma and immunoproliferative
neoplasms
Low grade myelodysplastic syndrome lesions

238.73
238.74
238.75
238.76

High grade myelodysplastic syndrome lesions
Myelodysplastic syndrome with 5q deletion
Myelodysplastic syndrome, unspecified
Myelofibrosis with myeloid metaplasia

289.83
714

Myelofibrosis
Rheumatoid arthritis and other inflammatory
polyarthropathies
Other thalassemia

646
648

664
666
674
677

6. Anemia due to
multiple myeloma
7. Anemia due to
myelodysplastic
syndrome

8. Anemia due to
myelofibrosis
9. Anemia due to
rheumatoid arthritis
10. Beta
Thalassemia
11. Blood unit
collection for
autotransfusion

72
73
74
75
203.0

282.49

99.02

Transfusion of previously collected autologous
Blood
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Table 3.3 ICD-9-CM procedures and diagnoses codes used to identify documented off-label unsupported
use of ESAs
Therapeutic use of
epoetin alfa

1. Cancer with no
indication of
chemotherapy
2. Anemia of chronic
disease

3. Hemorrhage

Selection criteria
ICD-9-CM descriptions
(ICD-9-CM diagnoses &
procedure codes and
drug use)
Known Off-label Unsupported Indications (OFU Known)
285.22
Anemia in neoplastic disease
141-239
Various types of neoplasm
V10
Personal history of malignant neoplasm
280
Iron deficiency anemias
281
Other deficiency anemias
282
Hereditary hemolytic anemias
283
Acquired hemolytic anemias
284
Aplastic anemia
285
Other and unspecified anemias
286
Coagulation defects
287
Purpura and other hemorrhagic conditions
289
Other diseases of blood and blood-forming
organs
430
Other diseases of blood and blood-forming
organs
431
Intracerebral hemorrhage
432
Other and unspecified intracranial hemorrhage
456.20
Esophageal varices in diseases classified
elsewhere with bleeding (bleeding)
455.2
Internal hemorrhoids with other complication
455.5
External hemorrhoids with other complication
(bleeding)
455.8
Unspecified hemorrhoids with other
complication (bleeding)
459
Other disorders of circulatory system
511.8
Other specified forms of pleural effusion
except tuberculous
530.21
Ulcer of esophagus with bleeding
530.82
Esophageal hemorrhage
530.0
Acute gastric ulcer with hemorrhage
531.1
Acute gastric ulcer with perforation
531.2
Acute gastric ulcer with hemorrhage and
perforation
531.4
Chronic or unspecified gastric ulcer with
hemorrhage
531.5
Chronic or unspecified gastric ulcer with
perforation
531.6
Chronic or unspecified gastric ulcer with
hemorrhage and perforation
532.1
Acute duodenal ulcer with perforation
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532.4
532.5
532.6
533.4

534.4
534.9
535.01
535.11
535.41
535.51
535.61
535.71
537.83
537.84
562.12
562.13
568.81
569.3
569.85
569.86
578
635.11

640.03
729.92
784.7
786.3
790.92
998.11
998.12
E870.0
28.7
44.4

Chronic or unspecified duodenal ulcer with
hemorrhage
Chronic or unspecified duodenal ulcer with
perforation
Chronic or unspecified duodenal ulcer with
hemorrhage and perforation
Chronic or unspecified peptic ulcer of
unspecified site with hemorrhage without
obstruction
Chronic or unspecified gastrojejunal ulcer with
hemorrhage
Gastrojejunal ulcer unspecified as acute or
chronic without hemorrhage or perforation
Acute gastritis with hemorrhage
Atrophic gastritis with hemorrhage
Other specified gastritis with hemorrhage
Unspecified gastritis and gastroduodenitis with
hemorrhage
Duodenitis with hemorrhage
Eosinophilic gastritis with hemorrhage
Angiodysplasia of stomach and duodenum
with hemorrhage
Dieulafoy lesion (hemorrhagic) of stomach and
duodenum
Diverticulosis of colon with hemorrhage
Diverticulitis of colon with hemorrhage
Hemoperitoneum (nontraumatic)
Hemorrhage of rectum and anus
Angiodysplasia of intestine with hemorrhage
Dieulafoy lesion (hemorrhagic) of intestine
Gastrointestinal hemorrhage
Legally induced abortion incomplete
complicated by delayed or excessive
hemorrhage
Threatened abortion antepartum
Nontraumatic hematoma of soft tissue
Epistaxis
Hemoptysis
Abnormal coagulation profile
Hemorrhage complicating a procedure
Hematoma complicating a procedure
Accidental cut puncture perforation or
hemorrhage during surgical operation
Control Of Hemorrhage After Tonsillectomy
And Adenoidectomy
Control Of Hemorrhage And Suture Of Ulcer
Of Stomach Or Duodenum
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49.95
57.93
60.94
4. Cardiac surgery

5. Acute use in critical
care/injury/trauma/fracture

V72.81
00.4
00.5
00.6
17.5
35
36
37
38
39
733.1
733.8
733.93-733.98
800-829
850-854
860-869
870-879
880-887
890-897
900-904
905-909

6. Other known off-label
use

910-919
920-924
925-929
958
959
E887
V54.1
V54.2
16.89
277.1
282.6
410
411
412
555
556
607.84
99.0

Control Of (Postoperative) Hemorrhage Of
Anus
Control Of (Postoperative) Hemorrhage Of
Bladder
Control Of (Postoperative) Hemorrhage Of
Prostate
Pre-operative cardiovascular examination
Adjunct Vascular System Procedures
Other Cardiovascular Procedures
Procedures On Blood Vessels
Additional Cardiovascular Procedures
Operations On Valves And Septa Of Heart
Operations On Vessels Of Heart
Other Operations On Heart And Pericardium
Incision, Excision, And Occlusion Of Vessels
Other Operations On Vessels
Pathologic fracture
Malunion and nonunion of fracture
Stress fracture of bones (various sites)
Fracture (various sites)
Intracranial Injury, Excluding Those With Skull
Fracture
Internal Injury Of Chest, Abdomen, And Pelvis
Open Wound Of Head, Neck, And Trunk
Open Wound Of Upper Limb
Open Wound Of Lower Limb
Injury To Blood Vessels
Late Effects Of Injuries, Poisonings, Toxic
Effects, And Other External Causes
Superficial Injury
Contusion With Intact Skin Surface
Crushing Injury
Certain early complications of trauma
Injury other and unspecified
Fracture cause unspecified
Aftercare for healing traumatic fracture
Aftercare for healing pathologic fracture
Anemia in porphyria cutanea tarda
Sickle-cell disease
Acute myocardial infarction
Other acute and subacute forms of ischemic
heart disease
Old myocardial infarction
Regional enteritis
Ulcerative enterocolitis
Sexual dysfunction
Blood transfusion
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Table 3.4 ICD-9-CM procedures codes of major surgeries used to identify on-label use of ESAs
Therapeutic use of epoetin alfa
Prophylaxis of blood transfusion
before and during surgical
procedure*

ICD-9-CM procedure

ICD-9-CM descriptions

00.7

Other Hip Procedures

00.8

Other Knee Procedures

01-05

Operations On The Nervous System

06-07

Operations On The Endocrine System

30-34

Operations On The Respiratory System

40-41

Operations On The Hemic And Lymphatic
System

42-54

Operations On The Digestive System

55-59

Operations On The Urinary System

60-64

Operations On The Male Genital Organs

65-71

Operations On The Female Genital Organs

72-75

Obstetrical Procedures

76-84

Operations On The Musculoskeletal
System

85-86

Operations On The Integumentary System

*Codes related to diagnostic procedures were not included
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Variable Measurements for Inferential Statistics

Independent variables
Independent variables of the multivariable regression models assessing the impact of
safety interventions on ESA prescribing patterns were the three events of the safety
interventions. During the six years period, five types of interventions had occurred, namely the
issuance of a public health advisory (November 2006), Dear Health Care Professional Letter
(January 2007), FDA black box warning (March 2007), reimbursement restriction (July 2007 and
April 2008), and REMS (March 2010). Interventions that occurred very close to one another
were consolidated because time-series study design suggested at least 10-12 time points between
each segment to accurately assess seasonality and trend impact. 192 As a result of event
consolidation, three specific events were chosen to represent interventions at three time points.
These events were the addition of black box warning in March 2007; the official implementation
of NCD in April 2008; and the implementation of REMS in March 2010. In the first period
between January 2005 and April 2008, three events had occurred: the issuance of the first public
health advisory (November 2006), Dear Health Care Professional Letter (January 2007), labeling
revision to include a black box warning (March 2007), and the announcement of NCD effective
(July 2007). The addition of a black box warning was chosen as a main intervention during this
nine months period. Black box warning was chosen over a public health advisory because we
believe that black box warning was more publicized and would have a more prominent effect on
ESA utilization than an advisory. We did not choose July 2007, the month which NCD first was
announced effective as the first intervention because the change in reimbursement policy was not
directly applicable to the inpatient setting and should have little effect in our sample. Moreover,
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little effect of the NCD during this period was anticipated because the announcement was only
made public in the CMS website and without any press release.
The second period of this analysis was between April 2008 and March 2010. During this
period, two events occurred: the official implementation of NCD on April 7, 2008 and the
revision of the black box warning on March 14, 2008. The official implementation of NCD was
chosen as a main event in this period because we believed that the official implementation of the
reimbursement restriction would have created a greater impact of the level of drug use, compared
to a revision of a black box warning already in place.
The third and final period of the analysis lasted between March 2010 and June 2011. The
implementation of REMS in March 2010 was the only event considered significant enough to
influence ESA prescribing.
Table 3.5 Independent variables for Specific Aim 2 and 3
Event
First Intervention
Public health advisory
Dear Healthcare Provider letter
Black box warning
National Coverage Determination announced effective
Black box warning update
Second Intervention
Black box warning update
National Coverage Determination Implemented
Third Intervention
REMS initial approval
REMS Implementation

Time period
November 2006
January 2007
March, 2007
July 2007
November 2007
March 2008
April 2008
February 2010
March 2010

*Bolded event and time period indicate the event and time of the intervention used in this study
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Dependent variables
Specific Aim 2
Monthly aggregated proportions of visits with ESA use for on-label, off-label supported,
and off-label unsupported indications were dependent variables for the time-series analysis.
Definitions for ONS, OFS, and OFU proportions used as dependent variables were provided
below.
1. On-label proportion
The proportion of encounters which ESAs were prescribed for on-label indications was
defined as the number of encounters with diagnoses codes that matched with on-label indications
for ESA use and had one order of ESAs (A), divided by the total number of encounters with
those diagnoses codes (1), in a given time period.
2. Off-label supported proportion
The proportion of encounters being prescribed ESAs for the off-label supported
indication was defined as the number of encounters with diagnoses codes that matched with onlabel indications for ESA use and had one order of ESAs (B), divided by the total number of
encounters with those diagnoses codes (2), in a given time period.
3. Off-label unsupported proportion
Since the total number of eligible encounters for ESA off-label unsupported indications
could not feasibly be obtained from the database, the proportion of visits with ESAs prescribed
for the off-label unsupported indication was calculated by dividing the number of encounters
with ESAs, but did not have diagnoses codes that matched with on-label or off-label supported
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indications of ESA use (C) + (D) by the total number of encounters with known OFU (3), in a
given time period.

12

36

Encounters with
ONS diagnoses

5C
A
1
Encounters with
ONS diagnoses
& ESA

Encounters with
known OFU
diagnoses

Encounters
with OFU
diagnoses &
ESA

D
7

Encounters with OFS
diagnoses & ESA

3B

Unidentif ied OFU
use of ESAs

2
4
Encounters with
OFS diagnoses

All ESA encounters 2005-2011

Figure 3.2 Proportion of ESA use as dependent variables for Specific Aim 2
ONS: On-label supported indications, OFS: Off-label supported indications, OFU: Off-label unsupported
indications.

First, all inpatient visits of patients aged 18 and above who had at least one record of
ESAs (epoetin alfa or darbepoetin alfa) were identified in the database. Two separate cohorts of
epoetin alfa and darbepoetin alfa were formed. Each user’s diagnoses, procedures, and
medications records were searched to categorize use of ESAs into ONS, OFS, or OFU using the
algorithm shown in Figure 3.2. The number of visits which ESAs were for prescribed for ONS,
OFS, and OFU indications in a month was calculated as respective numerator cohorts.
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All ESA use in adult patients seen in the inpatient settings without missing information on ICD-9-CM codes

Do their diagnoses match any of the ONS indications?

NO
Do their diagnoses match any of the OFS indications?

YES

On-label use
(ONS) numerator cohort

NO

YES

Off-label use, supported
(OFS) numerator cohort

Off-label use, unsupported
(OFU) numerator cohort

Figure 3.3 Schematic algorithm defining numerator cohorts for Specific Aim 2

Next, the monthly number of admissions eligible for receiving ESAs was calculated as
denominator cohorts. All visits of adult patients admitted to the inpatient settings during the
study period with diagnoses, procedure codes, and drug use of interest were included in the
sample and categorized into the ONS, OFS, or OFU cohorts using a hierarchy categorization
approach. First, diagnoses, procedures, and medication records of all admissions were searched
for ONS indications, if none of their diagnoses matched the ONS indications, the same sets of
records were searched for OFS indications and OFU accordingly. If diagnoses did not match
ONS, OFS, or documented OFU indications, such encounters were excluded from this part of the
analysis. It is important to note that the OFU denominator cohort only included visits with
conditions known to be treated with ESAs off-label identified earlier in Table 3.3. This approach
of using documented OFU conditions was taken because it was almost impossible to identify
encounters with all possible off-label unsupported use of ESAs. Examples of documented OFU
indications used in this study included its use in anemia of neoplastic disease not due to
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chemotherapy, anemia due to trauma, bleeding, and other chronic anemia. Categorization of
denominator cohorts followed the algorithm is shown in Figure 3.4.
All adult patients seen in the inpatient settings with complete information on DX/procedures/drugs

Do their diagnoses match any of the ONS indications?
NO
Do their diagnoses match any of the OFS indications?

YES

Do their diagnoses match any of the documented OFU indications?
YES

On-label use (ONS)
denominator cohort

Off-label use, supported
(OFS) denominator cohort

YES

Documented Off-label use,
unsupported (OFU)
denominator cohort

NO

Excluded

Figure 3.4 Schematic algorithm defining denominator cohorts for Specific Aim 2
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Specific Aim 3
Dependent variable was ESA use, defined as whether or not an eligible patient received
ESAs in a given month.
To assess the impact of the intervention on ESA prescribing patterns for the on-label,
off-label supported, and off-label unsupported indications, three population proportions which
were used as dependent variables were identified as following.
1. On-label: Proportion of patients with on-label conditions that were prescribed ESAs.
2. Off-label supported use: Proportion of patients with off-label supported conditions
that were prescribed ESAs.
3. Off-label unsupported use: Proportion of patients with off-label unsupported
conditions that were prescribed ESAs.
Similar steps were taken to identify the three cohorts: ONS, OFS, and documented OFU.
Once the three cohorts were identified, drug records of these eligible patients were searched to
determine if ESAs (epoetin alfa or darbepoetin alfa) were prescribed during a hospital stay. If a
record of ESAs was found, that patient was classified as a user (ESA use = 1). Without a record
of ESAs, that patient was a non-user (ESA use = 0). Schematic algorithm used to identify
patient cohorts for the analysis is shown in Figure 3.5.
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All adult patients seen in the inpatient settings without missing information on drug records

Do their diagnoses match any of the ONS indications?
NO

Do their diagnoses match any of the OFS indications?

YES

Do their diagnoses match any of the documented OFU indications?
YES
YES

On-label use
(ONS) Cohort

ESA = 1:
Received ESAs
ESA = 0:
Did not receive ESAs

Off-label use, supported
(OFS) Cohort

ESA = 1:
Received ESAs
ESA = 0:
Did not receive ESAs

Documented
Off-label use, unsupported
(OFU) Cohort

NO

Excluded

ESA = 1:
Received ESAs
ESA = 0:
Did not receive ESAs

Figure 3.5 Schematic algorithm selecting study sample for Specific Aim 3
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Covariates
Covariates included in the multivariable model used in Specific Aim 3 were patient
demographics of age, gender, and race; primary payer of the hospital services; patient clinical
conditions described by the proxies of admission type, discharge disposition, length of stay,
Combined Comorbidity Index; hospital characteristics including teaching status, bed size, and
geographic region, and physician specialty classified as specialist and non-specialist. We did not
differentiate between the rural and urban status because very few hospitals in our sample were
identified as rural hospitals. Due to small number of patients in the ‘other’ group of the
admission type and discharge disposition, the other ‘group’ was combined with ‘missing’ group
to obtain reliable estimates. Relevant studies identifying the aforementioned covariates as
predictors of drug use were described in detail under Section 3 of Chapter 2. Table 3.6 describes
the categorization of covariates used in the analytical models.
Table 3.6 Categorization of Covariates used in Specific Aim 3
Variable
Patient Characteristics
Demographics
Age

Variable Name

Description

age_in_years regrouped to
age_cat

18-30 = 1
31-50 = 6
51-64 = 2
65-74 = 3
75-84 = 4
85 and above = 5
Missing = 0
African American = 1
Other = 2
Caucasian = 3
Female = 0
Male = 1

Race

race regrouped to race_cat

Gender

Gender recoded to gender_cat

Clinical Conditions
Admission type

admission_type_code
regrouped to admission_ cat

Missing/Other = 0
Urgent = 1
Elective = 2
Emergency = 3
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Charlson Comorbidity Index
Length of Stay

cci
hos_los

Discharge status

discharge_disposition_key
regrouped to discharge_cat

Payer Type
Source of Payment

Hospital Characteristics
Geographic region

Bed size

Teaching status

Calculated from ICD-9-CM codes
Continuous, number of days from
admission date to discharge date
Missing/Other = 0
Expired = 1
Discharged to Hospice = 2
Discharged/transferred to
institutionalized care = 3
Discharged/transferred to
noninstitutionalized care = 4
Discharged to home/self care = 5

payer_id regrouped to payer_
cat

Missing = 0
Medicaid = 1
Commercial/Private/HMO
Managed Care = 2
Self-pay = 3
Other = 4
Medicare = 5

census_region regrouped to
region_cat

Midwest = 1
South = 2
West = 3
Northeast = 4
≤ 99 = 1
100-199 = 2
200-299 = 5
300-499 = 3
≥500 = 4
Teaching = 0
Non-teaching = 1

bed_size_range recoded to
bed_cat

teaching_facility_ind recoded to
teaching
Physician and Care Characteristics
Physician Specialty
medical_specialty regrouped to
medical_specialty_cat

Missing = 0
Specialist = 1
Non-specialist = 2

*Bolding indicates reference group. Reference group was coded into the last order for convenience
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Data Integration

Encounter information was captured in four main SAS datasets including patient,
diagnoses, procedure, and medication files containing patient demographic information, ICD-9CM codes, procedure codes, and medications used, respectively. Specific information including
dosing unit, diagnoses type, care setting, admission type, physician specialty, payer, and hospital
information are also provided in separate SAS files. Two master datasets were built by
integrating the files using the selection criteria specified above. The first dataset was used for
descriptive analysis of ESA users (patient level) and as numerator cohorts for aggregated timeseries analysis (visit level). The second dataset was used for the patient level analysis of the
impacts of safety interventions (Aim 3).
Descriptive analysis of ESA users and numerator cohorts for aggregated time-series analysis
Encounters with any order of epoetin alfa or darbepoetin alfa were first identified in the
medication dataset. This medication dataset contained medication information like generic
name, medication entered date, started date, and stopped date, care setting where medications
were ordered and dispensed, dose quantity, frequency, and route of administration. Visits which
ESAs were prescribed were linked to the two datasets containing diagnoses and procedure
information, and encounters file which comprised of patient’s age, admitted and discharged
dates, patient type, admission source, discharge disposition, primary payer information, patient
ID, and hospital ID. Only encounters of adult patients (18 years and above) admitted and
received medication on January 1, 2005 onward were retained in the sample. Lastly, the file was
merged with hospital and patient dataset for hospital and patient demographic information. For
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the patient level analysis (descriptive analyses), in such case that the same patients had more than
one encounter with the health system, only the first records were used in the study.
Outpatient encounters (hospital outpatient department, day surgical services, clinic,
dialysis centers, laboratory, and emergency department and observational units) constituted
22.0% of our overall sample. Visits to outpatient settings, institution, nursing home, and home
health services were excluded. The final inpatient cohort of 86,763 patients consisted of patients
who were admitted to a hospital (inpatient), pre-admitted patient, patients in an obstetrics
department, hospice, and skilled nursing facility (SNF). Hospice and SNF patients were
included in the inpatient group because of similarity in insurance reimbursement toward the
services (covered by Medicare Part A). The details of ESA use in each patient type reported in
Cerner database are shown in Table 3.6 and 3.7.
The integrated data contained information of 111,363 encounters (86,763 unique patients)
with at least one order of ESAs during their visit to the health system. Of these 111,363
encounters, 83,876 received epoetin alfa only (75.3%); 26,772 received darbepoetin alfa only
(24.0%); and 715 (0.64%) received both epoetin alfa and darbepoetin alfa during that single visit.
These encounters translated into 66,121 patients with epoetin alfa only (76.2%); 20,088 patients
with darbepoetin alfa only (23.2%); and 554 patients with both use of epoetin alfa and
darbepoetin alfa (0.6%)). Data integration steps used to identify ESA users (for descriptive
analysis numerator in Specific Aim 2a) are described in Figure 3.6.

94

Table 3.7 ESA inpatient users (encounter level) identified in Cerner database
Care settings
Any ESAs
Inpatient
Hospice
Inpatient
Obstetrics
Preadmit
Skilled Nursing Facility
Total (row %)

7 (0.01)
110,880 (99.57)
2 (0.00)
121 (0.11)
353 (0.32)
111,363 (100.00)

N Encounters (column %)
Epo
Darbe
5 (0.01)
83,441 (99.48)
2 (0.00)
101 (0.12)
327 (0.39)
83,876 (75.32)

2 (0.01)
26,731 (99.85)
0 (0.00)
19 (0.07)
20 (0.07)
26,772 (24.04)

Epo & Darbe
0 (0.00)
708 (99.02)
0 (0.00)
1 (0.00)
6 (0.84)
715 (0.64)

Table 3.8 ESA inpatient users (patient level) identified in Cerner database
Care settings
Any ESAs
Inpatient
Hospice
Inpatient
Obstetrics
Preadmit
Skilled Nursing Facility
Total (row %)

5 (0.01)
86,429 (99.62)
3 (0.00)
82 (0.09)
244 (0.28)
86,763 (100.00)

N Patient (column %)
Epo
Darbe
3 (0.01)
65,825 (99.55)
3 (0.00)
65 (0.10)
225 (0.34)
66,121 (76.21)

2 (0.01)
20,056 (99.84)
0 (0.00)
16 (0.08)
14 (0.07)
20,088 (23.15)

Epo & Darbe
0 (0.00)
548 (98.92)
0 (0.00)
1 (0.00)
5 (0.90)
554 (0.64)
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Encounter file

Medication file

Diagnosis file

Procedure file

Adult encounters admitted after Jan 05. Contains
admitted/discharged dates, age, and variables that can
be linked to information on hospital type, patient type,
admission type, discharge disposition, and payers

Encounters with at least one medication order
given after Jan 05. Contains medication
start/enter/stop dates, generic names, and
variables that can be linked to ordering
physicians, care setting where medications were
requested

Contains variables that can be linked
to ICD-9-CM diagnoses codes

Contains variables that can be linked
to ICD-9-CM procedures codes

-Diagnosis lookup file contains
information on ICD-9-CM
diagnosis codes, description, and
diagnosis priority

- Procedure lookup file
contains information on ICD-9CM procedure codes and
description

- Hospital lookup file contains information on
census region, bed size, teaching status,
urban status, and hospital type status
- Patient type lookup file
- Admission type lookup file
- Discharge disposition lookup file

- Care setting lookup file
- Physician lookup file contains medical
specialty information of physicians

Encounters of adult patients admitted (Jan 05- Jun 11) with at least one order of epoetin alfa or
darbepoetin alfa given between Jan 05 and Jun 11, with diagnosis and encounter information

Excluded encounters to the outpatient settings
N encounters = 111,363
N patients = 86,763
Unique encounters /patients of adult patients admitted (Jan 05- Jun 11) to the
inpatient settings with at least one order of epoetin alfa or darbepoetin alfa
given between Jan 05 and Jun 11, with diagnosis and encounter information

ONS

OFS

OFU

N encounters = 55,482
N patients = 42,218

N encounters = 8,958
N patients = 7,477

N encounters = 46,923
N patients = 37,068

1

Excluded Epoetin alfa
AND
Darbepoetin alfa users

*Using approved indications for epoetin alfa

Epoetin alfa users only

Darbepoetin alfa users only

N = 83,876 encounters
N = 66,121 patients

N = 26,772 encounters
N = 20,088 patients

N encounters = 715
N patients = 554

Epo - ONS

Epo - OFS

Epo - OFU

Darb - ONS

Darb - OFS

Darb - OFU

N encounters = 40,449
N patients = 31,333

N encounters = 6,901
N patients = 5,834

N encounters = 36,526
N patients= 28,954

N encounters = 14,650
N patients = 10,598

N encounters = 1,981
N patients =1,586

N encounters = 10,141
N patients =7,904

2

3

*Using approved indications for epoetin alfa

Descriptive analysis of Epo/Darb users (patient level) (Aim 1) and numerator cohorts (visit level) for aggregated time series (Aim 2) analyses

Figure 3.6 Data integration step of ESA users
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Denominator cohorts for aggregated time-series analysis (Aim 2) and Specific Aim 3
The denominator cohort for Specific Aim 2 and analytic cohort for Specific Aim3
consisted of any visits (or patients – Aim 3) with diagnoses of interest (See Table 3.1-3.4). For
consistency, we identified only visits from same hospitals as the ESA users that contributed
medication records into Cerner database. The dataset included inpatient visits (inpatient, preadmitted, obstetrics, hospice, and skilled nursing facility (SNF) encounters) in 128 unique
hospitals. The initial cohort included a total of 2,170,654 unique visits (1,815,028 patients) with
at least one condition specified as ONS, OFS, or documented OFU.
Of 2,170,654 encounters (1,815,028 patients), 912,141 encounters (750,321 patients) had
diagnoses that made them eligible for ESA approved treatments. These visits (or patients) were
classified as ONS cohort. 595,193 encounters (505,694 patients) had OFS diagnoses (OFS
cohort), and 663,320 encounters (559,031 patients) had documented OFU diagnoses (OFU
cohort). Data integration steps adopted in identifying all eligible cohorts for Specific Aim 2 and
3 are shown in Figure 3.7.
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Encounter file

Medication file

Diagnosis file

Procedure file

Adult encounters admitted after Jan 05.
Contains admitted/discharged dates, age, and
variables that can be linked to information on
hospital type, patient type, admission type,
discharge disposition, and payers

Encounters with at least order of
chemotherapeutic agents, HIV zidovudine,
hepatitis C ribavirin/interferon alfa
medications, which were given after Jan 05..
Contains medication start/enter/stop dates,
generic names, and variables that can be
linked to ordering physicians, care setting
where medications were requested

Encounters with ONS, OFS,
and documented OFU
diagnoses codes predefined
for ESA use.
Contains variables that can
be linked to ICD-9-CM
diagnoses codes

Encounters with ONS, OFS,
and documented OFU
procedure codes predefined
for ESA use.
Contains variables that can
be linked to ICD-9-CM
procedures codes

- Hospital lookup file contains
information on census region, bed size,
teaching status, urban status, and
hospital type status
- Patient type lookup file
- Admission type lookup file
- Discharge disposition lookup file

- Care setting lookup file
- Physician lookup file contains medical
specialty information of physicians

-Diagnosis lookup file
contains information on
ICD-9-CM diagnosis
codes, description, and
diagnosis priority

- Procedure lookup file
contains information on
ICD-9-CM procedure
codes and description

N Encounters = 2,170,654
N Patients = 1,815,028
Unique encounters of adult patients admitted (Jan 05- Jun 11)
with any predefined dx/proc/meds between Jan 05 and Jun 11

ONS

OFS

Documented OFU

N Encounters = 912,141
N Patients = 750,321

N Encounters = 595,193
N patients = 505,694

N Encounters = 663,320
N Patients = 559,013

Denominator cohorts for aggregated time series (Aim 2) and analytic cohort for Aim 3

Figure 3.7 Data integration steps of all eligible admissions

Patient Risk Adjustment
This study made use of a combined comorbidity score developed to appraise a patient’s
mortality risk based on his ICD-9-CM diagnoses codes193 to model patient’s clinical complexity.
The combined score of the Charlson Index with the Romano modification and van Walraven’s
adaptation of the Elixhauser system was developed by the Division of Pharmacoepidemiology
and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard
Medical School to improve upon existing scores in predicting 1-year mortality in older adults.
SAS codes we adapted to calculate validated combined comorbidity scores for this study were
provided by the developers.194 The use of the combined comorbidity score was justifiable in our
study as our population of users consisted largely of older adults. Since no specific
comorbidities were suggested by the literature as predictors of ESA prescribing, we did not
include specific cormobid conditions in the multivariable models but instead the combined
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comorbidity score to avoid multicollinearity between a set of comorbidities and comorbidity
score.

Statistical Analysis

To understand the prevalence of ESA therapy in patients admitted to Cerner hospitals,
descriptive analysis was performed. Patient demographics, clinical conditions, hospital
characteristics, and ordering physician specialties of patients receiving epoetin alfa or
darbepoetin alfa were aggregated over the study period of six and a half year and described with
means, standard deviations, and column percentages. The differences in these variables among
the two user groups were tested with chi-squares and t- statistics. Similarly, aggregated
characteristics of ONS, OFS, and OFU users were also tested with chi-squares and t- statistics.
The inferential analyses were based on two techniques: segmented regression modeling
for interrupted time-series (Aim 2), and generalized estimating equation (GEE) approach with
binary logistic regression technique (Aim 3a and 3b).
Segmented Times Series (Aim 2)
Segmented time series study design provided the strongest quasi-experimental approach
for investigating the longitudinal effect of the intervention. The lack of random assignment and
a control group accustomed in observational studies hindered the true estimation of an exposure
(intervention) on the outcomes. Internal validity of such study was therefore questionable
because systematic differences in observed and unobserved characteristics of the treatment and
non-treatment group were not accounted for. The time-series approach allowed for both visual
statistical assessment of how much the intervention affects the outcomes immediately and over
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time, transiently or permanently. The use of a control group was not necessarily with this study
design because each segment served as a control for the preceding segments. In this study,
monthly aggregate proportions of visits at which a patient received ESAs for a specific group of
indications (ONS, OFS, or OFU) were a unit of analysis. ONS proportion was defined as the
proportion of visits at which a patient was prescribed with ESAs for the indications approved by
the FDA (ONS), over the total number of visits at which a patients had clinical conditions
eligible for receiving ESAs on-label, the a given month. OFS and OFU proportions were
classified in a similar manner. Ordinary least square was chosen as the distribution of the data
was approximately continuous i.e. the data did not consists of a mass at the limits (zero and/or
one). First-differencing and suitable number of lags was included in the model to correct for
autocorrelation of each observation in the series and to obtain accurate standard errors of the
estimates.
Generalized Estimating Equations (Aim 3)
Previous studies identified hospital level differences in practices where patient’s
responses, though homogeneous within hospitals, may not be so across hospitals. In the
presence of clustered data and in the situation where consecutive observation was not
independent, the use of generalized estimating equations (GEE) approach was most appropriate.
Clustered GEE model improved inferences as accounting of correlation structure between
repeated observations provides unbiased and more efficient estimates of standard errors
compared to the falsely small standard errors in the un-clustering model.195, 196 In GEE,
correlation structure that adequately described the known or suspected correlations between
repeated observations was specified. The types of correlation structures commonly adopted
included exchangeable, autoregressive, dependent, independent and unstructured. The choice of
100

correlation structure relied on the nature of the data. This study specified an exchangeable
correlation structure as such type of correlation structure was the only one appropriate for
clustered data with no natural ordering of the subjects with the cluster.197
We chose binary logistic regression method as it allows for non-normal distribution of
the data. The binomial distribution and logit link function were specified to model with a
dichotomous outcome variable. An outcome variable in the binary logistic regression model is
defined as whether a patient with on-label, off-label supported, or off-label unsupported
conditions received ESAs in that given month. To obtain robust standard errors of the estimates,
we adjust for hospital level differences using hospital ID as a cluster variable.
A two-sided alpha of 0.05 is considered statistically significant for all analyses. SAS
(version 9.3 for Windows; SAS Institute, Cary, NC) and Stata (Stata 11; Stata Corp, College
Station, TX) was used for all analyses in this study.

Statistical Models

Specific Aim 2
To quantify the immediate and trend impact of the black box warning, NCD policy, and
REMS on the change in the proportion of visits which a patient was treated with ESAs, three
separate ordinary least square regressions for on-label, off-label supported, and off-label
unsupported ESA use were fit. Impacts of black box warning, NCD, and REMS on the level of
ESA use for the on-label and off-label indications were specified in the models shown below. A
set of month indicators was included in the model to adjust for monthly seasonality.
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Model 1: On-label (ONS)

YONSt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+
β7 intervention3 × t3 + M + et
Model 2: Off-label Supported (OFS)

YOFSt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+
β7 intervention3 × t3 + M + et
Model 3: Off-label Unsupported (OFU)

YOFUt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+
β7 intervention3 × t3 + M + et

Figure 3.8 Segmented regressions modeling interrupted time-series used in assessing the impact of the
interventions on ESA prescribing
YONSt : Proportion of ESA use among eligible visits
Coefficients: β0 Baseline proportion of ESA on-label use at t = 0; β1 Change in proportion of ESA on-label use (Yt) that occurs with
each month before the first intervention; β2 Level change in proportion of ESA on-label use immediately after the first intervention; β3
Change in the trend in proportion of ESA on-label use after the first intervention

Independent variables: intervention1 = Black Box Warning; intervention2 = National Coverage Determination; intervention3 = REMS

Time variable: t = number of month of the study period (1-78); t1 = number of month since the occurrence of the first intervention
(Mar 07) till the end of the study period (t1 =1-52); t2 = number of month since the occurrence of the second intervention (April 08)
(t1 = 1-39); t3 = number of month since the occurrence of the third intervention (Mar10) (t1 = 1- 16)

M: a set of month indicator variable to control for monthly seasonal effect;

A similar interpretation was applied for all three models. For the purpose of presentation
simplicity, only interpretation of Model 1 was given below.
In Specific Aim 2, YONSt was the monthly proportion of visits at which a patient was
prescribed with ESAs for on-label purposes over the total number of eligible visits in that month.
Variable t was a continuous variable indicating the number of month since the beginning of the
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study takes on values from 1 to 78. Intervention 1 was a dichotomous variable indicating the
issuance of black box warning; t1 equaled 0 for the months prior to that issuance and took the
values 1 to 51 indicating the numbers of months since issuance (March 2007; t1 = 1 in March
2007) to the end of the study period. Intervention 2 was a dichotomous variable indicating the
official implementation of NCD; t2 equaled 0 for the months prior to that when NCD was release
and took the values 1 to 39 indicating the numbers of months since the implementation (April
2008; t2 = 1 in April 2008) to end of the study period. Intervention 3 was a final dichotomous
variable marking the point in time when REMS was implemented; t3 takes a value of 0 for the
months prior to the third intervention and 1 through 15 indicating the numbers of months since
the implementation of REMS (March 2010; t3 = 1 in March 2010) until the end of the study
period.
The coefficients in the model can be interpreted as followed: β represents baseline
0

proportion of ESA use at t = 0; β was the change in proportion of ESA use (Yt) that occurred
1

with each month before the release of black box warning (Intervention 1); β level change in
2

proportion of ESA use immediately after the black box labeling change; β change in the trend in
3

the proportion of ESA use after black box warning. Similarly, β , and β represented level
4

6

change in the dependent variables immediately after the release of NCD (Intervention 2) and the
implementation of REMS (Intervention 3), respectively. Finally, β , and β represented changes
5

7

in the trend in the Y variables after the occurrence of each intervention, respectively.
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Specific Aim 3a and 3b
Three models using the same set of independent variables and covariates were fit
separately to determine the impacts of the interventions on the odds of an ESA being prescribed
to a patient with 1) on-label, 2) off-label supported, and 3) documented OFU conditions. Figure
3.3 specifies the models that were fit to examine the trend and immediate effects of the three
interventions on the odds of an ESA being prescribed to a patient.

Model 1: On-label (ONS)
Logit(ESA=1) = β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 +

β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et

Model 2: Off-label Supported (OFS)
Logit(ESA=1) = β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 +
β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et

Model 3: Documented Off-label Unsupported (Known OFU)
Logit(ESA=1) = β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 +
β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et
DEM = a vector of patient demographic variables; HEALTH = a vector of clinical conditions; HOS = hospital characteristics; PHYS =
physician specialty.

Figure 3.9 Models used to assess the impact of interventions on odds of being prescribed with ESAs for a
patient with on-label and off-label supported indications.

Again, since similar interpretation was applied for all three models. For the purpose of
presentation simplicity, only interpretation of Model 1 was given below.
In Model 1, logit (ESA=1) represented the odds of receiving ESAs in a patient with an
on-label conditions. All other independent variables were the same as specified under Specific
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Aim 1. DEM denotes a vector of patient demographic variables which included age (18-30, 3150, 51-60, 61-64, 65-74, 75-84, and 85 and above years old), gender (Male and Female), and
race (Caucasian, African-American, Hispanic, Other); Payer was specified as the primary payer
of the hospital services (Medicare, Medicaid, Private, Self-pay, and Other); HEALTH was a
vector of patient clinical conditions including admission status (Elective, Emergency, Urgent,
Other), length of stay, Comorbidity Index, and discharge status (Expired, Discharged to home,
Hospice, Institutionalized care, Non-institutionalized care, Other); HOS include hospital
characteristics variables such as geographic region (Northeast, Midwest, South, West), teaching
status (Teaching, Non-teaching), and bed size (<99, 100-199, 200-299, 300-499, 500 or more).
Lastly PHYS denotes physician specialty as non-specialist and specialist. Due to a large number
of observations with missing information, we created a category ‘Missing’ for the race, payer,
admission type, discharge status, and physician specialty variables.
The coefficients in the model can be interpreted as followed: β0 is the intercept presenting
baseline odds of receiving ESAs among patients with on-label indications when the effects of all
independent variables in the model were turned off; β1 represented the time trend prior to the first
intervention, the black box warning. β2 estimated the immediate effects of the first intervention
(black box warning). In a similar manner, β4 and β6 estimated the immediate effects of NCD and
REMS, respectively. β3 estimated the change in time trend after the issuance of black box
warning. β5 and β7 represented the change in time trends after the implementation of NCD and
REMS, respectively. Finally, et was the error term represents the variability not explained by the
model.
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Human subjects’ protection and data privacy

Cerner data are encrypted in such a way that no patient will be identified in order to
ensure minimal confidentiality risks to the patients. Access to the dataset was restricted to
individuals listed in the protocol. The data were maintained in a password-protected
environment. The study proposal was submitted to the Institution Review Board (IRB) at
Virginia Commonwealth University for an exemption 45 CFR 46.101(b)(4).198 The approval
number was HM 14257.
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CHAPTER 4
Results
Research results are presented in this chapter. The results are summarized into five
following sections:
1. Data Description
-

Study cohort for each specific aims

-

Overall prevalence and trend in ESA use from 2005 to 2011 by use category

2. Specific Aim 1
-

Descriptive summary of patient, hospital, and physician characteristics of ESA users

-

Descriptive summary of patient, hospital, and physician characteristics of epoetin alfa
and darbepoetin alfa by use category

-

Specific indications of ESAs in ONS, OFS, and OFU use category

3. Specific Aim 2
-

Trend in ESA On-label, off-label supported, and off-label unsupported therapy

-

Outlier Identification and Data manipulation

-

Time-series model selection

-

Impacts of black box warning, NCD, and REMS on proportion of visits with ESA use

4. Specific Aim 3
-

Outlier Identification and Data manipulation

-

Bivariate analysis of ESA users

-

GEE model selection

-

Impacts of black box warning, NCD, and REMS on odds of being prescribed with ESAs
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-

Associations of demographic, clinical, and hospital characteristics and the odds of being
prescribed with ESAs.

Data Description

Study cohorts for each specific aim

A total of 166,741 unique visits of 108,489 unique patients were reported to Cerner
health system, and received at least one order of any ESAs between January 1, 2005 and June 30,
2011. Among them, 111,363 encounters (66.8%) were admitted to the inpatient health system
while the rest were seen in the outpatient settings and excluded accordingly. Approximately
75.3% of the total inpatient encounters (n = 83,876 encounters: 66,121 patients) were prescribed
epoetin alfa only, and 24.0% (n = 26,772 encounters: 20,088 patients) were prescribed
darbepoetin alfa only. Less than one percent of them were prescribed both epoetin alfa and
darbepoetin alfa during the same visit (0.8%, n = 715 encounters: 554 patients). A total of 128
unique hospitals reported using any ESAs during the study period. Epoetin alfa was used in 124
hospitals in our sample while darbepoetin alfa was used in 91 hospitals. Sixty-four hospitals
reported the use of both epoetin alfa and darbepoetin alfa during the study period. The number
of reporting hospitals increased from 37 hospitals in the first year to 71 hospitals in the last year
of the study period. On average, the report of any use of ESAs came from approximately 50
hospitals per month. Lastly, during the 6.5-year study period, a total of 112 unique hospitals
reported ESA ONS use while 89 and 127 unique hospitals reported OFS and OFU use of ESAs,
respectively.
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The proportion of visits with ESA use for the ONS, OFS, and OFU indications was set up
from 111,363 unique visits with at least one ESA orders and 2,170,654 eligible admissions to
assess the impact of the interventions on ESA prescribing patterns (Specific Aim 2).
Finally, in order to assess the impacts of the interventions on the odds of receiving ESAs
in patients with specific on-label and off-label supported conditions and the associations of
demographic, clinical, and hospital characteristics on such likelihood (Specific Aim 3), a patient
is used as a unit of analysis. This analysis consisted of a total of 1,815,028 patients (750,321
ONS, 505,694 OFS, and 559,013 documented OFU).

Overall prevalence and trend in ESA use

ESA utilization patterns over time measured through the number of visits with any use of
erythropoietic drugs (epoetin alfa or darbepoetin alfa) per reporting hospital during the study
period is shown in Table 4.1 (annually) and Figure 4.1 (monthly).

Number of cases which an ESA was prescribed increased 44% from 240 per hospital in
2005 to 346 cases in 2006. ESA use decreased 13% to 302 cases in 2007; then utilization level
went up 9% to 328 cases in 2008. The largest reduction in use was in 2009 when there was a
50% reduction from 2008. ESA utilization level remained low from then through 2010. Overall,
ESA use in our sample decreased 33% from 2005 to 2010.

Epoetin alfa use increased 47% from approximately 211 cases per reporting hospital in
2005 to 310 cases in 2006. This increase was followed by a 27% drop in 2007 and a 15%
increase in epoetin alfa use in the following year. The number of visits which epoetin alfa was
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prescribed per hospital declined 54% in 2009, but increase again to 131 cases per hospital in
2010 (10% increase from 2009). Overall, epoetin alfa use decreased 38% from 2005 to 2010.

Overall use of darbepoetin alfa, however, increased 20% from 63 cases in 2005 to 76
cases in 2010. A year by year analysis showed that its use also increased in 2006 (44%).
However, in contrary to epoetin alfa, the number of visits which darbepoetin alfa was prescribed
per hospital continued to increase in 2007 (66% increase from 2006). After 2007, the level of
darbepoetin alfa use decreased every year until the end of the study period.

Table 4.1 Overall annual trend in the number of visits with ESA use per reporting hospital*
Number of visits with ESA use per reporting hospital

Drug

Total (any ESAs)
∆ from preceding year
Epoetin alfa
∆ from preceding year
Darbepoetin alfa
∆ from preceding year

2005

2006

2007

2008

2009

2010

239.7

345.8

302.0

327.9

163.1

161.6

-

+44.0%

-12.6%

+8.6%

-50.3%

-0.9%

211.0

310.4

225.9

259.0

118.6

131.0

-

+47.1%

-27.2%

+14.6%

-54.2%

+10.5%

63.3

91.1

151.0

131.1

103.6

75.7

-

+44.0%

+65.7%

-13.2%

-21.0%

-26.9%

%∆ (2005-2010)

-32.6%

-37.9%

+19.7%

*Only years with full-year reports were included
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To compare the trends in epoetin alfa and darbepoetin alfa over time, a graphical
representation of monthly drug use is shown in Figure 4.1. Any use of ESAs (epoetin alfa or
darbepotin alfa) is marked with -○- symbol while the use of epoetin alfa or darbepoetin alfa
alone is portrayed with -×- and -◊-, respectively. In general, changes in the level of darbepoetin
alfa use were delayed and fluctuated at a lesser extent compared to that of epoetin alfa.

Black box warning
begins

NCD
begins

REMS
begins

Figure 4.1 Monthly trend in use of ESAs, epoetin alfa, and darbepoetin alfa from January 2005 to June
2011 expressed in term of number of visits with ESA use per hospital

The number of visits which at least one ESA order was prescribed in a month in a
hospital increased steadily from 24 visits at the beginning of the study period to 32 visits per
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hospital per month in April 2006. After that, a sharp rise in the average number of visits with
ESAs was observed. There were close to 50 visits at which ESAs were ordered per hospital per
month during that period. However, beginning in October 2006, use of ESAs in our sample
started to show a declining trend that continued until the end of the study period. In the last
month of the study, there were as few as 16 visits per hospital which patients were prescribed
ESAs. The trend in overall ESA use in our sample was likely to be caused by epoetin alfa
because darbepoetin alfa utilization level, on the other hand, did not drop after October 2006 but
instead remained relatively stable at approximately 20 visits per hospital per month until April
2010. After April 2010, darbepoetin alfa use decreased to about 10 cases per hospital monthly
until the end of the study period.
ONS, OFS, and OFU use per hospital
The use of ESAs per hospital for the on-label, off-label supported, and off-label
unsupported indications is shown in Table 4.2 (annually) and Figure 4.2 (monthly).
Between 2005 and 2010, the number of visits with ESA on-label (ONS) use decreased
63% from 196 cases to 72 cases. The decline in ESA ONS use was observed starting in 2007
(21% reduction from 2006) with the largest decline seen in 2009 (57% reduction from 2008). A
similar trend was observed with ESA OFS use. ESA OFS use decreased 78.2% from 53 cases
per hospital in 2005 to only 11.6 cases in 2010, with the largest decline in 2009 (57%). ESA
OFU use, on the other hand, increased 80% from 57 cases to 102 cases. The largest increase in
ESA OFU use was in 2006. During that year, the number of visits with ESA OFU use per
hospital increased 78%.
Table 4.2 Annual trend in the number of visits with ESA use per reporting hospital by use category*

112

Number of visits with ESA use per reporting hospital

Use Category
2005

2006

2007

2008

2009

2010

195.9

245.8

194.6

202.5

86.6

72.2

-

+25.5%

-20.8%

+4.1%

-57.3%

-16.7%

53.3

44.3

46.1

36.8

15.8

11.6

-

-16.8%

3.9%

-20.2%

-57.1%

26.3%

56.7

100.9

114.7

128.6

95.9

102.0

-

+78.0%

+13.7%

+12.1%

-25.4%

+6.4%

%∆ (2005-2010)

Total (any ESAs)
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

-63.2%

-78.2%

+80.0%

*Only years with full-year reports are shown

Monthly trends in ESA use on-label and off-label (supported and unsupported) is shown
in Figure 4.2. On-label use of ESA is outlined with a long-dashed line while off-label supported
and off-label unsupported use are marked with solid and dotted lines, respectively.
On-label use of ESAs in our sample increased steadily from 20 visits per hospital per
month in January 2005 to 32 cases in November 2006. After than month, ESA on-label use
declined sharply. During the last months of the study, a hospital on average approximately
prescribed ESA in less than 10 visits per month. On the other hand, no fluctuation of level of
ESA use for off-label supported indications was observed in our sample; there was a slight
downward trending in the off-label supported use of ESAs throughout the study period. ESA
OFS use decreased from 7 visits per hospital per month to only one to two visits in the later
months. In contrast to ESA ONS and OFS use, ESA use for the unsupported indications (OFU)
increased from 6 visits in 2005 to 19 visits December 2006. This OFU use remained high, with a
slight increasing trend throughout the study period.
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Black box warning
begins

NCD
begins

REMS
begins

Figure 4.2 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported
indications from January 2005 to June 2011 expressed in term of number of visits with ESA use per
hospital

The annual trends in ESA use were broken down by drug. Changes in epoetin alfa and
darbepoetin alfa use per hospital per year for the on-label, off-label supported, and off-label
unsupported indications are shown Table 4.3.
The observed trends in ESA use described in the previous section were likely to be
contributed by the use of epoetin alfa which made up more than 75% of all ESA use in our
sample. Epoetin alfa ONS use increased 23% in the first year of the study period, but decreased
thereafter. Overall, similar to ESAs, epoetin alfa ONS use decreased 67% between 2005 and
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2010, with the largest decline in 2009 (-65%). Epoetin alfa OFS use also declined throughout
the whole study period (75%, 2005-2010), with the largest drop of 61% in 2009. Lastly, epoetin
alfa OFU use increase 93% over six years. The largest increase in epoetin alfa OFU use was
observed in 2006 where its use was almost doubled (99%).
In contrast to epoetin alfa, darbepoetin alfa ONS use did not decrease after 2005. Instead,
its use continued to increase until 2007, and decreased thereafter. There was also an increase of
73% and 71% in darbepoetin alfa OFS and OFU use in our sample in that year (2007),
respectively. At the end of the study period, darbepoetin alfa OFS use decreased 45% while
OFU use increased more than 111%.
Table 4.3 Annual trend in the number of visits with epoetin alfa and darbepoetin alfa use per reporting
hospital by use category*
Use Category

Number of visits with ESA use per reporting hospital
2005

2006

2007

2008

2009

2010

179.6

220.8

141.1

156.4

54.8

60.0

-

+22.9%

-36.1%

+10.8%

-64.9%

+9.4%

48.5

44.6

35.7

33.1

12.8

11.9

-

-8.0%

-20.1%

-7.3%

-61.2%

-7.0%

45.9

91.1

95.3

116.2

82.4

88.4

-

+98.5%

+4.6%

+21.9%

-29.1%

+7.3%

52.8

68.9

112.4

98.5

82.8

48.6

-

+30.5%

+63.1%

-12.3%

-16.0%

-41.3%

14.1

13.7

23.8

20.7

14.7

7.8

-

-2.6%

+73.3%

-12.8%

-28.9%

-47.2%

23.6

29.1

49.7

45.9

51.4

50.0

-

+23.4%

+70.5%

-7.6%

+12.0%

-2.7%

%∆ (2005-2010)

Epoetin alfa
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

-66.6%

-75.4%

+92.6%

Darbepoetin alfa
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

-8.0%

-44.7%

+111.8%

*Only years with full-year reports are shown
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Figure 4.3 and 4.4 show monthly trend in epoetin alfa and darbepoetin alfa use per
hospital, respectively. In general, ONS and OFS use in our sample decreased while OFU use
increased drastically after April 2006.

Black box warning
begins

NCD
begins

REMS
begins

Figure 4.3 Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of number of visits with ESA
use per hospital
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Black box warning
begins

NCD
begins

REMS
begins

Figure 4.4 Monthly trend in darbepoetin alfa use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of number of visits with ESA
use per hospital

The graphic representation shown in Figure 4.4 confirmed that the decline in the use of
darbepoetin alfa for the on-label indications was delayed compared to that in epoetin alfa ONS
use. Instead of a declining trend at the end of 2006, darbepoetin alfa ONS use continued to rise
until mid-2006, after which it remained relatively stable until early 2010. Darbepoetin alfa ONS
use then dropped drastically toward the end of the study period. In contrast to epoetin alfa OFS
use which trended downward throughout the study period, OFS use of darbepoetin alfa in fact
increased at first, and then leveled off after 2008. Finally, similarly to epoetin alfa, the use of
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darbepoetin alfa for the off-label unsupported indications rose after 2006, and remained
relatively stable until the end of the study period.

Specific Aim 1

Descriptive Statistics
Descriptive statistics were divided into three parts. The first part describes and compares
demographic data (age, race, sex, admission type, comorbidity, length of stay, and discharge
status), source of payment and hospital and physician characteristics between epoetin alfa (EPO)
and darbepoetin alfa (DARB) users. The EPO+DARB user group was not included in the
analysis due to its small sample size (554 patients). In the second part, differences in patient
demographic and clinical characteristics, and hospital and physician characteristics between ESA
users of each category (ONS, OFS, and OFU) were tested separately for each drug. Actual use
of ESA for specific ONS, OFS, and OFU indications was described under the final section.

Descriptive statistical analysis of demographic information of patients prescribed with
epoetin alfa or darbepoetin alfa only

Demographic data for patients who received only epoetin alfa or only darbepoetin alfa
were tested for statistically significant differences. Bivariates results are shown in Table 4.4.
The age of patients ranged from 18 to 85 years old, with the average age being 66 years old. The
late middle aged (51-64 years), young old (65-74 years), and older old (75-84 years) comprised
the largest group of ESA users. Slightly more female than male patients received ESAs.
Majority of ESA users in our sample were white (62.4%), had Medicare as their primary payer,
were admitted as emergency cases, and discharged home. The average length of stay was 12
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days (0 to 1,362 days) and on average, an ESA user had a comorbidity score of 1.6. Majority of
ESA users in this study were admitted to the hospitals located in the Northeast and the South
with more than 300 beds. Most of the hospitals were teaching hospitals (74.8%). Lastly, among
users without missing information on physician specialty, 61.1% of them were prescribed by a
specialist. It is important to note that though age, gender, race, discharge disposition, and
hospital characteristics were well captured in Cerner data, more than half of the payer
information of ESA users, and as high as 30-40% of the admission type and ordering physician
specialty were missing from the records.
There were significant differences between the EPO and DARB users with respect to
patient demographic characteristics, clinical characteristics, physician characteristics and hospital
characteristics. Overall, compared with those prescribed with epoetin alfa, those prescribed with
darbepoetin alfa were significantly younger (40.5% vs 46.9% non-elderly), and consisted of
slightly more male and Caucasians. Greater proportion of DARB users, compared to EPO users,
had Medicare as their primary payer. Fewer DARB users were admitted as emergency cases
compared to EPO users. Discharge status of both users was similar. However, drug utilization
was drastically different across the census regions. Patients admitted to the hospitals located in
the Midwest and the northeast received darbepoetin alfa to a greater extent compared to patients
in any other regions. On the other hand, epoetin alfa was used mostly in the hospitals located in
the Northeast and the South. Drug utilization was quite similar across hospital bed size, teaching
status, and ordering physician specialty categories.
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Table 4.4 Descriptive statistics for patients admitted to inpatient settings and had at least one order of
ESAs between January 01, 2005 and June 30, 2011
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender*
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other
Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range

N Patients 2005- 2011 (column %)
Any ESAs
Epo
Darb

Chi-sq,
p-value

2,273 (2.64)
12,362 (14.34)
21,686 (25.16)
19,430 (22.54)
20,811 (24.14)
9,647 (11.19)
86,209 (100.00)
66.1 (15.81)

1,580 (2.39)
8,912 (13.48)
16,350 (24.73)
15,035 (22.74)
16,470 (24.91)
7,774 (11.76)
66,121 (76.70)
66.7 (15.62)

693 (3.45)
3,450 (17.17)
5,336 (26.56)
4,395 (21.88)
4,341 (21.61)
1,873 (9.32)
20,088 (23.30)
64.1 (16.28)

389.15
p < 0.0001

41,564 (48.22)
44,636 (51.78)
86,200 (100)

31,583 (47.77)
34,533 (52.23)
66,116 (76.70)

9,981 (49.70)
10,103 (50.30)
20,084 (23.30)

22.91
p < 0.0001

53,799 (62.41)
24,473 (28.39)
6,149 (7.13)
1,788 (2.07)
86,209 (100.00)

40,517 (62.28)
19,332 (29.24)
5,254 (7.95)
1,018 (1.54)
66,121 (76.70)

13,282 (66.12)
5,141 (25.59)
895 (4.46)
770 (3.83)
20,088 (23.30)

783.95
p < 0.0001

24,548 (60.35)
3,471 (8.53)
5,839 (14.35)

17,666 (58.50)
2,541 (8.41)
4,338 (14.36)

6,882 (65.67)
930 (8.87)
1,501 (14.32)

888.47
p < 0.0001

1,700 (4.18)
5,120 (12.59)
45,531 (52.81)
86,209 (100.00)

1,162 (3.85)
4,492 (14.87)
35,922 (54.33)
66,121 (76.70)

538 (5.13)
628 (5.99)
9,609 (47.83)
20,088 (23.30)

38,243 (64.09)
10,598 (17.76)
10,694 (17.92)
137 (0.23)
26,537 (30.78)
86,209 (100.00)
1.62 (1.991),
-1 to 13
12.4 (18.72),
0 – 1,362

29,639 (64.90)
8,675 (19.00)
7,249 (15.87)
106 (0.23)
20,452 (30.93)
66,121 (76.70)
1.56 (1.967),
-1 to 13
12.1 (18.85),
0 - 1,362

8,604 (61.44)
1,923 (13.73)
3,445 (24.60)
31 (0.22)
6,085 (30.29)
20,088 (23.30)
1.80 (2.058)
-1 to 13
13.4 (18.24),
0 - 540

p < 0.0001

648.90
p < 0.0001

p < 0.0001
p < 0.0001
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Discharge status
Expired
5,974 (7.24)
4,615 (7.29)
Discharged to home/
37,211 (45.08)
28,465 (44.95)
self care
Discharged to Hospice
1,769 (2.17)
1,367 (2.16)
Discharged/transferred to
24,014 (29.09)
18,216 (28.77)
institutionalized care
Discharged/transferred to
12,942 (15.68)
10,163 (16.05)
noninstitutionalized care
Other
617 (0.75)
498 (0.79)
Not recorded
3,657 (4.24)
2,797 (4.23)
Total (row %)
86,209 (100.00)
66,121 (76.70)
Hospital Characteristics
Geographic region
Northeast
35,167 (40.79)
27,914 (42.22)
Midwest
18,197 (21.11)
8,406 (12.71)
South
26,628 (30.89)
23,793 (35.98)
West
6,217 (7.21)
6,008 (9.09)
Total (row %)
86,209 (100.00)
66,121 (76.70)
Bed size
≤ 99
2,358 (2.74)
1,889 (2.86)
100-199
7,823 (9.07)
5,324 (8.22)
200-299
15,864 (18.40)
10,919 (16.51)
300-499
26,270 (30.47)
21,419 (32.39)
≥500
33,894 (39.32)
26,461 (40.02)
Total (row %)
86,209 (100.00)
66,121 (76.70)
Teaching status
Teaching
64,455 (74.77)
49,660 (75.10)
Non-teaching
21,754 (25.23)
16,461 (24.90)
Total (row %)
86,209 (100.00)
66,121 (76.70)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
13,577 (15.75)
11,317 (17.12)
Surgeon
5197 (6.03)
3,253 (4.92)
Specialist
29,535 (34.26)
21,208 (32.07)
Not recorded
37,900 (43.96)
30,343 (45.89)
Total (row %)
86,209 (100.00)
66,121 (76.70)
*Nine patients with missing gender information were not tested.

1,359 (7.07)
8,746 (45.49)

41.55
p < 0.0001

425 (2.22)
5,798 (30.15)
2,779 (14.45)
119 (0.62)
860 (4.28)
20,088 (23.30)

7,253 (36.11)
9,791 (48.74)
2,835 (14.11)
209 (1.04)
20,088 (23.30)

13384.40
p < 0.0001

469 (2.33)
2,390 (11.90)
4,945 (24.62)
4,851 (24.15)
7,433 (37.00)
20,088 (23.30)

1174.51
p < 0.0001

14,795 (73.65)
5,293 (26. 53)
20,088 (23.30)

17.26
p < 0.0001

2,260 (11.25)
1,944 (9.68)
8,327 (41.45)
3,557 (37.62)
20,088 (23.30)

1550.28
p < 0.0001
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Descriptive statistical analysis of demographic information of patients prescribed with
epoetin alfa and darbepoetin alfa by use category

This part of the descriptive analysis examined characteristics of the ESA users by their
use category. Majority of ESA use in our sample was for on-label indications (48.7%), followed
by off-label unsupported (42.7%), and off-label supported indications (8.6%).
There were significant differences in the utilization of epoetin alfa and darbepoetin alfa
with respect to use categories. Darbepoetin alfa was used to a larger extent for on-label
indications compared to epoetin alfa; of 20,008 darbepoetin alfa users, 52.8% were for on-label
indications compared to 47.4% ONS of epoetin alfa users. Unsupported use of both drugs
constituted about 83.2% of all off-label use of the drugs. Table 4.5 summarizes percentages of
patients with epoetin alfa and darbepoetin alfa use by indication category.
Table 4.5 Number of ESA users in the inpatient settings by use categories
Use category
ONS
OFS
OFU
Total (row %)

N Patients (column %)
All ESA users
Epo only
42,218 (48.66)
31,333 (47.39)
7477 (8.62)
5,834 (8.82)
37,068 (42.72)
28,954 (43.79)
86,763
66,121 (76.70)

Darbe only
10,598 (52.76)
1,586 (7.90)
7,904 (39.35)
20,088 (23.30)

Chi-sq,
p-value
177.90
p < 0.0001
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Part 2.1: Any ESAs
There were statistically significant differences between users of ESAs for ONS, OFS, and
OFU indications with respect to all variables: age, gender, race, insurance status, admission type,
comorbidity index, length of stay, discharge disposition, geographic region, hospital size,
teaching status, and physician specialty. ESAs, regardless of their indications, were also for a
greater extent prescribed off-label to female. ESA utilization patterns were similar across
geographic regions, hospital bed size, teaching status, and ordering physician specialty
categories.
Compared with ONS and OFU users, there was greater proportion of older patients in the
OFS group. The average age of ESA-OFS group was 70 years old while that of ESA-ONS and
ESA-OFU groups were 65 and 66 years old, respectively. Greater proportion of ESA-OFS users
died in the hospital or was discharged to institutionalized care. There were fewer White and
Medicare patients in the OFU group compared to the other two groups. Also, admission type of
the OFU patients was, to the highest extent, not recorded in the database (60.3% compared 8.8%
and 11.1% of the ONS and OFS groups, respectively). However, among those with recorded
information, admission type did not vary across the three user groups. We found that the
majority of ESA patients in our sample were admitted to the hospitals as emergency cases.
Hospital length-of-stay was longest in the OFS group (14.7 days), followed by OFU (12.9 days),
while ONS patients stayed in the hospital for 11.8 days on average. Lastly, OFU patients had
much lower comorbidity index compared to the ONS and OFS patients (0.3 vs. 2.7 and 2.0).
Average age, L-O-S, and comorbidity indices of ESA drug recipients are illustrated in Figure 4.5
and 4.6, respectively. Descriptive statistics of ESA users by use category was shown in Table
4.6.
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Average Age of ESA Drug Recipients
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Figure 4.5 Average age of ESA drug recipients

Average L-O-S and Comorbidity Index (CCI) of ESA drug Recipients
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Figure 4.6 Average L-O-S and Average CCI of ESA drug recipients
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Table 4.6 Descriptive statistics for ESA users in the inpatient settings by use categories
Variable

N Patients by Use Category 2005-2011 (column %)
Any indications
ONS
OFS
OFU
Patient Characteristics
Demographics
Age
18-30
2,286 (2.63)
1,078 (2.55)
164 (2.19)
1,044 (2.82)
31-50
12,432 (14.33)
6,473 (15.33)
640 (8.56)
5,319 (14.35)
51-64
21,836 (25.17) 11,253 (26.65) 1,404 (18.78)
9,179 (24.76)
65-74
19,553 (22.54)
9,461 (22.41) 1,688 (22.58)
8,404 (22.67)
75-84
20,952 (24.15)
9,863 (23.36) 2,266 (30.31)
8,823 (23.80)
85+
9,704 (11.18)
4,090 (9.69) 1,315 (17.59)
4,299 (11.60)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62) 37,068 (42.72)
Average age (SD)
66.1 (15.81)
65.3 (15.64)
70.5 (15.07)
66.0 (16.00)
Gender*
Male
41,837 (48.22) 21,229 (50.29) 3,501 (46.82) 17,107 (46.16)
Female
44,917 (51.78) 20,988 (49.71) 3,976 (53.18) 19,953 (53.84)
Total (row %)
86,754 (100.00) 42,217 (48.66)
7,477 (8.62) 37,060 (42.72)
Race
Caucasian
54,172 (64.44) 26,636 (63.09) 5,799 (77.56) 21,737 (58.64)
African-American
24,608 (28.36) 12,105 (28.67) 1,220 (16.32) 11,283 (30.44)
Other
6,179 (7.12)
2,720 (6.44)
334 (4.47)
3,125 (8.43)
Not recorded
1,804 (2.08)
757 (1.79)
124 (1.66)
923 (2.94)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62) 37,068 (42.72)
Primary Payer
Source of Payment
Medicare
24,689 (28.46) 1,4550 (34.46) 2,910 (38.92)
7,229 (19.50)
Medicaid
3,486 (4.02)
1,902 (4.51)
345 (4.61)
1,239 (3.34)
Commercial/
5,886 (6.78)
3,008 (7.12)
623 (8.33)
2,255 (6.08)
Private/ HMO
Managed Care
Self-pay
1,702 (1.96)
855 (2.03)
192 (2.57)
655 (1.77)
Other
5,152 (5.94)
3,424 (8.11)
482 (6.45)
1,245 (3.36)
Not recorded
45,848 (52.84) 18,478 (43.77) 2,925 (39.12) 24,445 (65.95)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62) 37,068 (42.72)
Clinical Conditions
Admission type
Emergency
38,475 (44.34) 24,791 (58.72) 4,231 (56.59)
9,453 (25.50)
Urgent
10,665 (12.29)
6,445 (15.27) 1,376 (18.40)
2,844 (7.67)
Elective
10,755 (12.40)
7,288 (17.26) 1,038 (13.88)
2,429 (6.55)
Other/Not
26,868 (30.97)
3,694 (8.75)
832 (11.13) 22,342 (60.27)
recorded
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62) 37,068 (42.72)
Average CCI (SD)
1.62 (1.991),
2.72 (1.909),
2.00 (1.844),
0.29 (1.116),
-1 to 13
-1 to 13
0 to 11
0 to 9
Average LOS (SD),
12.5 (18.97),
11.8 (16.42),
14.7 (17.99),
12.9 (21.64),
range
0 to 1362
0 to 1029
0 to 340
0 to 1362

Chi-sq,
p-value

870.35
p < 0.0001

p < 0.0001
140.94
p < 0.0001

1046.09
p < 0.0001

4907.39
p < 0.0001

26164.05
p < 0.0001

p < 0.0001
p < 0.0001
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Discharge status
Expired
6,031 (6.95)
2,794 (6.62)
872 (11.66)
Discharged to
37,362 (43.06) 17,708 (41.94) 2,011 (26.90)
home/self care
Discharged to
1,809 (2.08)
940 (2.23)
258 (3.45)
Hospice
Discharged/
24,243 (27.94) 12,394 (29.36) 2,873 (38.42)
transferred to
institutionalized care
Discharged/
13,006 (14.99)
7,772 (18.41) 1,397 (18.68)
transferred to
noninstitutionalized
care
Other/Not
4,312 (4.97)
610 (1.44)
66 (0.88)
recorded
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62)
Hospital Characteristics
Geographic region
Northeast
35,513 (40.93) 16,422 (38.90) 3,415 (45.67)
Midwest
18,300 (21.09) 10,700 (25.34) 1,488 (19.90)
South
26,712 (30.79) 12,607 (29.86) 2,192 (29.32)
West
6,238 (7.19)
2,489 (5.90)
382 (5.11)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62)
Bed size
≤ 99
2,374 (2.74)
962 (2.28)
240 (3.21)
100-199
7,886 (9.09)
4,400 (10.42)
659 (8.81)
200-299
16,053 (18.50)
7,711 (18.26) 1,668 (22.31)
300-499
26,371 (30.39) 13,878 (32.87) 2,789 (37.30)
≥500
34,079 (39.28) 15,267 (36.16) 2,121 (28.37)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62)
Teaching status
Teaching
64,819 (74.71) 32,051 (75.92) 5,406 (72.30)
Non-teaching
21,944 (25.29) 10,167 (24.08) 2,071 (27.70)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
13,632 (15.71)
5,855 (13.87) 1,324 (17.71)
Surgeon
5,229 (6.03)
2,835 (6.72)
464 (6.21)
Specialist
29,669 (34.20) 15,698 (37.18) 2,748 (36.75)
Not recorded
38,233 (44.07) 17,830 (42.23) 2,941 (39.33)
Total (row %)
86,763 (100.00) 42,218 (48.66)
7,477 (8.62)
*Nine patients with missing gender information were not tested.

2,365 (6.07)
17,643 (47.60)

5502.15
p < 0.0001

611 (1.65)
8,976 (24.21)

3,837 (10.35)

3,636 (9.81)
37,068 (42.72)

15,676 (42.29)
6,112 (16.49)
11,913 (32.14)
3,367 (9.08)
37,068 (42.72)

1207.08
p < 0.0001

1,172 (3.16)
2,827 (7.63)
6,678 (18.00)
9,704 (26.18)
16,691 (45.03)
37,068 (42.72)

1,360.49
p < 0.0001

27,362 (73.82)
9,706 (26.18)
37,068 (42.72)

71.23
p < 0.0001

6,453 (17.41)
1,930 (5.21)
11,223 (30.28)
17,462 (47.11)
37,068 (42.72)

692.13
p < 0.0001
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Part 2.2: Use of Epoetin alfa Darbepoetin alfa
Descriptive analysis of patient characteristics, clinical conditions, hospital characteristics,
and physician specialty were done separately for epoetin alfa and darbepoetin alfa. Bivariate
results for epoetin alfa and darbepoetin alfa are described in Table 4.7 and 4.8, respectively.
Significant differences between the ONS, OFS, and OFU users of epoetin alfa and darbepoetin
with respect to patient demographic characteristics, clinical characteristics, physician
characteristics and hospital characteristics were comparable to those described above in the ESA
section. For example, those who used the drug for off-label supported indications were the
oldest, mostly White female, had higher hospital mortality, and were transferred to other
institutionalized care settings to a greater extent compared to patients in the other two groups.
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Table 4.7 Epoetin alfa by use category in the inpatient settings
Variable

N Patients by Use Category 2005-2011 (column %)
Any indications
ONS
OFS
OFU
Patient Characteristics
Demographics
Age
18-30
1,580 (2.39)
715 (2.28)
108 (1.85)
757 (2.61)
31-50
8,691 (13.48)
4,494 (14.34)
457 (7.83)
3,961 (13.68)
51-64
16,350 (24.73)
8,198 (26.16) 1,024 (17.55)
7,128 (24.62)
65-74
15,035 (22.74)
7,102 (22.67) 1,326 (22.73)
6,607 (22.82)
75-84
16,470 (24.91)
7,609 (24.28) 1,837 (31.49)
7,024 (24.26)
85+
7,774 (11.76)
3,215 (10.26) 1,082 (18.55)
3,477 (12.01)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82) 28,954 (43.79)
Average age (SD)
66.6 (15.62)
65.9 (15.43)
71.3 (14.70)
66.5 (15.84)
Gender*
Male
31,583 (47.77) 15,633 (49.89) 2,698 (46.25) 13,252 (45.78)
Female
34,533 (52.23) 15,700 (50.11) 3,136 (53.75) 15,697 (54.22)
Total (row %)
66,116 (100.00) 31,333 (47.39)
5,834 (8.82) 28,949 (43.79)
Race
Caucasian
40,517 (61.28) 19,471 (62.14) 4,486 (76.89) 16,560 (57.19)
African-American
19,332 (29.24)
9,266 (29.57)
995 (17.04)
9,072 (31.33)
Other
5,254 (7.95)
2,225 (7.10)
275 (4.71)
2,754 (9.51)
Not recorded
1,018 (1.54)
371 (1.18)
79 (1.35)
568 (1.96)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82) 28,954 (43.79)
Primary Payer
Source of Payment
Medicare
17,666 (26.72) 10,058 (32.10) 2,305 (39.51)
5,303 (18.32)
Medicaid
2,541 (3.84)
1,354 (4.32)
258 (4.42)
929 (3.21)
Commercial/
4,338 (6.56)
2,079 (6.64)
443 (7.59)
1,816 (6.27)
Private/ HMO
Managed Care
Self-pay
1,162 (1.76)
472 (1.51)
143 (2.45)
547 (1.89)
Other
4,492 (6.79)
3,247 (10.36)
448 (7.68)
797 (2.75)
Not recorded
35,922 (54.33) 14,123 (45.07) 2,237 (38.34) 19,562 (67.56)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82) 28,954 (43.79)
Clinical Conditions
Admission type
Emergency
29,639 (44.83) 18,950 (60.48) 3,449 (59.12)
7,240 (61.06)
Urgent
8,675 (13.12)
5,259 (16.78) 1,206 (20.67)
2,210 (25.01)
Elective
7,249 (10.96)
4,719 (15.06)
704 (12.07)
1,826 (7.63)
Other/Not
20,558 (31.09)
2,405 (7.68)
475 (8.14) 17,678 (61.06)
recorded
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82) 28,954 (43.79)
Average CCI (SD)
1.56 (1.967),
2.66 (1.911),
2.00 (1.823),
0.29 (1.128),
-1 to 13
-1 to 13
0 to 11
0 to 9
Average LOS (SD),
12.1 (18.85),
11.3 (15.91),
13.8 (16.49),
12.7 (21.94),
range
0 to 1362
0 to 1029
0 to 329
0 to 1362

Chi-sq,
p-value

719.96
p < 0.0001

108.12
p < 0.0001

911.14
p < 0.0001

4551.74
p < 0.0001

21689.07
p < 0.0001
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Discharge status
Expired
4,615 (6.98)
2,037 (6.50)
665 (11.40)
Discharged to
28,465 (43.05) 12,952 (41.34) 1,573 (26.96)
home/self care
Discharged to
1,367 (2.07)
715 (2.28)
207 (3.55)
Hospice
Discharged/
18,216 (27.55)
9,084 (28.99) 2,185 (37.45)
transferred to
institutionalized care
Discharged/
10,163 (15.37)
6,025 (19.23) 1,143 (19.59)
transferred to
noninstitutionalized
care
Other/Not
3,295 (4.98)
520 (1.66)
61 (1.05)
recorded
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82)
Hospital Characteristics
Geographic region
Northeast
27,914 (42.22) 12,618 (40.27) 2,688 (46.07)
Midwest
8,406 (12.71)
4,763 (15.20)
759 (13.01)
South
23,793 (35.98) 11,597 (37.01) 2,030 (34.80)
West
6,008 (9.09)
2,355 (7.52)
357 (6.12)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82)
Bed size
≤ 99
1,889 (2.86)
675 (2.15)
184 (3.15)
100-199
5,433 (8.22)
3,251 (10.38)
490 (8.40)
200-299
10,919 (16.51)
5,429 (17.33) 1,107 (18.97)
300-499
21,419 (32.39) 11,036 (35.22) 2,466 (42.27)
≥500
26,461 (40.02) 10,942 (34.92) 1,587 (27.20)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82)
Teaching status
Teaching
49,660 (75.10) 23,625 (75.40) 4,379 (75.06)
Non-teaching
16,461 (24.90)
7,708 (24.60) 1,455 (24.94)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
11,317 (17.12)
4,699 (15.00) 1,127 (19.32)
Surgeon
3,253 (4.92)
1,740 5.55)
277 (4.75)
Specialist
21,208 (32.07) 11,123 (35.50) 2,158 (36.99)
Not recorded
30,343 (45.89) 13,771 (43.95) 2,272 (38.94)
Total (row %)
66,121 (100.00) 31,333 (47.39)
5,834 (8.82)
*Five patients with missing gender information were not tested.

1,913 (6.61)
13,940 (48.15)

4041.55
p < 0.0001

445 (1.54)
6,947 (23.99)

2,995 (10.34)

2,714 (9.37)
28,954 (43.79)

12,608 (43.54)
2,884 (9.96)
10,166 (35.11)
3,296 (11.38)
28,954 (43.79)

713.65
p < 0.0001

1,030 (3.56)
1,692 (5.84)
4,383 (15.14)
7,917 (27.34)
13,932 (48.12)
28,954 (43.79)

1947.62
p < 0.0001

21,656 (74.79)
7,298 (25.21)
28,954 (43.79)

2.96
p = 0.2282

5,491 (18.96)
1,236 (4.27)
7,927 (27.38)
14,300 (49.39)
28,954 (43.79)

729.28
p < 0.0001
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Table 4.8 Darbepoetin alfa by use category in the inpatient settings
Variable

N Patients by Use Category 2005-2011 (column %)
Any indications
ONS
OFS
OFU
Patient Characteristics
Demographics
Age
18-30
693 (3.45)
356 (3.36)
54 (3.40)
283 (3.58)
31-50
3,450 (17.17)
1,734 (18.25)
180 (11.35)
1,336 (16.90)
51-64
5,336 (26.56)
2,982 (28.14)
367 (23.14)
1,987 (25.14)
65-74
4,395 (21.88)
2,295 (21.66)
350 (22.07)
1,750 (22.14)
75-84
4,341 (21.61)
2,182 (20.59)
412 (25.98)
1,747 (22.10)
85+
1,873 (9.32)
849 (8.01)
223 (14.06)
801 (10.13)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
7,904 (39.35)
Average age (SD)
64.10 (16.28)
63.3 (16.08)
67.6 (16.01)
64.4 (16.51)
Gender*
Male
9,981 (49.70)
5,452 (51.45)
776 (48.93)
3,753 (47.50)
Female
10,103 (50.30)
5,145 (48.55)
810 (51.07)
4,148 (52.50)
Total (row %)
20,084 (100.00) 10,597 (52.76)
1,586 (7.90)
7,901 (39.34)
Race
Caucasian
13,282 (66.12)
6,959 (64.56) 1,274 (79.46)
5,049 (63.88)
African-American
5,141 (25.59)
2,778 (27.14)
212 (14.29)
2,151 (27.21)
Other
895 (4.46)
480 (4.60)
57 (3.65)
358 (4.53)
Not recorded
770 (3.83)
381 (3.60)
43 (2.71)
346 (4.38)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
7,904 (39.35)
Primary Payer
Source of Payment
Medicare
6,682 (34.26)
4,403 (41.55)
592 (37.33)
1,887 (23.87)
Medicaid
930 (4.63)
540 (5.10)
84 (5.30)
306 (3.87)
Commercial/
1,501 (7.47)
907 (8.56)
173 (10.91)
421 (5.33)
Private/ HMO
Managed Care
Self-pay
538 (2.68)
383 (3.61)
48 (3.03)
107 (1.35)
Other
628 (3.13)
168 (1.59)
32 (2.02)
428 (5.41)
Not recorded
9,609 (47.83)
4,197 (39.60)
657 (41.42)
4,755 (60.16)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
7,904 (39.35)
Clinical Conditions
Admission type
Emergency
8,604 (42.83)
5,701 (55.38)
753 (43.47)
2,150 (27.20)
Urgent
1,923 (9.57)
1,141 (10.78)
166 (10.51)
616 (7.79)
Elective
3,445 (17.15)
2,529 (23.32)
326 (23.86)
590 (7.46)
Other/Not
6,116 (30.45)
1,227 (11.58)
341 (21.50)
4,548 (57.54)
recorded
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
7,904 (39.35)
Average CCI (SD)
1.80 (2.058)
2.92 (1.888)
2.01 (1.938)
0.26 (1.078)
-1 to 13
-1 to 13
0 to 11
0 to 9
Average LOS (SD),
13.4 (18.34)
12.9 (17.06) 17.45 (20.84)
13.3 (19.07)
range
0 to 540
0 to 398
0 to 340
0 to 540

Chi-sq,
p-value

146.21
p < 0.0001

28.63
p < 0.0001

172.85
p < 0.0001

1245.31
p < 0.0001

4707.65
p < 0.0001
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Discharge status
Expired
1,359 (6.77)
724 (6.83)
200 (12.61)
Discharged to
8,746 (43.54)
4,677 (44.13)
426 (26.86)
home/self care
Discharged to
427 (2.13)
216 (2.04)
51 (3.22)
Hospice
Discharged/
5,798 (28.86)
3,185 (30.15)
659 (41.55)
transferred to
institutionalized care
Discharged/
2,779 (13.83)
1,709 (16.13)
245 (15.45)
transferred to
noninstitutionalized
care
Other/Not
979 (4.87)
87 (0.82)
5 (0.32)
recorded
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
Hospital Characteristics
Geographic region
Northeast
7,253 (36.11)
3,610 (34.06)
691 (43.57)
Midwest
9,791 (48.74)
5,892 (55.60)
719 (45.33)
South
2,835 (14.11)
969 (9.14)
154 (9.71)
West
209 (1.04)
127 (1.20)
22 (1.39)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
Bed size
≤ 99
469 (2.33)
281 (2.65)
56 (3.53)
100-199
2,390 (11.90)
1,118 (10.55)
163 (10.28)
200-299
4,945 (24.62)
2,176 (20.53)
535 (33.73)
300-499
4,851 (24.15)
2,790 (26.33)
315 (19.86)
≥500
7,433 (37.00)
4,233 (39.94)
517 (32.60)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
Teaching status
Teaching
14,795 (73.65)
8,229 (77.65)
994 (62.67)
Non-teaching
5,293 (26.35)
2,369 (22.35)
592 (37.33)
Total (row %)
20,088 (100.00) 10,598 (52.76)
1,586 (7.90)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
2,260 (11.25)
1,130 (10.66)
195 (12.30)
Surgeon
1,944 (9.68)
1,086 (10.25)
183 (11.54)
Specialist
8,327 (41.45)
4,506 (42.52)
580 (36.57)
Not recorded
7,557 (37.62)
3,876 (36.57)
628 (39.60)
Total (row %)
12,531 (100.00)
6,722 (53.64)
958 (7.65)
*Four patients with missing gender information were not tested.

435 (5.50)
3,643 (46.09)

1550.59
p < 0.0001

160 (2.02)
1,954 (24.72)

825 (11.44)

887 (11.22)
7,904 (39.35)

2,952 (37.35)
3,180 (40.23)
1,712 (21.66)
60 (0.76)
7,904 (39.35)

800.45
p < 0.0001

132 (1.67)
1,109 (14.03)
2,234 (28.26)
1,746 (22.09)
2,683 (33.94)
7,904 (39.35)

347.01
p < 0.0001

5,572 (70.50)
2,332 (29.50)
7,904 (39.35)

226.22
p < 0.0001

935 (11.83)
675 (8.54)
3,241 (41.00)
3,053 (38.63)
4,851 (38.71)

46.21
p < 0.0001
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Specific indications of ESAs in ONS and OFU use category

Uses of epoetin alfa and darbepoetin alfa were further analyzed into individual
indications. Specific on-label uses of all ESAs, epoetin alfa, and darbepoetin alfa are described
in Table 4.9, 4.10, and 4.11 respectively). Chronic kidney disease (CKD) presented the highest
use of on-label ESA use (84.4%). On-label utilization pattern of epoetin alfa was similar to that
of the overall ESAs. As expected, the use of darbepoetin alfa on-label was prominent in CKD
while few HIV, anemic patients received darbepoetin alfa as this indication was not officially
approved for darbepoetin alfa by the FDA.
Part 3.1 On-label use of ESAs
Over the period of 6.5 years, the use of ESAs in CKD, among other on-label indications
increased from 78.6% in 2005 to 91.5% in 2011. ESA use in chemotherapy-induced anemia
remained relatively stable, while its use in HIV and surgical procedure fluctuated greatly
throughout the study period. Approximately 14% of ONS drug use was for patients undergoing
major elective surgery. Less than 10% of ESA ONS use was to treat anemia due to
chemotherapy. ESA drug use for zidovudine-induced anemia constituted less than 2% of onlabel drug use.
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Table 4.9 ONS use of ESA (either Epoetin alfa or Darbepoetin alfa, or both) indications within a category
are not mutually exclusive
ONS
conditions
CKD
CIA
HIV
Surgery
Any ONS

2005
4,731
(78.61)
420
(6.98)
90
(1.50)
350
(5.82)
6,018

2006
6,947
(81.26)
660
(7.72)
159
(1.86)
1,732
(20.26)
8,549

2007
6,881
(86.01)
538
(6.73)
143
(1.79)
1,090
(13.63)
8,000

Year
2008
2009
7,734
4,204
(84.41)
(87.78)
524
309
(5.72)
(6.45)
185
84
(2.02)
(1.75)
1,620
652
(17.68)
(13.61)
9,162
4,789

2010
4,104
(89.96)
281
(6.16)
60
(1.32)
478
(10.48)
4,562

2011
1,041
(91.48)
78
(6.85)
13
(1.14)
105
(9.23)
1,138

Total
35,642
(84.42)
2,810
(6.66)
734
(1.74)
6,027
(14.28)
45,213

Table 4.10 ONS use of Epoetin alfa only, indications within a category are not mutually exclusive
ONS
conditions
CKD
CIA
HIV
Surgery
Any ONS

2005
4,049
(77.49)
375
(7.18)
87
(1.67)
1,203
(23.02)
5,225

2006
5,672
(81.19)
518
(7.41)
142
(2.03)
1,385
(19.83)
6,986

2007
4,708
(86.64)
361
(6.64)
92
(1.69)
704
(12.96)
5,434

Year
2008
2009
5,481
2,628
(84.09)
(86.70)
318
189
(4.88)
(6.24)
149
57
(2.29)
(1.88)
1,186
411
(18.20)
(13.56)
6,518
3,031

2010
2,941
(89.72)
196
(5.98)
45
(1.37)
326
(9.95)
3,278

2011
786
(91.29)
60
(6.97)
11
(1.28)
88
(10.22)
861

Total
26,265
(83.83)
2,017
(6.44)
583
(1.86)
5,303
(16.92)
31,333

Table 4. 11 ONS use of Darbepoetin alfa only, indications within a category are not mutually exclusive
ONS
conditions
CKD
CIA
HIV
Surgery
Any ONS

2005
604
(94.08)
40
(6.23)
3
(0.47)
135
(21.03)
642

2006
1,214
(91.48)
135
(10.17)
16
(1.21)
331
(24.94)
1,327

2007
2,128
(93.83)
173
(7.63)
51
(2.25)
380
(16.75)
2,268

Year
2008
2009
2,221
1,562
(93.36)
(95.89)
202
117
(8.49)
(7.18)
36
27
(1.51)
(1.66)
427
241
(17.95)
(14.79)
2,379
1,629

2010
1,147
(95.03)
84
(6.96)
13
(1.08)
151
(12.51)
1,207

2011
252
(94.03)
17
(6.34)
2
(0.75)
17
(6.34)
268

Total
9,128
(93.91)
768
(7.90)
148
(1.52)
1,682
(17.30)
9,720

*Epo indications for HIV and surgery
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Separate analyses of use for epoetin alfa and darbepoetin alfa showed that chronic kidney
disease was the main use of both drugs in our sample. Approximately 83% and 93% of epoetin
alfa and darbepoetin alfa, respectively, in the ONS cohort, used the drugs to treat anemia of
CKD. Approximately 17% of the on-label use was for patients undergoing major surgeries.
Chemotherapy-induced anemia and zidovudine-induced anemia was responsible for
approximately 7% and 1.5% of ONS use in the sample. Comparison of ONS use of epoetin alfa
and darbepoetin alfa between 2005 and 2011 in the inpatient settings is illustrated in Figure 4.7.

Figure 4.7 ONS use of ESAs, epoetin alfa, and darbepoetin alfa from 2005-2011
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Part 3.2 Off-label supported use of ESAs
Among the eleven off-label indications with strong supporting scientific evidence (OFS),
acute kidney disease contributed the highest use of ESAs (4,514 patients, 60.4%), epoetin alfa
only (3,436 patients, 58.9%), and darbepoetin alfa only (1,369 patients, 55.6%) – data not shown.
Due to the relatively small sample size and large number of indications in this category, off-label
supported use of ESAs was not further subcategorized into individual conditions.
Part 3.3 Off-label unsupported use of ESAs
We were able to identified specific use of approximately 18% of the total off-label
unsupported use of ESAs in the dataset. The majority of identifiable OFU patients (60%) used
ESAs for chronic anemia conditions such as iron deficient-related anemia. The second largest
use of ESAs for identifiable off-label unsupported indications included anemia of neoplastic
disease in those not receiving concomitant chemotherapy, cardiac surgery, fractures and other
injuries, and various GI bleeding. Identifiable indications of ESAs neither approved nor
supported by scientific evidence are summarized in Table 4.12-4.14, and compared in Figure 4.8.
We additionally found that approximately four percent (1,072 patients) of epoetin alfa users with
OFU conditions had blood transfusion while 328 (4.1%) darbepoetin alfa users with OFU
conditions had blood transfusion.
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Documented OFU Conditions

Documented OFU Use of ESAs, Epoetin alfa,
or Darbepoetin alfa (2005-2011)
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Figure 4.8 Documented OFU use of ESAs, epoetin alfa, and darbepoetin alfa from 2005-2011
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Table 4.12 Defined OFU use of any ESAs, indications within a category are not mutually exclusive
ONS
conditions
Chronic
Anemia
Cancer
Bleeding
Injury
Cardiac
surgery
Blood
transfusion
Other known
OFU
Defined OFU
Any OFU

2005
675
(30.36)
510
(22.94)
194
(8.73)
177
(7.96)
350
(15.74)
284
(12.78)
19
(0.85)
1,127
(50.70)
2,223

2006
1,000
(24.33)
727
(17.69)
268
(6.52)
279
(6.79)
504
(12.26)
355
(8.64)
25
(0.61)
1,584
(38.54)
4,110

2007
865
(15.12)
611
(10.68)
260
(4.54)
334
(5.84)
333
(5.82)
224
(3.91)
32
(0.56)
1,464
(25.59)
5,722

Year
2008
648
(10.34)
386
(6.16)
206
(3.29)
166
(2.65)
494
(7.88)
288
(4.60)
50
(0.80)
1,116
(17.81)
6,267

2009
395
(7.16)
212
(3.84)
112
(2.03)
102
(1.85)
225
(4.08)
125
(2.26)
20
(0.36)
581
(10.53)
5,520

2010
241
(3.19)
132
(1.75)
85
(1.12)
57
(0.75)
156
(2.06)
122
(1.61)
13
(0.17)
440
(5.82)
7,563

2011
31
(0.55)
15
(0.26)
8
(0.14)
4
(0.07)
12
(0.21)
13
(0.23)
2
(0.04)
45
(0.79)
5,663

Total
3,855
(10.40)
2,593
(7.00)
1,133
(3.06)
1,119
(3.02)
2,074
(5.60)
1,411
(3.81)
161
(0.43)
6,357
(17.15)
37,068

Table 4.13 Defined OFU use of epoetin alfa only, indications within a category are not mutually exclusive
ONS
conditions
Chronic
Anemia
Cancer
Bleeding
Injury
Cardiac
surgery
Blood
transfusion
Other known
OFU
Defined OFU
Any OFU

2005
629
(35.48)
471
(26.57)
180
(10.15)
165
(9.31)
328
(18.50)
256
(14.44)
18
(1.02)
1,051
(59.28)
1,773

2006
850
(24.42)
611
(17.55)
227
(6.52)
242
(6.95)
427
(12.27)
280
(8.04)
22
(0.63)
1,347
(38.70)
3,481

2007
604
(13.46)
465
(10.36)
194
(4.32)
177
(3.94)
209
(4.66)
125
(2.79)
28
(0.62)
991
(22.09)
4,487

Year
2008
489
(9.85)
304
(6.13)
151
(3.04)
114
(2.30)
402
(8.10)
206
(4.15)
44
(0.89)
869
(17.51)
4,962

2009
316
(7.25)
164
(3.76)
92
(2.11)
88
(2.02)
188
(4.31)
91
(2.09)
17
(0.39)
477
(10.94)
4,360

2010
188
(3.22)
100
(1.71)
69
(1.18)
52
(0.89)
135
(2.31)
101
(1.73)
13
(0.22)
368
(6.30)
5,839

2011
27
(0.67)
13
(0.32)
8
(0.20)
4
(0.10)
10
(0.25)
13
(0.32)
1
(0.02)
40
(0.99)
4,052

Total
3,103
(10.72)
2,128
(7.35)
921
(3.18)
842
(2.91)
1,699
(5.87)
1072
(3.70)
143
(0.49)
5,143
(17.76)
28,954
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Table 4.14 Defined OFU use of darbepoetin alfa only, indications within a category are not mutually
exclusive
ONS
conditions
Chronic
Anemia
Cancer
Bleeding
Injury
Cardiac
surgery
Blood
transfusion
Other known
OFU
Defined OFU
Any OFU

2005
44
(10.30)
38
(8.90)
13
(3.04)
9
(2.11)
18
(4.22)
25
(5.85)
1
(0.23)
69
(16.16)
427

2006
144
(24.00)
112
(18.67)
39
(6.50)
35
(5.83)
74
(12.33)
73
(12.17)
3
(0.50)
226
(37.67)
600

2007
252
(20.79)
143
(11.80)
65
(5.36)
155
(12.79)
117
(9.65)
94
(7.76)
4
(0.33)
459
(37.87)
1212

Year
2008
158
(12.35)
82
(6.41)
54
(4.22)
49
(3.83)
91
(7.11)
82
(6.41)
6
(0.47)
244
(19.08)
1279

2009
78
(6.83)
47
(4.12)
20
(1.75)
14
(1.23)
36
(3.15)
33
(2.89)
3
(0.26)
103
(9.02)
1142

2010
52
(3.09)
32
(1.90)
16
(0.95)
5
(0.30)
20
(1.19)
21
(1.25)
0
(0.00)
70
(4.16)
1684

2011
4 (0.26)
(0.13)
2
(0.00)
0
(0.00)
0
(0.00)
2
(0.13)
0
(0.00)
1
(0.06)
5
(0.32)
1560

Total
732
(9.26)
456
(5.77)
207
(2.62)
267
(3.38)
358
(4.53)
328
(4.15)
18
(0.23)
1176
(14.88)
7904
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Specific Aim 2: Estimating the impacts of black box warning, NCD, and REMS on the on
proportion of visits with ESA use

Trends in ESA On-label, off-label supported, and off-label unsupported therapy

Annual trends in ESA ONS, OFS, and OFU use from 2005 to 2010 are shown in Table
4.15. These trends were measured in term of the proportion of visits which the drug was
prescribed over the total number of eligible admissions. Only full-year data was used to describe
the annual trends. In general, the proportions of epoetin alfa and darbepoetin alfa use for onlabel (ONS) and off-label supported (OFS) indications decreased from 2005 to 2011, while that
for off-label unsupported use (OFU) increase drastically.
Epoetin alfa ONS use increased 57% from 6.0% (2005) to 7.3% (2006) to 7.4% (2007).
At the same time, Darbepoetin alfa ONS use increased 250% from 1.0% (2005) to 1.7% (2006)
to 3.5% (2007). In 2008, ONS use of both drug started to decline. Epoetin alfa ONS use
decreased 76% from 7.4% (2007) to 5.0% (2008) to 1.8% (2009), after which its use increased
again slightly in 2010 (+1.3%). Darbepoetin alfa ONS use decreased 71% from 3.5% (2007) to
2.1% (2008) to 1.4% (2009), and to 1.0% (2010). Overall, in 6 years, epoetin alfa ONS use
declined 53% while the level of darbepoetin alfa ONS use remained the same.
We observed a continual reduction in the proportion of visits which epoetin alfa was used
in patients with OFS conditions. In contrast, darbepoetin alfa OFS use increased at the
beginning of the study period from 0.3% (2005) to 08% (2007) before it started to decreased.
Overall, epoetin alfa and darbepoetin alfa OFS use declined 85% and 54%, respectively.
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Similar to ONS use, we found that the OFU proportions increased at the beginning of the
study period (from 2005 to 2007), but reduced in 2008 and 2009. OFU use then surged in 2010.
These annual trends resulted in the overall increase in OFU use of 103% and 147% for epoetin
alfa and darbepoetin alfa between 2005 and 2011, respectively.
Table 4.15 Annual trend in the proportion of ESA use by use category*
Percent of visits with ESA use (%)

Use Category
2005

2006

2007

2008

2009

2010

%∆
(2005-2010)

Total (any ESAs)
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

6.9

8.9

10.8

7.1

3.2

3.2

-

+29.4%

+21.2%

-34.6%

-55.0%

+1.3%

2.8

2.4

2.4

1.7

0.6

0.5

-

-11.3%

-2.5%

-28.9%

-65.1%

-15.4%

3.7

6.3

7.0

7.0

5.2

7.8

-

+71.9%

+11.3%

-1.0%

-24.6%

+48.8%

6.0

7.3

7.4

5.0

1.8

2.2

-

+22.0%

+1.4%

-32.3%

-63.5%

+21.9%

2.5

2.0

1.6

1.3

0.4

0.4

-

-19.1%

-19.2%

-23.1%

-67.8%

-7.4%

3.0

5.4

5.6

5.5

4.1

6.0

-

+80.6%

+3.8%

-0.6%

-26.8%

+48.8%

1.0

1.7

3.5

2.1

1.4

1.0

-

+68.5%

+105.1%

-40.1%

-34.3%

-26.3%

0.3

0.5

0.8

0.4

0.2

0.1

-

+67.6%

+68.5%

-42.4%

-57.2%

-33.3%

0.7

1.0

1.5

1.4

1.2

1.8

-

+34.0%

+50.3%

-2.0%

-16.7%

+50.2%

-53.2%

-81.9%

+112.6%

Epoetin alfa
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

-62.7%

-85.0%

+103.0%

Darbepoetin alfa
ONS
∆ from preceding year
OFS
∆ from preceding year
OFU
∆ from preceding year

+.03%

-53.5%

+147.0%

*Only years with full-year reports are shown
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The proportions of visits with ESA use for the on-label, off-label supported, and off-label
unsupported were plotted against time to illustrate monthly trends in ESA use. In Figure 4.5,
monthly proportions of visits with ESA use for on-label indications are marked with -○- symbol
while that for off-label supported and off-label unsupported are marked with -×- and
-□-, respectively.
ESA use for on-label indication showed an increasing trend from 5.5% at month 1
(January 2005) to 10.3% at month 22 (October 2006), after which its use leveled off slightly to
7.7% in June 2007. A sudden increase in the percent of visits with ESA use was observed at
month 31 (July 2007). ESA on-label use level remained high for six months at approximately
18%. After that, a rapid drop to 7.9% at month 37 (January 2008) was observed. Off-label
supported use of ESAs (OFS) remained relative stable from 2005 to early 2008, and declined
slightly afterward. OFU use, however, began to increase from an average of 3.6% in 2005 to
6.4% (2006-September 2008). After October 2008, OFU use started to rise sharply (> 500%).
Similar trends were observed when use was broken down by drug. Monthly trends for each use
category of epoetin alfa and darbepoetin alfa are illustrated in Figure 4.9 and 4.11, respectively.
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Black box warning
begins

NCD
begins

REMS
begins

Figure 4.9 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported
indications from January 2005 to June 2011 expressed in term of proportion of visits with ESA use over
total number of eligible visits
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Black box warning
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NCD
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REMS
begins

Figure 4.10 Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with
ESA use over total number of eligible visits
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Black box warning
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NCD
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Figure 4.11 Monthly trend in darbepoetin use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with
ESA use over total number of eligible visits
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Outlier Identification and Data Manipulation

Outliers or wild data points referred to spurious observations that were highly
inconsistent with the rest of the series. An outlier was usually dealt with by checking the original
data for errors, replacing the observation with imputed values, or deleting such observations.189
Outliers oftentimes make the inference unreliable or even invalid and thus it was important to
detect and remove such outliers.
Two possible set of outliers were detected in our data. In the ONS series, we observed a
drastic increase in the percent of visits after month 30. ONS utilization level remained high for
six month then dropped off suddenly at month 37. Secondly, possible outliers were detected in
the all OFU series after month 70 when the proportion increased sharply. We did not believe
that such extreme changes in the series were caused by any external interventions, but such
sudden changes were likely to cause by errors in data collection and reporting of the eligible
admissions that could not be corrected. At month 31-36, we found that even though the number
of visits which a drug was prescribed remained relatively stable, the number of ONS eligible
admission changed suspiciously. During those six months, the number of admissions with ONS
conditions was halved from that at month 30 and resumed to normal level at month 37.
Likewise, at month 70, there was a rise in the number of visits with ESA OFU use and a drop in
the number admissions with known OFU conditions, leading to an extreme shift on the OFU
proportion after month 70. Similar outliers were also detected for both EPO and DARB series.
To account for these spurious data points before modeling interrupted time-series
(Specific Aim 2), values during the outlier months were imputed using time-series forecasting
method. A series that minimized root mean square errors was fit to generate predicted y values
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that were to be used in the subsequent analysis. Forecasting assumes that the trend in proportion
continued from month 30 into month 31 to 36 as if the ONS series was left to continue without
any interventions. The same approach was used from month 71 onward for the OFU series. The
adjusted series with imputed values replacing the outliers are shown in Figure 4.12-4.14. These
series were used in the subsequent interrupted time-series analysis.

Black box warning
begins

NCD
begins

REMS
begins

Figure 4.12 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported
indications from January 2005 to June 2011 expressed in term of proportion of visits with ESA use over
total number of eligible visits after data manipulation
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Figure 4.13 Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with
ESA use over total number of eligible visits after data manipulation
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Figure 4.14 Monthly trend in darbepoetin alfa use for the on-label, off-label supported, and off-label
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with
ESA use over total number of eligible visits after data manipulation
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Time-Series Model selection

The application of time series to model ESA prescribing patterns and the effects of the
intervention on the utilization patterns relied on several statistical assumptions. In order to
obtain unbiased OLS estimation, it was important to assume that the error terms and all
explanatory variables were uncorrelated for all time periods. More importantly, serial correlation
(autocorrelation) must not be present in the data. Serial correlation referred to the existence of
the correlations between the observations’ errors terms in different periods. The existence of
serial correlation implied heteroskedasticity of the variance over time resulting in falsely
estimation of the standard errors. Only once the assumption of having no serial correlation was
fulfilled that the OLS estimator became the best linear unbiased estimator (BLUE).
In an attempt to fit the best time-series model for our data, several approaches were
taken to attenuate serial correlations and produce stationary series. First, autocorrelation patterns
at different lags were assessed. Serial correlation was virtually detected with the sample
autocorrelation function plot (ACF) generated by -proc arima- with identify statement. The slow
decay in the ACF plot shown in Panel B of Figure 4.15, 4.16, and 4.17 indicated that correlation
exists between the dependent variable (proportion of visits with ESA use) and the value in the
previous period for all three models (ONS, OFS, and OFU). This slow decay in the ACF plots
also implied that the series was nonstationary. Second, white noise test, which intended to test a
hypothesis that none of the autocorrelations were significantly different from zero, confirmed the
existence of autocorrelation as the null hypothesis was rejected strongly for all possible lag
values (p < 0.0001). Autocorrelations were tested in epoetin alfa and darbepoetin alfa model
and similar results of strong autocorrelation were observed (data not shown).
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Figure 4.15 Diagnostic of autocorrelation in the ESA-ONS series
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Figure 4.16 Diagnostic of autocorrelation in the ESA-OFS series
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Figure 4.17 Diagnostic of autocorrelation in the ESA-OFU series

To eliminate serial correlation, the use of first-differencing method of the series was
suggested.199, 200 First-differencing referred to a transformation on a time series constructed by
taking the difference of adjacent time period, where the earlier time period was subtracted from
the later time period.201 First differencing of the data resolved the issue of serial correlation in
the ONS and OFU models (all white noise test p-values > 0.05, data not shown). However, the
white noise test revealed the remaining of serial correlations in the OFS model (all p-value <
0.05, data not shown). First-differencing series and autocorrelation plots after first-differencing
of the ESA- ONS, ESA-OFS, and ESA-OFU series are shown in Figure 4.18, 4.19, and 4.20.
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Figure 4.18 Diagnostic of autocorrelation in the ESA-ONS series after first-differencing

Figure 4.19 Diagnostic of autocorrelation in the ESA-OFS series after first-differencing
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Figure 4.20 Diagnostic of autocorrelation in the ESA-OFU series after first-differencing

As mentioned earlier, the presence of autocorrelation in the model resulted in inaccuracy
of standard errors even when the coefficients were estimated in an unbiased manner. To correct
for autocorrelation remained in the OFS series and to obtain accurate standard errors of the
estimates, Newey-West’s serial correlation-robust estimation was applied to all models. Newey
n (29)
and West suggested the integer part of 4(
as the number of lags in the model if no
)
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specific theory can otherwise be specified.201 This approach corrected for autocorrelation
remained in the first-differencing OFS series and was also a more conservative approach of
correcting for any autocorrelation that may still remain undetected in the ONS and OFU series.
Figure 4.21 – 4.23 show the residual plots of the first-differencing ONS, OFS, and OFU when
the series were re-estimated with a lag of four (as calculated with Newey-West’s method). The
residuals for all three series appeared to follow a normal distribution.
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Figure 4.21 Residual normality diagnostic of first-differenced ESA-ONS series with a lag of four

Figure 4.22 Residual normality diagnostic of first-differenced ESA-OFS series with a lag of four
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Figure 4.23 Residual normality diagnostic of first-differenced ESA-OFU series with a lag of four

The interventions were tested with segmented ordinary least-square regressions once that
the endogeneous pattern in the series was reduced to random through transformation and
modeling. Using the estimating equations specified in Chapter 3: Yt= β0 + β1t + β2intervention1 +
β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+ β7 intervention3
× t3 + M2-M12 + et, the final model included first-differencing of all variables and NeweyWest’s serial correlation-robust estimation with the lag of four time periods. Since the
aggregated time series was monthly, a set of 11 months variables (M2-M12) were included in the
model to account of seasonal cycles.
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Impacts of Safety interventions on the proportion of visits with ESA use

The aim of this analysis was to determine if the three safety interventions: black box
warning (BBW), national coverage determination (NCD), and risk evaluation and mitigation
strategies program (REMS) were associated with change in ESA on-label, off-label supported,
and off-label unsupported use. The parameters estimated from the time-series analysis are given
in Table 4.16, 4.17, and 4.18 for overall ESAs, epoetin alfa, and darbepoetin alfa, respectively.
On-label use of ESAs (ONS)
From the beginning of our study period in January 2005 to the issuance of a black box
warning there was a non-significant, increasing trend in ESA on-label use (0.1% increase in the
use proportion per month, p = 0.1360). The addition of a black box warning onto ESA label in
March 2007 was associated with a significant 1.2 percentage point drop in the proportion of
visits with ESA on-label use to all ONS eligible visits (95% CI -1.979, -0.358, p = 0.0050). The
use of ESAs for the on-label indications continued in a decreasing trend after the first
intervention (β = -0.142, p = 0.1970). No other statistical significant reduction in the proportion
was found though NCD and REMS resulted in non-significant decreased in the level of ONS
prescribing (β NCD = -0.608, p = 0.1340; β REMS = -0.738, p = 0.0730).
Off-label supported use of ESAs (OFS)
Black box warning issuance did not significantly lead to a significant reduction in ESA
on-label supported use (OFS) like the change in reimbursement policy National Coverage
Determination did in April 2008. NCD was the only significant intervention for OFS use. There
was a significant 0.3 percentage point drop in the proportion of visits with ESA-OFS use after
the coverage change in April 2008 (95% CI -0.447, -0.182, p < 0.0001). Finally, REMS did not
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have any significant impact on the level of ESA use for OFS indications (β REMS = -0.017, p =
0.7720).
Off-label unsupported use of ESAs (OFU)
None of the intervention appeared to have an effect on the utilization patterns of ESAs
for the off-label unsupported indications (OFU).
Epoetin alfa
The analysis was re-performed by specific drug: epoetin alfa (Table 4.17) and
darbepoetin alfa (Table 4.18). Black box warning appeared to have no significant effect on the
level of epoetin alfa use, for any indications (all p-values > 0.5). NCD resulted in a 0.3%
immediate drop in the proportion of OFS-EPO use in at the first month after the intervention was
implemented (95% CI -0.437, -0.170, p < 0.0001) and non-significant decreasing trends
afterward. REMS, on the other hand, did not have any significant impact of epoetin alfa
utilization patterns.
Darbepoetin alfa
Black box warning reduced level of darbepoetin alfa on-label use significantly darbepoetin alfa use drop 0.6% after the intervention took place (95% CI -0.670, 0.433, p <
0.0001). In our sample, the reversed effect of black box warning was observed in the off-label
use. Black box warning resulted in a significant rise in off-label supported and unsupported use
of darbepoetin alfa in April 2007 (02% and 0.9% increase for OFS and OFU darb use,
respectively). National coverage determination led to a significant increase in on-label use only
(0.4% point reduction, 95% CI -0.466, -0.256, p < 0.0001). Finally, the use of darbepoetin alfa

157

was most affected by REMS. There was a significant 0.5% percentage point drop in the
proportion of visits which darbepoetin alfa was used on-label (95% CI -0.637, -0.443, p <
0.0001) and also for off-label unsupported indications (95% CI -0.805, -0.223, p < 0.0010) in
April 2010, one month after the implementation of REMS.
None of the intervention effect appeared to be permanent. No significant changes in the
trend of use continued after the implementation of the interventions though non-significantly
decreasing trends were observed.
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Table 4.16 Relative Impacts of Interventions on proportion of ESA use by use category
Variable
β
Model 1: ONS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 2: OFS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 3: OFU
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change

NeweyWest SE

Parameters
95 % Confidence
Interval

t-statistics

p-value

0.131

0.0867

[-0.042, 0.305]

1.51

0.1360

-1.169*
-0.142

0.4052
0.1090

[-1.979, - 0.358]
[-0.360, 0.076]

-2.88
-1.30

0.0050
0.1970

-0.608
-0.101

0.4001
0.1791

[-1.409, 0.192]
[-0.459, 0.257]

-1.52
-0.56

0.1340
0.5750

-0.738
0.076

0.4035
0.2369

[-1.545, 0.070]
[-0.398, 0.550]

-1.83
0.32

0.0730
0.7490

-0.005

0.0634

[-0.132, 0.121]

-0.08

0.9330

0.167
-0.023

0.0876
0.0889

[-0.008, 0.343]
[-0.201, 0.155]

1.91
-0.26

0.0610
0.7940

-0.315*
-0.014

0.0661
0.0732

[-0.447, -0.182]
[-0.160, 0.133]

-4.76
-0.19

< 0.0001
0.8520

-0.017
0.011

0.0597
0.0537

[-0.137, 0.102]
[-0.097, 0.118]

-0.29
0.20

0.7720
0.8420

0.134

0.1578

[-0.182, 0.450]

0.85

0.3980

0.597
-0.202

0.4455
0.1900

[-0.295, 1.488]
[-0.582, 0.178]

1.34
-1.06

0.1860
0.2920

0.205
0.078

0.4205
0.1651

[-0.637. 1.046]
[-0.252, 0.409]

0.49
0.47

0.6280
0.6370

-0.434
-0.047

0.4667
0.1647

[-1.368, 0.500]
[-0.377, 0.282]

-0.93
-0.29

0.3560
0.7760
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Table 4.17 Relative Impacts of Interventions on proportion of epoetin alfa use by use category
Variable
β
Model 1: ONS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 2: OFS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 3: OFU
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change

NeweyWest SE

Parameter
95 % Confidence
Interval

t-statistics

p-value

0.046

0.0927

[-0.140, 0.232]

0.50

0.6220

-0.596
-0.063

0.4294
0.1594

[-1.456, 0.263]
[-0.382, 0.255]

-1.39
-0.40

0.1700
0.6920

-0.177
-0.078

0.4048
0.1976

[-0.987, 0.633]
[-0.474, 0.317]

-0.44
-0.40

0.6630
0.6930

-0.138
0.070

0.4058
0.2090

[0.0950, 0.674]
[-0.348, 0.488]

-0.34
0.33

0.7340
0.7390

-0.026

0.0520

[-0.130, 0.079]

-0.49

0.6250

0.021
0.014

0.0770
0.0691

[-0.133, 0.175]
[-0.124, 0.152]

0.27
0.20

0.7880
0.8390

-0.303*
-0.015

0.0669
0.0563

[-0.437, -0.170]
[-0.128, 0.097]

-4.54
-0.27

< 0.0001
0.7870

0.043
0.001

0.0585
0.0467

[-0.074, 0.160]
[-0.092, 0.095]

0.73
0.03

0.4660
0.9750

0.117

0.1150

[-0.113, 0.347]

1.02

0.3120

-0.117
-0.114

0.2737
0.1465

[-0664, 0.431]
[-0.407, 0.179]

-0.43
-0.78

0.6710
0.4410

-0.014
-0.016

0.2653
0.1288

[-0.545, 0.517]
[-0.273, 0.242]

-0.05
-0.12

0.9580
0.9040

0.221
-0.044

0.2941
0.1393

[-0.367, 0.810]
[-0.323, 0.235]

0.75
-0.32

0.4550
0.7540
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Table 4.18 Relative Impacts of Interventions on proportion of darbepoetin alfa use by use category
Variable
β
Model 1: ONS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 2: OFS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 3: OFU
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change

NeweyWest SE

Parameter
95 % Confidence
Interval

t-statistics

p-value

0.088

0.0437

[0.000, 0.175]

2.00

0.0500

-0.552*
-0.084

0.0591
0.0564

[-0.670, -0.433]
[-0.197, 0.028]

-9.34
-1.50

< 0.0001
0.1400

-0.361*
-0.021

0.0524
0.0498

[-0.466, -0.256]
[-0.121, 0.078]

-6.90
-0.43

< 0.0001
0.6700

-0.540*
0.007

0.0485
0.0429

[-0.637, -0.443]
[-0.079, 0.093]

-11.13
0.17

< 0.0001
0.8650

0.020

0.0163

[-0.013, 0.053]

1.22

0.2260

0.158*
-0.038

0.0533
0.0533

[0.052, 0.265]
[-0.098, 0.022]

2.97
-1.26

0.0040
0.2140

0.011
0.002

0.0485
0.0286

[-0.086, 0.108]
[-0.056, 0.059]

0.23
0.06

0.8160
0.9540

-0.049
0.010

0.0471
0.0170

[-0.143, 0.046]
[-0.024, 0.044]

-1.03
0.59

0.3080
0.5540

0.018

0.0652

[-0.113, 0.148]

0.27

0.7880

0.870*
-0.102

0.1775
0.0786

[0.515, 1.255]
[-0.259, 0.056]

4.90
-1.29

< 0.0001
0.2010

0.361*
0.101

0.1625
0.0604

[0.036, 0.686]
[-0.020, 0.222]

2.22
1.68

0.0300
0.0990

-0.537*
-0.007

0.1568
0.0515

[-0.850, -0.223]
[-0.110, 0.096]

-3.42
-0.14

0.0010
0.8900
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Specific Aim 3: Estimating the impact of of black box warning, NCD, and REMS on odds
of a patient being prescribed with ESAs

Outlier identification and Data manipulation

Similar to the visit level analysis in the previous section, we observed a sudden drop in
the number of patients admitted to Cerner hospitals with ONS conditions at month 31-36. This
reduction was similar to that in the denominator cohort of eligible visits used for a time-series
analysis and was likely to cause by errors in data recording. Since it was not possible to impute
the number of eligible patients, we decided to drop observations at month 31-36 completely from
the analysis. No other possible outliers were found in other use cohorts and all patients with
OFS and OFU indications were retained in the subsequent analysis.
As demonstrated in the descriptive analysis of ESA users, missing information on race,
admission type, discharge disposition, primary payer, and medical specialty was common in our
data. To retain as many subjects as possible in our final analytical cohort, we opted to conctruct
a ‘Missing’ category to be in the analytical models. This approach was adopted for all variables
with vast number of missing values. However, due to a small number of observations with
missing gender information (N = 174 patients), these observations were excluded completely
from the analysis.
The ONS cohort consisted of 730,412 patients with ONS conditions. Among them,
33,004 patients (15.6%) received ESAs (N epoetin alfa = 25,494 (77.2%) and N darbepoetin =
7,724 alfa (23.4%)). The OFS cohort consisted of 505,658 patients with OFS conditions, 5,140
(1.0%) of which were prescribed with ESAs (N epoetin alfa = 4,093 (%), N darbepoetin alfa =
1,089 (%)). The OFU cohort consisted of 559,917 patients with documented OFU conditions,
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4,491 (0.80%) of which received ESAs (N epoetin alfa = 3,736 (83.1%), N darbepoetin alfa =
780 (17.4%)). Number of epoetin alfa and darbepoetin alfa users did not sum to the total number
of ESA users as some patients received both drugs during the same visit.

Bivariate analysis

Patients with ONS conditions

Bivariate chi-square tests showed statistically significant differences for all demographic,
hospital characteristic, and physician characteristic variables between ONS+ESA users and ONS
patients who did not use ESAs. Compared to patients with ONS conditions who did not receive
the drug, ESA users appeared to older (mean age 65.4 (SD 15.61) vs. 58.4 (SD 18.52)), consisted
of greater proportion of male, African-American, and had Medicare as their primary payer. ESA
users were more complex than the non-users as they had greater comorbidity score (CCI 2.64
(SD 1.917) vs. CCI 1.19 (1.804)) and tended to stay in the hospital for a longer period of time
(LOS 11.6 (SD 15.63) vs. 4.3 (6.42)). Greater proportion of ESA users was admitted as
emergency cases, but fewer were discharged home. To a larger extent, ESA ONS users were
discharged to hospice, institutionalized and non-institutionalized care, or died in the hospital
compared to the non-users with the same indications. Patients admitted to larger hospitals with
greater than 300 beds, and teaching hospitals received ESAs to a greater extent than patients in
seen in non-teaching, and small hospitals. Finally, greater proportion of ESA users were
admitted by non-specialists compared to the ONS patients who did not receive the drug. Similar
results were observed in the separate analyses of epoetin alfa and darbepoetin alfa. Descriptive
results are shown in Table 4.19, 4.20, and 4.21 for ESA, epoetin alfa, and darbepoetin alfa users,
respectively).
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Table 4.19 Descriptive analysis of users and non-users of ESAs with ONS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with ONS conditions (column %)
Total
ESA Users
Non-users

Chi-sq,
p-value

62,556 (8.56)
180,601 (24.73)
184,676 (25.28)
129,368 (17.71)
117,046 (16.02)
56,165 (7.69)
730,412 (100.00)
58.8 (18.45)

831 (2.52)
4,969 (15.06)
8,777 (26.59)
7,432 (22.52)
7,722 (23.40)
3,273 (9.92)
33,004 (4.52)
65.4 (15.61)

61,725 (8.85)
175,632 (25.19)
175,899 (25.22)
121,936 (17.48)
109,324 (15.68)
52,892 (7.58)
697,408 (95.48)
58.4 (18.52)

4652.73
p < 0.0001

302,245 (41.38)
428,167 (58.62)
730,412 (100.00)

16,525 (50.07)
16,479 (49.93)
33,004 (4.52)

285,720 (40.97)
411,688 (59.03)
697,408 (95.48)

1076.00
p < 0.0001

561,384 (76.86)
115,395 (15.80)
34,898 (4.78)
18,735 (2.56)
730,412 (100.00)

20,571 (62.33)
9,622 (29.15)
2,212 (6.70)
599 (1.81)
33,004 (4.52)

540,813 (77.55)
105,773 (15.17)
32,686 (4.69)
18,136 (2.60)
697,408 (95.48)

5195.68
p < 0.0001

163,596 (22.40)
40,052 (5.48)
134,077 (18.36)

10,970 (33.24)
1,462 (4.43)
2,246 (6.81)

152,626 (21.88)
38,590 (5.53)
131,831 (18.90)

6044.95
p < 0.0001

23,582 (3.23)
105,115 (14.39)
263,990 (36.14)
730,412 (100.00)

676 (2.05)
2,865 (8.68)
14,785 (44.80)
33,004 (4.52)

22,906 (3.28)
102,250 (14.66)
249,205 (35.73)
697,408 (95.48)

256734 (35.15)
81658 (11.18)
290265 (39.74)
101,755 (13.93)
730,412 (100.00)
1.26 (1.834),
-1 to 14
4.6 (7.25),
0 to 814

19962 (60.48)
5145 (15.59)
5487 (16.63)
2,410 (7.30)
33,004 (4.52)
2.64 (1.917),
-1 to 13
11.6 (15.63),
0 to 588

236772 (33.68)
76513 (10.97)
284778 (40.83)
99,345 (14.24)
697,408 (95.48)
1.19 (1.804),
-1 to 14
4.3 (6.42),
0 to 814

12650.48
p < 0.0001

16,526 (2.26)

2,285 (6.92)

14,241 (2.04)

14167.57

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
428,180 (58.62)
self care
Discharged to Hospice
8,356 (1.14)
Discharged/transferred to
106,950 (14.64)
institutionalized care
Discharged/transferred to
95,472 (13.07)
noninstitutionalized care
Other/Not recorded
74,928 (10.26)
Total (row %)
730,412 (100.00)
Hospital Characteristics
Geographic region
Northeast
331,785 (45.42)
Midwest
153,858 (21.06)
South
202,856 (27.77)
West
41,913 (5.74)
Total (row %)
730,412 (100.00)
Bed size
≤ 99
43,083 (5.90)
100-199
107,679 (14.74)
200-299
146,974 (20.12)
300-499
178,578 (24.45)
≥500
254,098 (34.79)
Total (row %)
730,412 (100.00)
Teaching status
Teaching
523,350 (71.65)
Non-teaching
207,062 (28.35)
Total (row %)
730,412 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
73,589 (10.07)
Specialist
288,084 (39.44)
Not recorded
368,739 (50.48)
Total (row %)
730,412 (100.00)

13,729 (41.60)

414,451 (59.43)

p < 0.0001

753 (2.28)
9,820 (29.75)

7,603 (1.09)
97,130 (13.93)

5,978 (18.11)

89,494 (12.83)

439 (1.33)
33,004 (4.52)

74,489 (10.68)
697,408 (95.48)

12,578 (38.11)
8,157 (24.72)
10,084 (30.55)
2,185 (6.62)
33,004 (4.52)

319,207 (45.77)
145,701 (20.89)
192,772 (27.64)
39,728 (5.70)
697,408 (95.48)

768.88
p < 0.0001

756 (2.29)
3,582 (10.85)
5,953 (18.04)
11,150 (33.78)
11,563 (35.04)
33,004 (4.52)

42,327 (6.07)
104,097 (14.93)
141,021 (20.22)
167,428 (24.01)
242,535 (34.78)
697,408 (95.48)

2424.64
p < 0.0001

24,799 (75.14)
8,205 (24.86)
33,004 (4.52)

498,551 (71.49)
198,857 (28.51)
697,408 (95.48)

207.04
p < 0.0001

4,765 (14.44)
11,032 (33.43)
17,207 (52.14)
33,004 (4.52)

68,824 (9.87)
277,052 (39.73)
351,532 (50.41)
697,408 (95.48)

988.76
p < 0.0001
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Table 4.20 Descriptive analysis of users and non-users of epoetin alfa with ONS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with ONS conditions (column %)
Total
Epo Users
Non-users

Chi-sq,
p-value

62,556 (8.56)
180,601 (24.73)
184,676 (25.28)
129,368 (17.71)
117,046 (16.02)
56,165 (7.69)
730,412 (100.00)
58.5 (18.50)

584 (2.29)
3,656 (14.34)
6,668 (26.16)
5,785 (22.69)
6,155 (24.14)
2,646 (10.38)
25,494 (3.49)
66.0 (15.45)

61,972 (8.79)
176,945 (25.10)
178,008 (25.25)
123,583 (17.53)
110,891 (15.73)
53,519 (7.59)
704,918 (96.51)
58.8 (18.45)

4079.00
p < 0.0001

302,245 (41.38)
428,167 (58.62)
730,412 (100.00)

12,643 (49.59)
12,851 (50.41)
25,494 (3.49)

289,602 (41.08)
415,316 (58.92)
704,918 (96.51)

734.39
p < 0.0001

561,384 (76.86)
115,395 (15.80)
34,898 (4.78)
18,735 (2.56)
730,412 (100.00)

15,593 (61.16)
7,721 (30.29)
1,870 (7.34)
310 (1.22)
25,494 (3.49)

545,791 (77.43)
107,674 (15.27)
33,028 (4.69)
18,425 (2.61)
704,918 (96.51)

4904.77
p < 0.0001

163,596 (22.40)
40,052 (5.48)
134,077 (18.36)

7,899 (30.98)
1,128 (4.42)
1,672 (6.56)

155,697 (22.09)
38,924 (5.52)
132,405 (18.78)

4064.66
p < 0.0001

23,582 (3.23)
105,115 (14.39)
263,990 (36.14)
730,412 (100.00)

390 (1.53)
2,756 (10.81)
11,649 (45.69)
25,494 (3.49)

23,192 (3.29)
102,359 (14.52)
252,341 (35.80)
704,918 (96.51)

256,734 (35.15)
81,658 (11.18)
290,265 (39.74)
101,755 (13.93)
730,412 (100.00)
1.26 (1.834),
-1 to 14
4.6 (7.25),
0 to 814

15,736 (61.72)
4,295 (16.85)
3,739 (14.67)
1,724 (6.76)
25,494 (3.49)
2.58 (1.913),
-1 to 13
11.1 (15.4),
0 to 588

240,998 (34.19)
77,363 (10.97)
286,526 (40.65)
100,031 (14.19)
704,918 (96.51)
1.21 (1.813),
-1 to 14
4.4 (6.69),
0 to 814

11220.11
p < 0.0001

16,526 (2.26)

1,728 (6.78)

14,798 (2.10)

10584.91

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
428,180 (58.62)
self care
Discharged to Hospice
8,356 (1.14)
Discharged/transferred to
106,950 (14.64)
institutionalized care
Discharged/transferred to
95,472 (13.07)
noninstitutionalized care
Other/Not recorded
74,928 (10.26)
Total (row %)
730,412 (100.00)
Hospital Characteristics
Geographic region
Northeast
331,784 (45.42)
Midwest
153,858 (21.06)
South
202,856 (27.77)
West
41,913 (5.74)
Total (row %)
730,412 (100.00)
Bed size
≤ 99
43,083 (5.90)
100-199
107,679 (14.74)
200-299
146,974 (20.12)
300-499
178,578 (24.45)
≥500
254,098 (34.79)
Total (row %)
730,412 (100.00)
Teaching status
Teaching
523,350 (71.65)
Non-teaching
207,062 (28.35)
Total (row %)
730,412 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
73,589 (10.07)
Specialist
288,084 (39.44)
Not recorded
368,739 (50.48)
Total (row %)
730,412 (100.00)

10,505 (41.21)

417,675 (59.25)

p < 0.0001

598 (2.35)
7,450 (29.22)

7,758 (1.10)
99,500 (14.12)

4,829 (18.94)

90,643 (12.86)

384 (1.51)
25,494 (3.49)

74,544 (10.57)
704,918 (96.51)

9,860 (38.68)
4,000 (15.69)
9,541 (37.42)
2,093 (8.21)
25,494 (3.49)

321,925 (45.67)
149,858 (21.26)
193,315 (27.42)
39,820 (5.65)
704,918 (96.51)

1794.34
p < 0.0001

540 (2.12)
2,714 (10.65)
4,386 (17.20)
9,306 (36.50)
8,548 (33.53)
25,494 (3.49)

42,543 (6.04)
104,965 (14.89)
142,588 (20.23)
169,272 (24.01)
245,550 (34.83)
704,918 (96.51)

2634.36
p < 0.0001

18,930 (74.25)
6,564 (25.75)
25,494 (3.49)

504,420 (71.56)
200,498 (28.44)
704,918 (96.51)

88.01
p < 0.0001

3,993 (15.66)
8,762 (34.37)
12,739 (49.97)
25,494 (3.49)

69,596 (9.87)
279,322 (39.62)
356,000 (50.50)
704,918 (96.51)

992.29
p < 0.0001

167

Table 4.21 Descriptive analysis of users and non-users of darbepoetin alfa with ONS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with ONS conditions (column %)
Total
Darb Users
Non-users

Chi-sq,
p-value

62,556 (8.56)
180,601 (24.73)
184,676 (25.28)
129,368 (17.71)
117,046 (16.02)
56,165 (7.69)
730,412 (100.00)
58.8 (18.46)

251 (3.25)
1,348 (17.45)
2,154 (27.89)
1,701 (22.02)
1,624 (21.03)
646 (8.36)
7,724 (1.06)
63.7 (16.01)

62,305 (8.62)
179,253 (24.80)
182,522 (25.26)
127,667 (17.67)
115,422 (15.97)
55,519 (7.68)
722,688 (98.94)
58.7 (18.47)

653.79
p < 0.0001

302,245 (41.38)
428,167 (58.62)
730,412 (100.00)

3,983 (51.57)
3,741 (48.43)
7,724 (1.06)

298,262 (41.27)
424,426 (58.73)
722,688 (98.94)

333.94
p < 0.0001

561,384 (76.86)
115,395 (15.80)
34,898 (4.78)
18,735 (2.56)
730,412 (100.00)

5,133 (66.46)
1,949 (25.23)
347 (4.49)
295 (3.82)
7,724 (1.06)

556,251 (76.97)
113,446 (15.70)
34,551 (4.78)
18,440 (2.55)
722,688 (98.94)

598.96
p < 0.0001

163,596 (22.40)
40,052 (5.48)
134,077 (18.36)

3,133 (40.56)
340 (4.40)
583 (7.55)

160,463 (22.20)
39,712 (5.50)
133,494 (18.47)

2651.50
p < 0.0001

23,582 (3.23)
105,115 (14.39)
263,990 (36.14)
730,412 (100.00)

287 (3.72)
116 (1.50)
3,265 (42.27)
7,724 (1.06)

23,295 (3.22)
104,999 (14.53)
260,725 (36.08)
722,688 (98.94)

256,734 (35.15)
81,658 (11.18)
290,265 (39.74)
101,755 (13.93)
730,412 (100.00)
1.26 (1.834),
-1 to 14
4.6 (7.25),
0 to 814

4,336 (56.14)
884 (11.44)
1,775 (22.98)
729 (9.44)
7,724 (1.06)
2.83 (1.916),
-1 to 13
13.4 (17.71),
0 to 398

252,398 (34.92)
80,774 (11.18)
288,490 (39.92)
101,026 (19.98)
722,688 (98.94)
1.24 (1.826),
-1 to 14
4.6 (7.00),
0 to 814

1643.67
p < 0.0001

16,526 (2.26)

582 (7.53)

15,944 (2.21)

3682.14

p < 0.0001

p < 0.0001
p < 0.0001

168

Discharged to home/
428,180 (58.62)
self care
Discharged to Hospice
8,356 (1.14)
Discharged/transferred to
106,950 (14.64)
institutionalized care
Discharged/transferred to
95,472 (13.07)
noninstitutionalized care
Other/Not recorded
74,928 (10.26)
Total (row %)
730,412 (100.00)
Hospital Characteristics
Geographic region
Northeast
331,785 (45.42)
Midwest
153,858 (21.06)
South
202,856 (27.77)
West
41,913 (5.74)
Total (row %)
730,412 (100.00)
Bed size
≤ 99
43,083 (5.90)
100-199
107,679 (14.74)
200-299
146,974 (20.12)
300-499
178,578 (24.45)
≥500
254,098 (34.79)
Total (row %)
730,412 (100.00)
Teaching status
Teaching
523,350 (71.65)
Non-teaching
207,062 (28.35)
Total (row %)
730,412 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
73,589 (10.07)
Specialist
288,084 (39.44)
Not recorded
368,739 (50.48)
Total (row %)
730,412 (100.00)

3,277 (42.43)

424,903 (58.79)

p < 0.0001

162 (2.10)
2,465 (31.91)

8,194 (1.13)
104,485 (14.46)

1,182 (15.30)

94,290 (13.05)

56 (0.73)
7,724 (1.06)

74,872 (10.36)
722,688 (98.94)

2,879 (37.27)
4,183 (54.16)
566 (7.33)
96 (1.24)
7,724 (1.06)

328,906 (45.51)
149,675 (20.71)
202,290 (27.99)
41,817 (5.79)
722,688 (98.94)

5622.26
p < 0.0001

220 (2.85)
886 (11.47)
1,648 (21.34)
1,882 (34.37)
3,088 (39.98)
7,724 (1.06)

42,863 (5.93)
106,793 (14.78)
145,326 (20.11)
176,696 (24.45)
251,010 (34.73)
722,688 (98.94)

246.02
p < 0.0001

6,016 (77.89)
1,708 (22.11)
7,724 (1.06)

517,334 (71.58)
205,354 (28.42)
722,688 (98.94)

149.44
p < 0.0001

816 (10.56)
2,310 (29.91)
4,598 (59.53)
7,724 (1.06)

72,773 (10.07)
285,774 (39.54)
364,141 (50.39)
722,688 (98.94)

308.29
p < 0.0001
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Patients with OFS conditions

Bivariate chi-square tests showed statistically significant differences between OFS+ESA
users and OFS patients for all demographic, hospital characteristic, and physician characteristic
variables with an exception of teaching status and darbepoein alfa ESA-OFS use.
Overall OFS patients consisted of relatively young population (average age 49.5 (SD
24.14)) who were largely women (75.4%). Interestingly, OFS+ESA group consisted of much
older patients than the non-users population (average age 70.1 (SD 15.40)). Due to the nature of
conditions defined as eligible OFS conditions such as postpartum anemia, only 25% of the OFS
cohort was men. However, almost 50% of ESA-OFS users were male. More than half of ESA
users had Medicare as their primary payer compared to the non-users (38% vs 17% Medicare
patients). ESA users with OFS conditions were also sicker than the non-users (CCI 1.94 (SD
1.823) vs. CCI 1.02 (1.443)), stayed in the hospital much longer, (L-O-S 15.7 (SD 19.48) vs. 4.2
(6.67)), more frequently were admitted as emergency cases (57.2%), discharged to hospice,
institutionalized and non-institutionalized care, or died in the hospital. Results from bivariate
analysis of the OFS cohort showed a similar pattern in patient and hospital characteristics of
ESA users compared to the ONS cohort. For instance, erythropoietins were used to a much
higher extent in large and teaching hospitals. Descriptive results are shown in Table 4.22, 4.23,
and 4.24 for ESA, epoetin alfa, and darbepoetin alfa users, respectively).
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Table 4.22 Descriptive analysis of users and non-users of ESAs with OFS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFS conditions (column %)
Total
ESA Users
Non-users

Chi-sq,
p-value

171,290 (33.87)
104,642 (20.69)
57,998 (11.47)
52,212 (10.33)
69,200 (13.69)
50,316 (9.95)
505,658 (100.00)
49.5 (24.14)

132 (2.57)
464 (9.03)
976 (18.99)
1,177 (22.90)
1,488 (28.95)
903 (17.57)
5,140 (1.02)
70.1 (15.40)

171,158 (34.20)
104,178 (20.81)
57,022 (11.39)
51,035 (10.200
67,712 (13.53)
49,413 (9.87)
500,518 (98.98)
49.2 (24.13)

4081.87
p < 0.0001

124,431 (24.61)
381,227 (75.39)
505,658 (100.00)

2,408 (49.85)
2,732 (53.15)
5,140 (1.02)

122,023 (24.38)
378,495 (75.62)
500,518 (98.98)

1384.49
p < 0.0001

359,136 (71.02)
83,978 (16.61)
48,549 (9.60)
13,995 (2.77)
505,658 (100.00)

3,901 (75.89)
877 (17.06)
256 (4.98)
106 (2.06)
5,140 (1.02)

355,235 (70.97)
83,101 (16.60)
48,293 (9.65)
13,889 (2.77)
500,518 (98.98)

142.80
p < 0.0001

89,213 (17.64)
68,541 (13.55)
85,682 (16.94)

1,954 (38.02)
250 (4.86)
441 (8.58)

87,259 (17.43)
68,291 (13.64)
85,241 (17.03)

1925.67
p < 0.0001

17,817 (3.52)
63,645 (12.59)
180,760 (35.75)
505,658 (100.00)

124 (2.41)
328 (6.38)
2,043 (39.75)
5,140 (1.02)

17,693 (3.53)
6,3317 (12.65)
178,717 (35.71)
500,518 (98.98)

190,791 (37.73)
115,098 (22.76)
160,897 (31.82)
38,872 (7.69)
505,658 (100.00)
1.03 (1.450),
0 to 13
4.3 (7.02),
0 to 1354

2,938 (57.16)
953 (18.54)
729 (14.18)
520 (10.12)
5,140 (1.02)
1.94 (1.823),
0 to 11
15.7 (19.48),
0 to 340

187,853 (37.53)
114,145 (22.81)
160,168 (32.00)
38,352 (7.66)
500,518 (98.98)
1.02 (1.443),
0 to 13
4.2 (6.67),
0 to 1354

1107.60
p < 0.0001

16,428 (3.25)

682 (13.27)

15,746 (3.15)

6930.42

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
358,259 (70.85)
self care
Discharged to Hospice
6,327 (1.25)
Discharged/transferred to
62,864 (12.43)
institutionalized care
Discharged/transferred to
45,160 (8.93)
noninstitutionalized care
Other/Not recorded
16,620 (3.29)
Total (row %)
505,658 (100.00)
Hospital Characteristics
Geographic region
Northeast
206,082 (40.76)
Midwest
116,911 (23.12)
South
143,890 (28.46)
West
38,775 (7.67)
Total (row %)
505,658 (100.00)
Bed size
≤ 99
51,918 (10.27)
100-199
73,374 (14.51)
200-299
130,516 (25.81)
300-499
135,871 (26.87)
≥500
113,979 (22.54)
Total (row %)
505,658 (100.00)
Teaching status
Teaching
345,003 (68.23)
Non-teaching
160,655 (31.77)
Total (row %)
505,658 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
56,927 (11.26)
Specialist
206,183 (40.78)
Not recorded
242,548 (47.97)
Total (row %)
505,658 (100.00)

1,284 (24.98)

356,975 (71.32)

p < 0.0001

185 (3.60)
2014 (39.18)

6,142 (1.23)
60850 (12.16)

926 (18.02)

44,234 (8.84)

49 (0.95)
5,140 (1.02)

16,571 (3.31)
500,518 (98.98)

2,148 (41.79)
1,105 (21.50)
1,601 (31.15)
286 (5.56)
5,140 (1.02)

203,934 (40.74)
115,806 (23.14)
142,289 (28.43)
38,489 (7.69)
500,518 (98.98)

50.48
p < 0.0001

152 (2.96)
385 (7.49)
1,015 (19.75)
2,062 (40.12)
1,526 (29.69)
5,140 (1.02)

51,766 (10.34)
72,989 (14.58)
129,501 (25.87)
133,809 (26.73)
112,453 (22.47)
500,518 (98.98)

977.44
p < 0.0001

3,828 (74.47)
1312 (25.53)
5,140 (1.02)

341,175 (68.16)
159,343 (31.84)
500,518 (98.98)

93.46
p < 0.0001

850 (16.54)
1,887 (36.71)
2,403 (46.75)
5,140 (1.02)

56,077 (11.20)
204,296 (40.82)
240,145 (47.98)
500,518 (98.98)

151.16
p < 0.0001
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Table 4.23 Descriptive analysis of users and non-users of epoetin alfa with OFS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFS conditions (column %)
Total
Epo Users
Non-users

Chi-sq,
p-value

171,290 (33.87)
104,642 (20.69)
57,998 (11.47)
52,212 (10.33)
69,200 (13.69)
50,316 (9.95)
505,658 (100.00)
49.5 (24.14)

93 (2.27)
331 (8.09)
726 (17.74)
939 (22.94)
1,237 (30.22)
767 (18.74)
4,093 (0.81)
70.9 (15.07)

171,197 (33.87)
104,311 (20.69)
57,272 (11.47)
51,273 (10.33)
67,963 (13.69)
49,549 (9.95)
501,565 (99.19)
49.3 (24.13)

3455.82
p < 0.0001

124,431 (24.61)
381,227 (75.39)
505,658 (100.00)

1,882 (45.98)
2,211 (54.02)
4,093 (0.81)

122,549 (24.43)
379,016 (75.57)
501,565 (99.19)

1016.04
p < 0.0001

359,136 (71.02)
83,978 (16.61)
48,549 (9.60)
13,995 (2.77)
505,658 (100.00)

3,072 (75.05)
731 (17.86)
219 (5.53)
71 (1.73)
4,093 (0.81)

356,064 (70.99)
83,247 (16.60)
48,330 (9.64)
13924 (2.78)
501,565 (99.19)

106.89
p < 0.0001

89,213 (17.64)
68,541 (13.55)
85,682 (16.94)

1,539 (37.60)
187 (4.57)
327 (7.99)

87,674 (17.48)
68,354 (13.63)
85,355 (17.02)

1499.30
p < 0.0001

17,817 (3.52)
63,645 (12.59)
180,760 (35.75)
505,658 (100.00)

90 (2.20)
308 (7.53)
1,642 (40.12)
4,093 (0.81)

17,727 (3.53)
63,337 (12.63)
179,118 (35.71)
501,565 (99.19)

190,791 (37.73)
115,098 (22.76)
160,897 (31.82)
38,872 (7.69)
505,658 (100.00)
1.03 (1.450),
0 to 13
4.3 (7.02)
0 to 1354

2,437 (59.54)
826 (20.18)
495 (12.09)
335 (8.18)
4,093 (0.81)
1.94 (1.801),
0 to 11
14.8 (18.24),
0 to 329

188,354 (37.55)
114,272 (22.78)
160,402 (31.98)
38,537 (7.68)
501,565 (99.19)
1.02 (1.445),
0 to 13
4.3 (6.78),
0 to 1354

1038.18
p < 0.0001

16,428 (3.25)

533 (13.02)

15,895 (3.17)

5382.59

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
358,259 (70.85)
self care
Discharged to Hospice
6,327 (1.25)
Discharged/transferred to
62,864 (12.43)
institutionalized care
Discharged/transferred to
45,160 (8.93)
noninstitutionalized care
Other/Not recorded
16,620 (3.29)
Total (row %)
505,658 (100.00)
Hospital Characteristics
Geographic region
Northeast
206,082 (40.76)
Midwest
116,911 (23.12)
South
143,890 (28.46)
West
38,775 (7.67)
Total (row %)
505,658 (100.00)
Bed size
≤ 99
51,918 (10.27)
100-199
73,374 (14.51)
200-299
130,516 (25.81)
300-499
135,871 (26.87)
≥500
113,979 (22.54)
Total (row %)
505,658 (100.00)
Teaching status
Teaching
345,003 (68.23)
Non-teaching
160,655 (31.77)
Total (row %)
505,658 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
56,927 (11.26)
Specialist
206,183 (40.78)
Not recorded
242,548 (47.97)
Total (row %)
505,658 (100.00)

1,019 (24.90)

357,240 (71.23)

p < 0.0001

154 (3.76)
1,564 (38.21)

6,173 (1.23)
61300 (12.22)

777 (18.98)

44,383 (8.85)

46 (1.12)
4,093 (0.81)

16,574 (3.30)
501,565 (99.19)

1,740 (42.51)
585 (14.29)
1,497 (36.57)
271 (6.62)
4,093 (0.81)

204,342 (40.74)
116,326 (23.19)
142,393 (28.39)
38,504 (7.68)
501,565 (99.19)

243.69
p < 0.0001

121 (2.96)
285 (6.96)
722 (17.64)
1,832 (44.76)
1,133 (27.68)
4,093 (0.81)

51,797 (10.33)
73,089 (14.57)
129,794 (25.88)
134,039 (26.72)
112,846 (22.50)
501,565 (99.19)

1023.39
p < 0.0001

3,113 (76.06)
980 (23.94)
4,093 (0.81)

341,890 (68.16)
159,675 (31.84)
501,565 (99.19)

116.65
p < 0.0001

764 (18.67)
1,555 (37.99)
1,774 (0.81)
4,093 (0.81)

56,163 (11.20)
204,628 (48.00)
240,774 (40.80)
501,565 (99.19)

227.39
p < 0.0001
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Patients with OFU conditions

In contrary to the ONS and OFS cohort, small differences in the average age of ESA
users and non-users were observed in patients with OFU indications (average age OFU+ESAs
64.8 vs 61.6 for OFU group). Slightly greater proportion of female and African American OFU
patients received ESAs (17% vs 12%). Medicare remained as the major payer of ESA in the
OFU population but the differences between the users and non-users were less obvious compared
to that in the ONS and OFS cohorts. ESA users with OFU conditions were sicker, stayed in the
hospital longer, more frequently discharged to institutionalized and non-institutionalized care.
Finally, the use of ESAs for OFU indications was higher in medium to large hospitals (300-499
beds). Descriptive results are shown in Table 4.24, 4.25, and 4.26 for ESA, epoetin alfa, and
darbepoetin alfa users, respectively).
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Table 4.24 Descriptive analysis of users and non-users of darbepoetin alfa with OFS conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFS conditions (column %)
Total
Darb Users
Non-users

Chi-sq,
p-value

171,290 (33.87)
104,642 (20.69)
57,998 (11.47)
52,212 (10.33)
69,200 (13.69)
50,316 (9.95)
505,658 (100.00)
49.5 (24.14)

40 (3.67)
136 (12.49)
260 (23.88)
248 (22.77)
262 (24.06)
143 (13.13)
1,089 (0.22)
66.8 (16.12)

171,250 (33.94)
104,506 (20.71)
57,738 (11.44)
51,964 (10.30)
68,938 (13.66)
50,173 (9.94)
504,569 (99.78)
49.4 (24.15)

736.48
p < 0.0001

124,431 (24.61)
381,227 (75.39)
505,658 (100.00)

546 (50.14)
543 (49.86)
1,089 (0.22)

123,885 (24.55)
380,684 (75.45)
504,569 (99.78)

383.41
p < 0.0001

359,136 (71.02)
83,978 (16.61)
48,549 (9.60)
13,995 (2.77)
505,658 (100.00)

859 (78.88)
156 (14.33)
38 (3.49)
36 (3.31)
1,089 (0.22)

358,277 (71.01)
83,822 (16.61)
48,511 (9.61)
13,959 (2.77)
504,569 (99.78)

56.51
p < 0.0001

89,213 (17.64)
68,541 (13.55)
85,682 (16.94)

425 (39.03)
66 (6.06)
120 (11.02)

88,788 (17.60)
68,475 (13.57)
85,562 (16.96)

452.61
p < 0.0001

17,817 (3.52)
63,645 (12.59)
180,760 (35.75)
505,658 (100.00)

34 (3.12)
21 (1.93)
423 (38.84)
1,089 (0.22)

17,783 (3.52)
63,624 (12.61)
180,337 (35.74)
504,569 (99.78)

190,791 (37.73)
115,098 (22.76)
160,897 (31.82)
38,872 (7.69)
505,658 (100.00)
1.03 (1.450),
0 to 13
4.3 (7.02),
0 to 1354

525 (48.21)
130 (11.94)
241 (22.13)
193 (17.72)
1,089 (0.22)
1.90 (1.885),
0 to 10
20.4 (25.06),
0 to 340

190,266 (37.71)
114,968 (22.79)
160,656 (31.84)
38,679 (7.67)
504,569 (99.78)
1.03 (1.449),
0 to 13
4.3 (6.89),
0 to 1354

263.10
p < 0.0001

16,428 (3.25)

154 (14.14)

16,274 (3.23)

1650.54

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
358,259 (70.85)
self care
Discharged to Hospice
6,327 (1.25)
Discharged/transferred to
62,864 (12.43)
institutionalized care
Discharged/transferred to
45,160 (8.93)
noninstitutionalized care
Other/Not recorded
16,620 (3.29)
Total (row %)
505,658 (100.00)
Hospital Characteristics
Geographic region
Northeast
206,082 940.76)
Midwest
116,911 (23.12)
South
143,890 (28.46)
West
38,775 (7.67)
Total (row %)
505,658 (100.00)
Bed size
≤ 99
51,918 (10.27)
100-199
73,374 (14.51)
200-299
130,516 (25.81)
300-499
135,871 (26.87)
≥500
113,979 (22.54)
Total (row %)
505,658 (100.00)
Teaching status
Teaching
345,003 (68.23)
Non-teaching
160,655 (31.77)
Total (row %)
505,658 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
56,927 (11.26)
Specialist
206,183 (40.78)
Not recorded
242,548 (47.97)
Total (row %)
505,658 (100.00)

272 (24.98)

357,987 (70.95)

p < 0.0001

31 (2.85)
472 (43.34)

6,296 (1.25)
62,392 (12.37)

157 (14.42)

45,003 (8.92)

3 (0.28)
1,089 (0.22)

16,617 (3.29)
504,569 (99.78)

433 (39.76)
527 (48.39)
111 (10.19)
18 (1.65)
1,089 (0.22)

205,649 (40.76)
116,384 (23.07)
143,779 (28.50)
38,757 (7.68)
504,569 (99.78)

481.16
p < 0.0001

31 (2.85)
105 (9.64)
309 (28.37)
236 (21.67)
408 (37.47)
1,089 (0.22)

51,887 (10.28)
73,269 (14.52)
130,207 (25.81)
135,635 (26.88)
113,571 (22.51)
504,569 (99.78)

197.97
p < 0.0001

744 (68.32)
345 (31.68)
1,089 (0.22)

344,259 (68.23)
160,310 (31.77)
504,569 (99.78)

0.0042
p = 0.9485

93 (8.54)
341 (31.31)
655 (60.15)
1,089 (0.22)

56,834 (11.26)
205,842 (40.80)
241,893(47.94)
504,569 (99.78)

67.88
p < 0.0001
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Table 4.25 Descriptive analysis of users and non-users of ESAs with documented OFU conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFU conditions (column %)
Total
ESA Users
Non-users

Chi-sq,
p-value

37,399 (6.69)
110,811 (19.83)
145,430 (26.02)
107,065 (19.16)
104,715 (18.74)
53,497 (9.57)
558,917 (100.00)
61.7 (17.94)

215 (4.79)
688 (15.32)
1,057 (23.54)
969 (21.58)
1,062 (23.65)
500 (11.13)
4,491 (0.80)
64.8 (17.19)

37,184 (6.71)
110,123 (19.86)
144,373 (26.04)
106,096 (19.14)
103,653 (18.70)
52,997 (9.56)
554,426 (99.20)
61.6 (17.95)

165.33
p < 0.0001

275,478 949.29)
283,439 (50.71)
558,917 (100.00)

1,922 (42.80)
2,569 (57.20)
4,491 (0.80)

273,556 (49.34)
280,870 (50.66)
554,426 (99.20)

76.32
p < 0.0001

452,164 (80.900
69,234 (12.390
22,491 (4.02)
15,028 (2.69)
558,917 (100.00)

3,358 (74.77)
773 (17.21)
284 (6.32)
76 (1.69)
4,491 (0.80)

448,806 (80.95)
68,461 (12.35)
22207 (4.01)
14,952 (2.70)
554,426 (99.20)

182.33
p < 0.0001

137,606 (24.62)
25,966 (4.65)
88,676 (15.87)

1,254 (27.92)
234 (5.21)
586 (13.05)

136,352 (24.59)
25,732 (4.64)
88,090 (15.89)

321.63
p < 0.0001

26,006 (4.65)
83,757 (14.99)
196,906 (35.23)
558,917 (100.00)

126 (2.81)
347 (7.73)
1,944 (43.29)
4,491 (0.80)

25,880 (4.67)
83,410 (15.04)
194,962 (35.16)
554,426 (99.20)

302,620 (54.14)
75,339 (13.48)
121,033 (21.65)
59,925 (10.72)
558,917 (100.00)
0.65 (1.373),
0 to 11
4.6 (7.96),
0 to 1430

2,201 (49.01)
860 (19.15)
729 (16.23)
701 (15.61)
4,491 (0.80)
1.48 (2.164),
0 to 9
14.4 (19.02),
0 to 369

300,419 (54.19)
74,479 (13.43)
120,304 (21.70)
59,224 (10.68)
554,426 (99.20)
0.64 (1.363),
0 to 11
4.5 (7.75),
0 to 1430

292.36
p < 0.0001

13,947 (2.50)

280 (6.23)

13,667 (2.47)

2570.57

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
340,227 (60.87)
self care
Discharged to Hospice
7,457 (1.33)
Discharged/transferred to
92,573 (16.56)
institutionalized care
Discharged/transferred to
60,531 (10.83)
noninstitutionalized care
Other/Not recorded
44,182 (7.90)
Total (row %)
558,917 (100.00)
Hospital Characteristics
Geographic region
Northeast
242,258 (43.34)
Midwest
114,295 (20.45)
South
173,037 (30.96)
West
29,327 (5.25)
Total (row %)
558,917 (100.00)
Bed size
≤ 99
27,733 (4.96)
100-199
76,368 (13.660
200-299
109,642 (19.620
300-499
148,829 (26.630
≥500
196,345 (35.13)
Total (row %)
558,917 (100.00)
Teaching status
Teaching
405,948 (72.63)
Non-teaching
152,969 (27.37)
Total (row %)
558,917 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
77,760 (13.91)
Specialist
193,374 (34.600
Not recorded
287,783 (51.49)
Total (row %)
558,917 (100.00)

1,524 (33.93)

338,703 (61.09)

p < 0.0001

144 (3.21)
1,658 (36.92)

7,313 (1.32)
90,915 (16.40)

838 (18.66)

59,693 (10.77)

47 (1.05)
4,491 (0.80)

44,135 (7.96)
554,426 (99.20)

1,778 (39.59)
769 (17.12)
1,598 (35.58)
346 (7.70)
4,491 (0.80)

240,480 (43.37)
113,526 (20.48)
171,439 (30.92)
28,981 (5.23)
554,426 (99.20)

122.56
p < 0.0001

79 (1.76)
291 (6.48)
841 (18.73)
1,951 (43.44)
1,329 (29.59)
4,491 (0.80)

27,654 (4.99)
76,077 (13.72)
108,801 (19.62)
146,878 (26.49)
195,016 (35.17)
554,426 (99.20)

786.64
p < 0.0001

3,349 (74.57)
1,142 (25.43)
4,491 (0.80)

402,599 (72.62)
151,827 (27.38)
554,426 (99.20)

8.57
p = 0.0034

799 (17.79)
1,558 (34.69)
2,134 (47.52)
4,491 (0.80)

76,961 (13.88)
191,816 (34.60)
285,649 (51.52)
554,426 (99.20)

62.84
p < 0.0001
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Table 4.26 Descriptive analysis of users and non-users of epoetin alfa with documented OFU conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFU conditions (column %)
Total
Epo Users
Non-users

Chi-sq,
p-value

37,399 (6.69)
110,811 (19.83)
145,430 (26.02)
107,065 (19.16)
104,715 (18.74)
53,497 (9.57)
555,181 (100.00)
61.7 (17.94)

145 (3.88)
563 (15.07)
897 (24.01)
813 (21.76)
900 (24.09)
418 (11.19)
3,736 (0.67)
65.3 (16.70)

37,254 (6.71)
110,248 (19.86)
144,533 (26.03)
106,252 (19.14)
103,815 (18.70)
53,079 (9.56)
558,917 (99.33)
61.6 (17.95)

174.31
p < 0.0001

275,478 (49.29)
283,439 (50.71)
555,181 (100.00)

1,599 (42.80)
2,137 (57.20)
3,736 (0.67)

273,879 (49.33)
281,302 (50.67)
558,917 (99.33)

63.34
p < 0.0001

452,164 (80.90)
69,234 (12.39)
22,491 (4.02)
15,028 (2.69)
555,181 (100.00)

2,782 (74.46)
646 (17.29)
252 (6.75)
56 (1.50)
3,736 (0.67)

449,382 (80.94)
68,588 (12.35)
22,239 (4.01)
14,972 (2.70)
558,917 (99.33)

181.29
p < 0.0001

137,606 (24.62)
25,966 (4.65)
88,676 (15.87)

1,027 (27.49)
196 (5.25)
473 (12.66)

136,579 (24.60)
25,770 (4.64)
88,203 (15.89)

277.47
p < 0.0001

26,006 (4.65)
83,757 (14.99)
196,906 (43.98)
555,181 (100.00)

87 (2.33)
310 (8.30)
1,643 (43.98)
3,736 (0.67)

25,919 (4.67)
83,447 (15.03)
195,263 (35.17)
558,917 (99.33)

302,620 (54.14)
75,339 (13.48)
121,033 (21.65)
59,925 (10.72)
555,181 (100.00)
0.65 (1.373),
0 to 11
4.6 (7.96),
0 to 1430

1,898 (50.80)
787 (21.07)
613 (16.41)
438 (11.72)
3,736 (0.67)
1.50 (2.17),
0 to 9
14.1 (19.06),
0 to 369

300,722 (54.17)
74,552 (13.43)
120,420 (21.69)
59,487 (10.71)
558,917 (99.33)
0.64 (1.365),
0 to 11
4.5 (7.79),
0 to 1430

219.66
p < 0.0001

13,947 (2.50)

230 (6.16)

13,717 (2.47)

2077.96

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
340,227 (60.87)
self care
Discharged to Hospice
7,457 (1.33)
Discharged/transferred to
92,573 (16.56)
institutionalized care
Discharged/transferred to
60,531 (10.83)
noninstitutionalized care
Other/Not recorded
44,182 (7.90)
Total (row %)
555,181 (100.00)
Hospital Characteristics
Geographic region
Northeast
242,258 (43.34)
Midwest
114,295 (20.45)
South
173,037 (30.96)
West
29,327 (5.25)
Total (row %)
555,181 (100.00)
Bed size
≤ 99
27,733 (4.96)
100-199
76,368 (13.66)
200-299
109,642 (19.62)
300-499
148,829 (26.63)
≥500
196,345 (35.13)
Total (row %)
555,181 (100.00)
Teaching status
Teaching
405,948 (72.63)
Non-teaching
152,969 (27.37)
Total (row %)
555,181 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
77,760 (13.91)
Specialist
193,374 (34.60)
Not recorded
287,783 (51.49)
Total (row %)
555,181 (100.00)

1,284 (34.37)

338,943 (61.05)

p < 0.0001

132 93.53)
1,353 (36.22)

7,325 (1.32)
91,220 (16.43)

695 (18.60)

59,836 (10.78)

42 (1.12)
3,736 (0.67)

44,140 (7.95)
558,917 (99.33)

1,405 (37.61)
531 (14.21)
1,462 (39.13)
338 (9.05)
3,736 (0.67)

240,853 (43.38)
113,764 (20.49)
171,575 (30.90)
28,989 (5.22)
558,917 (99.33)

284.76
p < 0.0001

69 (1.85)
216 (5.78)
570 (15.26)
1,822 (48.77)
1,059 (28.35)
3,736 (0.67)

27,664 (4.98)
76,152 (13.72)
109,072 (19.65)
147,007 (26.48)
195,286 (35.18)
558,917 (99.33)

1022.68
p < 0.0001

2,881 (77.11)
855 (22.89)
3736 (0.67)

403,067 (72.60)
152,114 (27.40)
558,917 (99.33)

38.03
p < 0.0001

666 (17.83)
1,372 (36.72)
1,698 (45.45)
3,736 (0.67)

77,094 (13.89)
192,002 (34.58)
286,085 (51.53)
558,917 (99.33)

72.97
p < 0.0001
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Table 4.27 Descriptive analysis of users and non-users of darbepoetin alfa with documented OFU
conditions
Variable
Patient Characteristics
Demographics
Age
18-30
31-50
51-64
65-74
75-84
85+
Total (row %)
Average age (SD)
Gender
Male
Female
Total (row %)
Race
Caucasian
African-American
Other
Not recorded
Total (row %)
Primary Payer
Source of Payment
Medicare
Medicaid
Commercial/Private/HMO
Managed Care
Self-pay
Other
Not recorded
Total (row %)
Clinical Conditions
Admission type
Emergency
Urgent
Elective
Other/ Not recorded
Total (row %)
Average CCI (SD)
Average LOS (SD), range
Discharge status
Expired

N Patients with OFU conditions (column %)
Total
Darb Users
Non-users

Chi-sq,
p-value

37,399 (6.69)
110,811 (19.83)
145,430 (26.02)
107,065 (19.16)
104,715 (18.74)
53,497 (9.57)
558,917 (100.00)
61.66 (17.94)

71 (9.10)
129 (16.54)
165 (21.15)
161 (20.64)
171 (21.92)
83 (10.64)
780 (0.14)
62.3 (19.17)

37,328 (6.690
110,682 (19.83)
145,265 (26.03)
106,904 (19.15)
104,544 (18.73)
53,414 (9.57)
558,137 (99.86)
61.7 (17.94)

24.22
p = 0.0002

275,478 (49.29)
283,439 (50.71)
558,917 (100.00)

335 (42.95)
445 (57.05)
780 (0.14)

275,143 (49.30)
282,994 (50.70)
558,137 (99.86)

12.56
p = 0.0004

452,164 (80.90)
69,234 (12.39)
22,491 (4.02)
15,028 (2.69)
558,917 (100.00)

595 (76.28)
131 (16.79)
34 (4.36)
20 (2.56)
780 (0.14)

451,569 (80.91)
69,103 (12.38)
22,457 (4.02)
15,008 (2.69)
558,137 (99.86)

14.57
p = 0.0022

137,606 (24.62)
25,966 (4.65)
88,676 (15.87)

234 (30.00)
38 (4.87)
116 (14.87)

137,372 (24.61)
25,928 (4.65)
88,560 (15.87)

70.82
p < 0.0001

26,006 (4.650
83,757 (14.99)
196,906 (35.23)
558,917 (100.00)

39 (5.00)
37 (4.74)
316 (40.51)
780 (0.14)

25,967 (4.65)
83,720 (15.00)
196,590 (35.22)
558,137 (99.86)

302,620 (54.14)
75,339 (13.48)
121,033 (21.65)
59,925 (10.72)
558,917 (100.00)
0.65 (1.373),
0 to 11
4.6 (7.96),
0 to 1,430

312 (40.00)
75 (9.62)
120 (15.38)
273 (35.00)
780 (0.14)
1.39 (2.113),
0 to 9
16.4 (19.22),
1 to 141

302,308 (54.16)
75,264 (13.48)
120,913 (21.66)
59,652 (10.69)
558,137 (99.86)
0.65 (1.372),
0 to 11
4.6 (7.92),
0 to 1,430

481.11
p < 0.0001

13,947 (2.50)

51 (6.54)

13,896 (2.49)

537.65

p < 0.0001

p < 0.0001
p < 0.0001
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Discharged to home/
340,227 (60.87)
self care
Discharged to Hospice
7,457 (1.33)
Discharged/transferred to
92,573 (16.56)
institutionalized care
Discharged/transferred to
60,531 (10.83)
noninstitutionalized care
Other/Not recorded
44,182 (7.90)
Total (row %)
558,917 (100.00)
Hospital Characteristics
Geographic region
Northeast
242,258 (43.34)
Midwest
114,295 (20.45)
South
173,037 (30.96)
West
29,327 (5.25)
Total (row %)
558,917 (100.00)
Bed size
≤ 99
27,733 (4.96)
100-199
76,368 (13.66)
200-299
109,642 (19.62)
300-499
148,829 (26.63)
≥500
196,345 (35.13)
Total (row %)
558,917 (100.00)
Teaching status
Teaching
405,948 (72.63)
Non-teaching
152,969 (27.37)
Total (row %)
558,917 (100.00)
Physician Characteristics
Ordering Physician Specialty
Non-specialist
77,760 (13.91)
Specialist
193,374 (34.60)
Not recorded
287,783 (51.49)
Total (row %)
558,917 (100.00)

246 (31.54)

339,981 (60.91)

p < 0.0001

14 (1.79)
319 (40.90)

7,443 (1.33)
92,254 (16.53)

145 (18.59)

60,386 (10.82)

5 (0.64)
780 (0.14)

44,177 (7.92)
558,137 (99.86)

388 (49.74)
244 (31.28)
139 (17.82)
9 (1.15)
780 (0.14)

241,870 (43.34)
114,051 (20.43)
172,898 (30.98)
29,318 (5.25)
558,137 (99.86)

120.70
p < 0.0001

10 (1.28)
77 (9.87)
285 (36.54)
131 (16.790
277 (35.51)
780 (0.14)

27,723 (4.97)
76,291 (13.67)
109,357 (19.59)
148,698 (26.64)
196,068 (35.13)
558,137 (99.86)

171.94
p < 0.0001

481 (61.67)
299 (38.33)
780 (0.14)

405,467 (72.65)
152,670 (27.35)
558,137 (99.86)

47.24
p < 0.0001

134 (17.18)
189 (24.23)
457 (58.59
780 (0.14)

77,626 (13.91)
193,185 (34.61)
287,326 (51.48)
558,137 (99.86)

37.90
p < 0.0001
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GEE Model Selection

The objective of this specific aim was to determine the impacts of safety interventions on
ESA utilization patterns and associations of patient demographics, clinical characteristics,
hospital characteristics, and physician characteristics with ESA on-label and off-label
prescribing. These variables were selected a priori based on the literature review described in
Chapter 2.
In order to obtain reliable estimates of the parameter, it was important to identify whether
multicollinearity existed. Multicollinearity referred to linear correlations among explanatory
variables in the estimating which can result in bias estimation of coefficients. A diagnostics of
multicollinearity was done using OLS estimation because such test was not possible in logistic
regression. Multicollinearity was not detected (VIFb values < 4 for all time-constant explanatory
variables, data not shown). The final model included all variables used in the bivariate analysis
except for hospital length of stay because its inclusion caused failure in the convergence of the
correlation matrix and iteration process of standard errors of the GEE models.
The GEE models were specified using a binomial distribution and a logit link. The link
and distribution was appropriate in modeling categorical dependent variable, ESA use, in this
case. Exchangeable correlation structure was selected because of the non-ordering nature of
patients within the hospital clusters.197 An alternative to exchangeable correlation structure is
unstructured matrix. However, this choice was not selected because of the large number of time

b

Variance Inflation Factor (VIF) value represents the inflation of the variance of an estimated coefficient beyond

what would have resulted if there was no collinearity. VIF less than 4 implies acceptable level of correlation among
explanatory variables in the models.
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points in our data. All correlations at all time points must be estimated if unstructured
correlation matrix were specified. If unstructured matrix were to be used instead of the
exchangeable matrix, we were likely to have encountered a computation constraint, reduction of
power of statistical tests, and non-convergence issues of the estimates.
The variables included in the model came from five main domains: intervention and time
variables, patient demographic characteristics, patient clinical characteristics, hospital
characteristics, and physician characteristics. The selected binary logistic regression model can
be specified as followed: Logit(ESA=1) = β0 + β1t + β2intervention1 + β3intervention1 × t1 +
β4intervention2 + β5intervention2 × t2 + β6intervention3+ β7 intervention3 × t3 + DEM +
HEALTH + HOS + PHYS + et
Intervention variables: Three indicator variables: black box warning (BBW), NCD, and REMS,
were included in the model. The intervention indicator variable indicated the immediate month
after which the intervention was implemented. The interaction terms of intervention indicator
variable and time indicated the monthly time trend after the intervention.
Patient demographic variables (DEM): Patient demographics included were age, race, gender,
and primary payer. The variable age was categorized into six different age groups: young adult
(18-30 years), middle-aged (31-50 years), late middle-age (51-64 years), young old (65-74
years), older old (75-84 years), and oldest old (85 years and above). The reference group used
for age group was adult aged between 31 and 50 years old. The gender reference group was
male. The race variables included Caucasian, African-American, Other, and Missing. Caucasian
group was used as a reference. The primary payer variable included Medicare, Medicaid,
Private, Self-pay, Other, and Missing. Medicare was the reference category.
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Patient clinical characteristics (HEALTH): Clinical variables included admission type,
comorbidity index, and discharge disposition. Variable indicating hospital length-of-stay was
dropped from the final model because addition of this variable created convergence issue of the
estimate: Admission type was categorized into Emergency, Urgent, Elective, and Other/Missing,
and admission through an emergency department was used as the reference category.
Comorbidity index was added into the model as a continuous variable. Finally, discharge type
was categorized into Discharged to home, Expired, Discharged to hospice, Discharged to
institutionalized care, Discharged to non-institutionalized care, and Other/Missing. Discharged
to home category was use as a reference group.
Hospital characteristics (HOS): These variables included census region where the hospital was
located: Northeast, Midwest, South, and West, where the Northeast region was use as a
reference, teaching status, where non-teaching hospital group was used as a reference category,
and hospital size (number of beds), Bed size variable was categorized in less than 99 beds, 100199 beds, 200-299 beds (reference), 300-499 beds, and more than 500 beds.
Physician characteristics (PHY): The only physician characteristic used in the analytical model
was physician specialty. Medical specialty of admitting physicians were categorized into Nonspecialist, Specialist, and Missing, with Non-specialist as the reference category.
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Aim 3a: Impacts of black box warning, NCD, and REMS on odds of being prescribed ESAs

Impacts of the interventions on ESA utilization patterns

Impact of black box warning, NCD, and REMS on the odds of being prescribed ESAs for
the on-label, off-label supported, and off-label unsupported indications are summarized in Table
4.28, 4.29, and 4.30, respectively.
Addition of a black box warning onto ESA labels did not significantly affect the odds of a
patient receiving the drug for any indications. However, there was a marginally insignificant
decrease in the odds of receiving ESAs among patients with ONS indications (OR 0.870, 95% CI
0.750, 1.008, p = 0.0645). National coverage determination (NCD), on the other hand, was
associated with significant reduction in the odds of using the drugs once implemented. The
impact of NCD was observed across three use categories. Patients with ONS, OFS, and OFU
conditions were 0.13 times (95% CI 0.760, 0.986, p = 0.0299), 0.20 times (95% CI 0.716, 0.891,
p < 0.0001), and 0.38 times (95% 0.474, 0.817, p < 0.0006), respectively, less likely to receive
ESAs after the change in reimbursement policy. Moreover, patients with on-label and off-label
supported conditions were 0.046 times (95% CI 0.931, 0.977, p = 0.000) and 0.06 times (95%
0.902, 0.974, p = 0.0009) less likely to use the drugs, with every month after NCD. No
significant impact of REMS was found on the on-label and off-label use of ESAs.

Impacts of the interventions on epoetin alfa utilization patterns

The impact of safety interventions on individual erythropoietic drugs were assessed using
the binary logistic regression models with the same set of independent variables. In the epoetin
alfa mode, the impact of black box warning was observed in off-label unsupported prescribing
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only. A patient with off-label unsupported indications admitted in April 2007 was 0.394 times
less likely to received epoetin alfa, compared to than those admitted in before that month. NCD,
on the other hand, significantly reduced the odds of a patient receiving epoetin alfa off-label
immediately after its implementation. A patient admitted to the hospital with off-label supported
indication and off-label unsupported indications in April 2008 was 0.20 times (95% CI 0.691,
0.921, p = 0.0021) and 0.47 times (95% 0.383, 0.729, p = 0.0001) less likely to be prescribed
with epoetin alfa, compared than similar patients admitted before that month. Moreover, after
the NCD, the odds of a patient with off-label supported indication in receiving the drug was
reduced by 0.07 times per month (95% CI 0.879, 0.975, p = 0.0032). Finally, the
implementation of REMS was not associated with any change in the odds of receiving epoetin
alfa.

Impacts of the interventions on darbepoetin alfa utilization patterns

There appeared to be small but statistically significant increases in the off-label
unsupported use of darbepoetin alfa during the study period (OR 1.079, 95% CI 1.038, 1.122, p
<0.0001). While we observed neither the impact of black box warning nor REMS on the onlabel use of darbepoetin alfa, NCD was associated with significant reduction in the odds of
receiving darbepoetin alfa on-label. A patient with ONS conditions was 9.6% less likely to use
darbepoetin alfa after the change in reimbursement policy was put in place. There were small but
statistically significant decreases in the use of darbepoetin alfa for OFS and OFU conditions after
the issuance of a black box warning (OR 0.957, 95% CI 0.918, 0.998, p = 0.0410, and OR 0.848,
95% CI 0.75, 0.958, p = 0.0079). Similarly, we found small but statistically significant
decreases in the use of darbepoetin alfa associated with NCD implementation in patients with the

188

conditions for OFS indications. Risk Evaluation and Mitigation Strategy program (REMS) did
not have any significant impacts on the use of darbepoetin for any indications.
Table 4.28 Relative Impacts of Interventions on the odds of receiving any ESA therapy by Use Category
Variable
β
Model 1: ONS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Model 2: OFS
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change
Time
BBW
Immediate
Level Change
NCD
Immediate
Level Change
REMS
Immediate
Level Change

Exp (β)

Parameter
SE of
95% Confidence
Exp (β)
Interval

ChiSquare

p-value

-0.04

0.967

0.0024

[0.992, 1.001]

2.06

0.1516

-0.140
0.005

0.870
1.005

0.0657
0.0067

[0.750, 1.008]
[0.992, 1.019]

3.42
0.61

0.0645
0.4354

-0.143*
-0.047*

0.867*
0.954*

0.0572
0.0120

[0.762, 0.986]
[0.931, 0.977]

4.71
14.28

0.0299
0.0002

0.097
0.027

1.102
1.028

0.1163
0.0257

[0.896, 1.355]
[0.979, 1.079]

0.84
1.19

0.3594
0.2748

0.0004

1.000

0.0071

[0.987, 1.014]

< 0.01

0.9554

-0.101
0.007

0.904
1.007

0.0922
0.0115

[0.740, 1.104]
[0.985, 1.030]

0.99
0.42

0.3208
0.5170

-0.225*
-0.065*

0.799*
0.937*

0.0445
0.0184

[0.716, 0.891]
[0.902, 0.974]

16.26
10.97

<0.0001
0.0009

0.197
1.218
0.1557
0.008
1.008
0.0310
Model 3: Documented OFU
0.012*
1.011*
0.0049

[0.948, 1.565]
[0.949, 1.071]

2.38
0.07

0.1231
0.7890

[1.002, 1.021]

5.66

0.0173

-0.245
-0.029

0.783
0.971

0.1407
0.0196

[0.550, 1.114]
[0.934, 1.011]

1.85
2.08

0.1734
0.1495

-0.474*
-0.008

0.622*
0.992

0.0865
0.0279

[0.474, 0.817]
[0.939, 1.049]

11.63
0.08

0.0006
0.7835

-0.079
-0.010

0.924
0.991

0.1839
0.0274

[0.626, 1.365]
[0.938, 1.046]

0.16
0.12

0.6926
0.7309

*Statistically significance at α = 0.05
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Table 4.29 Relative Impacts of Interventions on odds of receiving epoetin alfa therapy by Use Category
Variable
β
Model 1: ONS
Time
-0.006
BBW
Immediate
-0.184
Level Change
0.004
NCD
Immediate
-0.159
Level Change
0.051*
REMS
Immediate
0.236
Level Change
0.044
Model 2: OFS
Time
-0.006
BBW
Immediate
-0.202
Level Change
0.022
NCD
Immediate
-0.226*
Level Change
-0.077*
REMS
Immediate
0.223
Level Change
0.026
Model 3: Documented OFU
Time
0.004
BBW
Immediate
-0.502*
Level Change
0.009
NCD
Immediate
-0.638*
Level Change
-0.031
REMS
Immediate
-0.116
Level Change
-0.010

Exp (β)

SE

Parameter
95% Confidence
Interval

Chi-Sq

p-value

0.995

0.0043

[0.986, 1.003]

1.65

0.1991

0.832
1.004

0.0931
0.0107

[0.668, 1.036]
[0.983, 1.025]

2.70
0.13

0.1004
0.7133

0.853
0.950*

0.0861
0.0177

[0.700, 1.040]
[0.916, 0.986]

2.47
7.47

0.1159
0.0063

1.266
1.045

0.1642
0.0323

[0.982, 1.633]
[0.983, 1.110]

3.31
2.01

0.0687
0.1561

0.994

0.0085

[0.978, 1.011]

0.47

0.4926

0.817
1.022

0.1195
0.0157

[0.613, 1.088]
[0.992, 1.053]

1.91
2.02

0.1667
0.1548

0.798*
0.926*

0.0585
0.0243

[0.691, 0.921]
[0.879, 0.975]

9.49
8.68

0.0021
0.0032

1.250
1.026

0.2215
0.0392

[0.883, 1.769]
0.952, 1.106

1.59
0.46

0.2077
0.4990

1.004

0.0054

[0.993, 1.014]

0.48

0.4879

0.606*
1.009

0.1130
0.0184

[0.420, 0.873]
[0.974, 1.046]

7.23
0.25

0.0072
0.6187

0.528*
0.970

0.0868
0.0285

[0.383, 0.729]
[0.915, 1.027]

15.08
1.10

0.0001
0.2949

0.891
0.991

0.2054
0.0310

[0.567, 1.400]
[0.932, 1.053]

0.25
0.09

0.6153
0.7607

*Statistically significance at α = 0.05
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Table 4.30 Relative Impacts of Interventions on odds of receiving darbepoetin alfa therapy by Use
Category
Variable
β
Model 1: ONS
Time
0.005
BBW
Immediate
-0.046
Level Change
0.008
NCD
Immediate
-0.101*
Level Change
-0.047*
REMS
Immediate
-0.261
Level Change
0.003
Model 2: OFS
Time
0.039
BBW
Immediate
-0.007
Level Change
-0.044*
NCD
Immediate
-0.205
Level Change
-0.046*
REMS
Immediate
0.164
Level Change
-0.051
Model 3: Documented OFU
Time
0.076*
BBW
Immediate
0.199
Level Change
-0.165*
NCD
Immediate
0.113
Level Change
0.024
REMS
Immediate
0.277
Level Change
-0.051

Exp (β)

SE

Parameter
95% Confidence
Interval

Chi-Sq

p-value

1.001

0.0067

[0.992, 1.018]

0.55

0.4575

0.955
1.008

0.1043
0.0138

[0.771, 1.183]
[0.981, 1.035]

0.18
0.34

0.6713
0.5602

0.904*
0.955*

0.0272
0.0128

[0.852, 0.959]
[0.930, 0.980]

11.29
11.98

0.0008
0.0005

0.770
1.003

0.1367
0.0426

[0.544, 1.091]
[0.923, 1.090]

2.17
< 0.01

0.1410
0.9504

1.039

0.0122

[1.016, 1.064]

10.80

0.0010

0.993
0.957*

0.1197
0.0205

[0.784, 1.258]
[0.918, 0.998]

0.00
4.17

0.9559
0.0410

0.814
0.955*

0.0923
0.0170

[0.652, 1.017]
[0.923, 0.989]

3.28
6.59

0.0700
0.0103

1.178
0.950

0.1738
0.0460

[0.883, 1.573]
[0.864, 1.045]

1.24
1.11

0.2658
0.2918

1.079*

0.0213

[1.038, 1.122]

14.93

0.0001

1.220
0.848*

0.5823
0.0526

[0.479, 3.109]
[0.751, 0.958]

0.17
7.05

0.6774
0.0079

1.120
1.025

0.3500
0.0645

[0.607, 2.066]
[0.906, 1.159]

0.13
0.15

0.7180
0.7004

1.319
0.950

0.6838
0.0617

[0.477, 3.643]
[0.837, 1.079]

0.28
0.62

0.5938
0.4302

*Statistically significance at α = 0.05
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Aim 3b Associations of covariates and ESA On-label use

The same binary logistic regressions using GEE used in Specific Aim 3a were fit to
assess the associations of patient demographics, clinical characteristics, hospital characteristics,
and physician characteristics with ESA on-label and off-label prescribing. The three models
include: ESA-ONS, ESA-OFS, and ESA-Documented OFU. We did not distinguish between the
two erythropoietic drugs in these models. The reference categories for each of the categorical
independent variables in the model made up of White males aged 31-50 who had Medicare as
their primary payer, admitted as emergent patients, discharged to home, by a non-specialist, to
non-teaching hospitals located in the Northeast region which had between 200 and 299 beds.
Results from each model were divided for ease of understanding into three parts: patient
demographic, clinical condition, and hospital and physician characteristics. Associations of these
variables and on-label, off-label supported, and off-label unsupported of ESAs in the inpatient
settings are shown in Table 4.31-4.39.
Part 1: On-label use of ESAs
The regression results of patient demographics as possible predictors of ESA on-label
prescribing are summarized in Table 4.31. Young adult (18-30 years) were 0.29 times less likely
to be prescribed with ESA for on-label indications compared to the middle aged adult in the age
range of 31 to 50 years (95% CI 0.658, 0.763, p < 0.0001). The late middle-age (51-64 years),
on the other hand, were 1.20 times more likely to be prescribed with ESAs (95% CI 1.119,
1.296, p < 0.0001). Being of aged 65 to 84 years, a patient was not found to be statistically more
or less likely than the young adult to be prescribed with ESAs. Lastly, being the oldest old
(above 85 years) was associated with decreased odds of receiving ESAs on-label (0.31 times less
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likely, 95% CI 0.597, 0.790, p < 0.0001). The odds of receiving ESAs also depended on
patient’s gender. Female patients were 0.12 time less likely to receive ESAs on-label (95%
0.857, 0.915, p < 0.0001). Patient’s race was strongly associated with the odds of being
prescribed with ESAs. Compared to Caucasian, African-American were 1.715 times more likely
to receive ESAs (95% CI 1.557, 1.889, p < 0.0001). Similarly, patients of ‘Other’ race were 1.46
times more likely than Caucasian to receive ESAs (95% CI 1.307, 1.621, p < 0.0001). Finally,
compared to Medicare patients, patients with other health insurance types were less likely to
receive ESA on-label. For example, private insurance patients were 0.40 times less likely than
Medicare patients to be prescribed with ESAs. Those who had to pay for the healthcare services
out-of-pocket (the “Self-pay” group) were 0.48 times less likely to use ESAs, compared to
Medicare patients.
The regression results of patient clinical conditions as possible predictors of ESA onlabel prescribing are shown in Table 4.32. Compared to “Emergent” patients, patient who were
admitted to the hospitals as elective cases were 0.60 times less likely to be prescribed ESAs onlabel (95% CI 0.322, 0.490, p < 0.0001). The odds of receiving ESAs increased substantially
with more complex patients measured through combined comorbidity score. The odds of
receiving ESAs increased 1.20 times with one unit increase in the comorbidity index (95%
1.174, 1.232, p < 0.0001). Lastly, discharge disposition was a strong predictor of ESA on-label
prescribing. Compared to the patients who were discharged to home, those who expired in the
hospitals were 1.98 times more like to use ESAs (95% 1.784, 2.196, p < 0.0001). Patients who
needed to be transferred to hospice, institutionalized, or non-institutionalized care were all more
likely to use ESAs compared to those who were discharged to home.
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No significant differences in the odds of ESA on-label prescribing were found among
hospitals across geographic regions. Being admitted to small hospitals of fewer than 99 beds
reduced the odds of receiving ESAs 0.48 times compared to medium-sized hospitals (95% CI
0.0036, 0.819, p < 0.0001). On the other hand, the odds of receiving ESAs increased 1.59 times
if a patient was being admitted to relatively larger hospitals (300-499 beds). Finally, admitting
physicians, whether be a non-specialist or specialist, was not associated with the odds of using
ESA on-label. Associations of hospital characteristics and physician specialty and ESA on-label
prescribing can be found in Table 4.33.
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Table 4.31 Associations of patient demographic and ESA ONS use
Variable
β
Demographics
Age
18-30
31-50 (reference)
51-64
65-74
75-84
85+
Gender
Male (reference)
Female
Race
Caucasian
(reference)
African-American
Other
Missing
Source of Payment
Medicare
(reference)
Medicaid
Commercial/
Private/ HMO
Managed Care
Self-pay
Other
Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-0.345*
0.186*
0.053
-0.055
-0.376*

0.709*
1.204*
1.054
0.946
0.687*

0.0269
0.0450
0.0593
0.0613
0.0492

[0.658, 0.763]
[1.119, 1.296]
[0.944, 1.177]
[0.834, 1.074]
[0.597, 0.790]

82.66
24.73
0.89
0.73
27.52

<.0001
<.0001
0.3458
0.3938
<.0001

-0.122*

0.885*

0.0148

[0.857, 0.915]

53.06

<.0001

-

-

-

-

-

-

0.539*
0.375*
0.071

1.715*
1.455*
1.074

0.0845
0.0799
0.0624

[1.557, 1.889]
[1.307, 1.621]
[0.958, 1.203]

119.99
46.62
1.49

<.0001
<.0001
0.2218

-

-

-

-

-

-

-0.260*
-0.504*

0.771*
0.604*

0.0599
0.0386

[0.662, 0.898]
[0.533, 0.684]

11.20
62.38

0.0008
<.0001

-0.654*
-0.274*
-0.217*

0.520*
0.760*
0.805*

0.0334
0.0716
0.0589

[0.459, 0.590]
[0.632, 0.915]
[0.697, 0.929]

103.93
8.46
8.80

<.0001
0.0036
0.003
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Table 4.32 Associations of clinical conditions and ESA ONS use
Variable
β
Clinical Conditions
Admission type
Emergency
(reference)
Urgent
Elective
Other/Missing
Average CCI (SD)
Discharge status
Discharged to
home/self care
(reference)
Expired
Discharged to
Hospice
Discharged/
transferred to
institutionalized care
Discharged
/transferred to
noninstitutionalized
care
Other/Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

-

-0.037
-0.924*
-0.478*
0.184*

0.964
0.397*
0.620*
1.203*

0.0532
0.0426
0.0604
0.0147

[0.865, 1.074]
[0.322, 0.490]
[0.512, 0.751]
[1.174, 1.232]

0.45
74.21
24.05
228.08

0.5015
<.0001
<.0001
<.0001

-

-

-

-

-

-

0.683*
0.174*

1.979*
1.191*

0.1050
0.0767

[1.784, 2.196]
[1.049, 1.351]

165.56
7.34

<.0001
0.0068

0.658*

1.932*

0.0778

[1.785, 2.090]

267.43

<.0001

0.434*

1.543*

0.0528

[1.443, 1.650]

160.71

<.0001

-0.167

0.847

0.1032

[0.667, 1.075]

1.87

0.1715
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Table 4.33 Associations of hospital and physician characteristics and ESA ONS use
Variable
β
Hospital Characteristics
Geographic region
Northeast
(reference)
Midwest
0.147
South
0.112
West
0.142
Bed size
<99
-0.646*
100-199
-0.032
200-299
(reference)
300-499
0.465*
≥500
0.214
Teaching status
Non-teaching
(reference)
Teaching
-0.049
Physician Characteristics
Physician Specialty
Non-specialist
(reference)
Specialist
-0.057
Missing
0.020

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

1.158
1.119
1.153

0.2375
0.2636
0.3265

[0.775, 1.731]
[0.705, 1.775]
[0.662, 2.008]

0.51
0.23
0.25

0.4739
0.6343
0.6158

0.524*
0.968
-

0.1192
0.2022
-

[0.336, 0.819]
[0.643, 1.458]
-

8.07
0.02
-

0.0045
0.8774
-

1.592*
1.238

0.3635
0.3184

[1.018, 2.490]
[0.748, 2.049]

4.15
0.69

0.0418
0.4063

-

-

-

-

-

0.952

0.1904

[0.643, 1.409]

0.06

0.8061

-

-

-

-

-

0.945
1.020

0.0976
0.1321

[0.772, 1.157]
[0.792, 1.315]

0.30
0.02

0.5835
0.8776
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Part 2: Off-label supported of ESAs
Results of binary logistic regression assessing association of patient demographics and
the prescribing of ESAs for the off-label supported indications are shown in Table 4.34. Older
age appeared as a strong possible predictor of the off-label supported use of ESAs. Being older
was associated with the increased odds of receiving ESAs for the off-label supported indications.
For example, the young old at age of 65 to 74 years old were 1.91 times more likely than the
middle-aged patients to be prescribed with ESAs off-label (95% 1.494, 2.434, p < 0.0001) while
the young adult (aged 18-30 years) were 0.65 times less likely than the reference group to
receive ESAs for these indications. Female patients were 0.20 times less likely to use ESAs for
the off-label supported indications. Being and African-American remained a significant predictor
of ESA off-label (OR 1.214, 95% CI 1.082, 1.362, p = 0.0010). In general, patients with other
type of health insurance were less likely than Medicare patients to received ESAs for off-label
indications. Having to pay for the services out-of-pocket reduced the odds of using the drug by
0.46 times compared to using Medicare coverage (95% CI 0.402, 0.739, p <0.0001).
Associations between clinical conditions and the odds of receiving ESAs for the off-label
supported indications are shown in Table 4.35. Neither patient’s admission type nor comorbidity
index was associated with the odds of receiving ESAs in patients with ESAs off-label supported
conditions. Nonetheless, patients admitted as elective cases were marginally significant of being
of greater odds of receiving the drugs compared to the emergent cases. Lastly, discharge
disposition remained as one of the strongest predictors of this type of ESA prescribing. For
instance, compared to those who were discharged to home, patients who expired had a 4.92 times
greater odds of receiving the drug (95% CI 4.075, 5.932, p < 0.0001). Likewise, those
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discharged to hospice, institutionalized, or non-institutionalized care were approximately four
times more likely to use ESAs off-label (all p-values < 0.0001).
Similar logistic regression results were observed between ESA on-label and off-label
supported prescribing, with regards to hospital and physician characteristics. Teaching status,
hospital geographic region, or physician specialty was not associated with the increased odds of
receiving the drug. On the other hand, being admitted to smaller hospitals of less than 199 beds
decreased the odds of using ESAs for these indications about half (OR<99 beds 0.504, 95% CI
0.278, 0.912, p < 0.0236; OR100-199 beds 0.593, 95% CI 0.405, 0.868, p < 0.0072), while admission
to larger hospitals with 300-499 beds was associated with 2.433 times increase in the odds of
drug use (95% CI 1.630, 3.630, p < 0.0001). Associations of hospital and physician
characteristics and ESA off-label supported use are summarized in Table 4.36.
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Table 4.34 Associations of patient demographic and ESA OFS use
Variable
β
Demographics
Age
18-30
31-50 (reference)
51-64
65-74
75-84
85+
Gender
Male (reference)
Female
Race
Caucasian
(reference)
African-American
Other
Missing
Source of Payment
Medicare
(reference)
Medicaid
Commercial/
Private/ HMO
Managed Care
Self-pay
Other
Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-1.032*
0.588*
0.645*
0.397*
0.062

0.356*
1.800*
1.907*
1.488*
1.064

0.0351
0.1681
0.2373
0.2231
0.1626

[0.294, 0.432]
[1.499, 2.162]
[1.494, 2.434]
[1.109, 1.996]
[0.789, 1.436]

109.90
39.65
26.88
7.02
0.16

<.0001
<.0001
<.0001
0.0080
0.6849

-0.228*

0.796*

0.0324

[0.735, 0.862]

31.47

<.0001

-

-

-

-

-

-

0.194*
0.055
0.035

1.214*
1.056
1.036

0.0713
0.0908
0.0982

[1.082, 1.362 ]
[0.892, 1.250]
[0.860, 1.248]

10.88
0.40
0.14

0.0010
0.5265
0.7096

-

-

-

-

-

-

-0.274*
-0.153

0.760*
0.858

0.0645
0.0680

[0.644, 0.898]
[0.734, 1.002]

10.43
3.75

0.0012
0.0528

-0.607*
-0.298*
-0.234*

0.545*
0.742*
0.791*

0.0847
0.0830
0.0910

[0.402, 0.739]
[0.596, 0.924]
[0.632, 0.992]

15.27
7.10
4.14

<.0001
0.0077
0.0419
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Table 4.35 Associations of clinical conditions and ESA OFS use
Variable
β
Clinical Conditions
Admission type
Emergency
(reference)
Urgent
Elective
Other/Missing
Average CCI (SD)
Discharge status
Discharged to
home/self care
(reference)
Expired
Discharged to
Hospice
Discharged/
transferred to
institutionalized care
Discharged/
transferred to
noninstitutionalized
care
Other/Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

-

0.150
-0.179
0.056*
0.010

1.162
0.836
1.058*
1.010

0.0902
0.0626
0.2276
0.0173

[0.998, 1.613]
[0.722, 1.352]
[0.694, 0.968]
[0.977, 1.045]

0.07
3.72
5.72
0.35

0.7936
0.0539
0.0168
0.5525

-

-

-

-

-

-

1.593*
1.434*

4.917*
4.194*

0.4709
0.5560

[4.075, 5.932]
[3.234, 5.438]

276.43
116.94

<.0001
<.0001

1.457*

4.291*

0.3494

[3.658, 5.034]

320.01

<.0001

1.121*

3.067*

0.2029

[2.694, 3.492]

287.01

<.0001

-0.043

0.958

0.3291

[0.489, 1.878]

0.02

0.9009
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Table 4.36 Associations of hospital and physician characteristics and ESA OFS use
Variable
β
Hospital Characteristics
Geographic region
Northeast
(reference)
Midwest
-0.295
South
0.140
West
-0.070
Bed size
<99
-0.686*
100-199
-0.522*
200-299
(reference)
300-499
0.889*
≥500
0.522
Teaching status
Non-teaching
(reference)
Teaching
-0.198
Physician Characteristics
Physician Specialty
Non-specialist
(reference)
Specialist
-0.024
Missing
-0.118

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

0.744
1.150
0.932

0.1893
0.2392
0.3249

[0.452, 1.226]
[0.765, 1.729]
[0.471, 1.846]

1.35
0.45
0.04

0.2458
0.5020
0.8402

0.504*
0.593*
-

0.1526
0.1154
-

[0.278, 0.912]
[0.405, 0.868]
-

5.12
7.21
-

0.0236
0.0072
-

2.433*
1.686

0.4968
0.4588

[1.630, 3.630]
[0.989, 2.874]

18.94
3.68

<.0001
0.0551

0.820

0.1849

[0.527, 1.276]

0.77

0.3789

-

-

-

-

-

0.976
0.889

0.1227
0.1480

[0.763, 1.249]
[0.642, 1.232]

0.04
0.50

0.8479
0.4805
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Part 3: Off-label unsupported use of ESAs
Results from logistic regression of demographic domain and off-label unsupported
indications are shown in Table 4.37. Age was not predictor of ESA use in this case. Being a
female with off-label unsupported indications, opposite to other indications, increased the odds
of receiving ESAs by 1.15 times. Race remained statistically associated with the increased odds
of ESAs prescribing where African-American were 1.40 times more likely to use ESAs (95% CI
1.222, 1.610, p < 0.0001), and patient with “Other” race were 1.24 times more likely (95% CI
1.088, 1.417, p = 0.0013), compared to Caucasian. The effect of primary payer on ESA
prescribing was also less prominent for the off-label unsupported indications. Compared to
Medicare patients, no other insurance type but “Self-pay” was associated with the decreased
odds of receiving ESAs for such indications. Patients with off-label unsupported indications
who paid for the care by themselves were 0.24 times less likely than Medicare patients to use the
drugs.
Patients with off-label unsupported indications admitted to the hospital as urgent cases
were 1.41 times more likely to be prescribed ESAs as compared to patients admitted to the
hospital as emergency cases. With one unit increase in patient’s comorbidity index measuring
clinical complexity, the odds of being prescribed ESAs for off-label unsupported indications
increased 1.23 times (95% CI 1.168, 1.289, p < 0.0001). Similar results as other type of ESA
prescribing were observed for discharge disposition, with the odds of receiving the drugs being
increased as a patient was discharged to anywhere else but home. For instance, the odds of using
the drugs for an admitted patient with off-label unsupported indications who were discharged to
institutionalized care increased by 3.58 times compared to patients who were discharged home
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(95% CI 2.981, 4.309, p < 0.0001). Associations of patient clinical conditions and ESA off-label
unsupported use are summarized in Table 4.38.
Finally, hospital size was the only significant predictor of ESA off-label unsupported
prescribing. Patients admitted to smaller hospitals with fewer than 99 beds were 0.57 times less
likely to be prescribed ESAs (95% CI 0.209, 0.875, p = 0.0200) compared to those admitted to
“200-299 beds” category. On the other hand, patients in 300-499 and ≥ 500 beds hospitals were
2.19 times (95% CI 1.334, 3.609, p = 0.0020) and 1.91 times (95% CI 1.143, 3.193, p = 0.0136)
more likely to use ESAs for off-label unsupported indications. Associations of hospital and
physician characteristics and ESA off-label unsupported use are summarized in Table 4.39.
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Table 4.37 Associations of patient demographic and ESA OFU use
Variable
β
Demographics
Age
18-30
31-50 (reference)
51-64
65-74
75-84
85+
Gender
Male (reference)
Female
Race
Caucasian
(reference)
African-American
Other
Missing
Source of Payment
Medicare
(reference)
Medicaid
Commercial/
Private/ HMO
Managed Care
Self-pay
Other
Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

0.007
0.062
0.131
0.045
-0.176

1.007
1.064
1.140
1.046
0.838

0.1197
0.0501
0.0817
0.0911
0.0887

[0.798, 1.271]
[0.971, 1.167]
[0.991, 1.312]
[0.882, 1.241]
[0.681, 1.032]

0.00
1.75
3.36
0.27
2.77

0.9529
0.1859
0.0667
0.6049
0.0958

0.137*

1.147*

0.0344

[1.081, 1.216]

20.80

<.0001

-

-

-

-

-

-

0.339*
0.217*
-0.156

1.403*
1.242*
0.855

0.0987
0.0837
0.0934

[1.222, 1.610]
[1.088, 1.417]
[0.690, 1.059]

23.17
10.35
2.05

<.0001
0.0013
0.1521

-

-

-

-

-

-

0.096
-0.058

1.101
0.944

0.1056
0.0772

[0.912, 1.329]
[0.804, 1.108]

1.00
0.50

0.3166
0.4795

-0.278*
-0.092
0.013

0.758*
0.912
1.013

0.0557
0.0978
0.1422

[0.656, 0.875]
[0.739, 1.125]
[0.769, 1.333]

14.26
0.74
0.01

0.0002
0.3899
0.9287
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Table 4.38 Associations of clinical conditions and ESA OFU use
Variable
β
Clinical Conditions
Admission type
Emergency
(reference)
Urgent
Elective
Other/Missing
Average CCI (SD)
Discharge status
Discharged to
home/self care
(reference)
Expired
Discharged to
Hospice
Discharged/
transferred to
institutionalized care
Discharged/
transferred to
noninstitutionalized
care
Other/Missing

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

-

0.341*
-0.019
0.549*
0.205*

1.406*
0.981
1.732*
1.227*

0.0978
0.0794
0.2885
0.0309

[1.224, 1.611]
[0.837, 1.150]
[1.249, 2.401]
[1.168, 1.289]

23.94
0.06
10.86
66.15

<.0001
0.8139
0.0010
<.0001

-

-

-

-

-

-

1.011*
0.713*

2.747*
2.040*

0.4199
0.3243

[2.036, 3.706]
[1.494, 2.786]

43.70
20.10

<.0001
<.0001

1.277*

3.584*

0.3367

[2.981, 4.309]

184.63

<.0001

0.981*

2.666*

0.2833

[2.165, 3.283]

85.12

<.0001

-0.651

0.521

0.1528

[0.293, 0.926]

4.94

0.0263
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Table 4.39 Associations of hospital characteristics and ESA OFU use
Variable
β
Hospital Characteristics
Geographic region
Northeast
(reference)
Midwest
-0.244
South
0.137
West
-0.265
Bed size
<99
-0.851*
100-199
-0.452
200-299
(reference)
300-499
0.786*
≥500
0.647*
Teaching status
Non-teaching
(reference)
Teaching
-0.2674
Physician Characteristics
Physician Specialty
Non-specialist
(reference)
Specialist
0.206
Missing
0.296

Parameters
SE
95% Confidence
Interval

Exp (β)

Chi-Sq

p-value

-

-

-

-

-

0.784
1.147
0.768

0.2048
0.3079
0.2907

[0.470, 1.308]
[0.678, 1.941]
[0.365, 1.613]

0.87
0.26
0.49

0.3511
0.6098
0.4849

0.427*
0.637
-

0.1562
0.1624
-

[0.209, 0.875]
[0.386, 1.049]
-

5.41
3.14
-

0.0200
0.0766
-

2.194*
1.910*

0.5571
0.5007

[1.334, 3.609]
[1.143, 3.193]

9.57
6.10

0.0020
0.0136

-

-

-

-

-

0.7654

0.2211

[0.4344, 1.3484

0.86

0.3547

-

-

-

-

-

1.229
1.344

0.1541
0.1403

[0.961, 1.572]
[1.095, 1.649]

2.71
8.02

0.0998
0.0046
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CHAPTER 5
Discussion and Conclusions
This chapter summarizes the findings and provides discussion of the results by specific
aims. Limitations of the database and study design are described, and their effects on the internal
and external validity of the study results are acknowledged. Practical implications of the study
finding and suggestions of possible future direction of the research are also discussed in this final
chapter.

Summary of Findings

In this research, we examined demographics, clinical conditions, hospital characteristics,
and physician specialty of epoetin alfa and darbepoetin alfa users who were admitted to Cerner
hospitals. Differences in such characteristics between the three patient groups were also
described and statistically tested. Descriptive results indicated that users of epoetin alfa and
darbepoetin alfa were statistically different with respect to demographics, clinical conditions,
hospital characteristics, and physician specialty. Additionally, significant differences were also
found among ONS, OFS, and OFU users of epoetin alfa and darbepoetin alfa.
The first primary objective of this study was to determine if the three major safety
interventions implemented during the study period had significant impacts on these three types
of ESA prescribing. Prior to the first black box warning in 2007, ESA prescribing in all three
labeling categories showed increasing use trends (Figure 4.14). Black box warning significantly
reduced the level of ESA ONS use. This reduction in ONS use was driven by darbepoetin alfa
use (0.6% decrease in use), not epoetin alfa. OFS use, on the other hand, was affected only by
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the change in reimbursement policy (NCD) in April 2008. In contrast to the effect of black box
warning on ONS use, this reduction in the level of OFS use was driven by epoetin alfa (0.3%
reduction) and not darbepoetin. Lastly, we did not find that any safety interventions significantly
affected the level of ESA use for OFU indications. However, we found that when OFU use of
ESAs was reanalyzed by specific drugs, there were insignificant reductions in the level of
epoetin alfa OFU use following all three interventions. Nonetheless, the level of OFU
darbepoetin alfa use instead significantly increased after black box warning and NCD, causing
the overall non-significant effects of the interventions when the two drugs were analyzed
collectively. REMS, on the other hand, significantly reduced the level of OFU darbepoetin use.
In order to determine if the interventions were associated with the reduction in the
likelihood of the receiving ESAs, three patients groups eligible to receive ESAs were defined a
priori based on an evidence-based medicine framework. The ONS eligible cohort included any
patients admitted to Cerner hospitals with ICD-9-CM diagnoses and procedure codes, and drug
codes indicated the presence of CKD, chemotherapy-induced anemia, HIV, and major surgical
procedures. The OFS cohorts included patients with non-chronic kidney disease, hepatitis C,
congestive heart failure, radiotherapy, anemia due to puerperium, multiple myeloma,
myelodysplastic syndrome, myelofibrosis, rheumatoid arthritis, beta thalassemia, and
autotransfusion. The known OFU cohort included only patients with conditions known to be
treated with ESAs, but did not have sufficient scientific evidence supporting its use. These
conditions were anemia of neoplasm diseases without the use of concurrent chemotherapy,
chronic anemia, bleeding, injury, cardiac surgeries, blood transfusion, and other OFU use such as
irritable bowel syndromes (IBS) and Crohns’ disease. We found that NCD significantly reduced
the odds of using ESAs for patients with on-label, off-label supported, and off-label unsupported
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conditions. Black box warning and REMS, on the other hand, did not significantly affect ESA
prescribing patterns.
In the final specific aim, we used the same logistic regression models to assess
associations of patient demographics, clinical conditions, and hospital and physician
characteristics with ESA on-label and off-label prescribing. A few predominant characteristics
of patients receiving ESA therapy suggested by the binary logistic regression results included
age, gender, race, source of payment admission type, discharge status, bed size, and teaching
status of the hospitals.
The odds of receiving ESAs in patients with ONS and OFS conditions increased with
age, up until the older old age of 75 years old was reached. After this age, a patient became less
likely to receive the drug. Female patients with ONS and OFS conditions were less likely to use
ESAs compared to male. The opposite gender effect was found in OFU use. In this use category,
female patients with OFU conditions were more likely to use ESAs compared to male patients.
African-American and patients with Medicare were more likely to receive the drugs compared to
their counterparts, for all three conditions.
Clinical conditions, especially places of discharge, were strongly associated with the odds
of receiving ESAs for all indications. Compared to those discharged to home, patients who
needed to be transferred, or discharged to other units/care settings were much more likely to be
prescribed with ESAs. Patients admitted as elective cases were less likely to use ESAs compared
to those admitted as emergent cases, though the results were marginally significant in OFU
prescribing. More complex patients with ONS and OFU conditions were more likely to use
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ESAs. Nonetheless, associations of patient’s clinical complexity and the increased odds of using
ESAs were not observed in patients with OFS conditions.
Finally, our finding suggested that hospital size was strongly associated with the ESA
use. Being admitted to larger hospitals increased the odds of receiving ESAs for on-label, offlabel supported, and off-label unsupported indications. No significant associations between
hospital geographic regions or teaching status, and ESA use were found for any use category.

Discussion of Results by Aim

Specific Aim 1

Previous studies focused on the impact of safety interventions on the use of
erythropoiesis-stimulating agents in the outpatient settings,184, 185 thus very little was known
regarding its use in patient admitted to the hospitals. Additionally, most studies collectively
analyzed darbepoetin alfa and epoetin alfa as ESAs and rarely distinguish between the two
drugs.181-184, 187 Our descriptive findings shows that the two erythropoietic drugs were used
differently in the inpatient settings. Darbepoetin alfa was used to a greater extent for on-label
indications (52.8%) compared to epoetin alfa (47.4%). Greater proportion of darbepoetin alfa
users was prescribed the drug for chronic kidney disease (93.9% darbepoetin alfa vs 83.8%
epoetin alfa), while the use of the two drugs for chemotherapy-induced anemia, zidovudineinduced anemia, and surgical procedures was similar. These findings were consistent with the
growth in popularity of darbepoetin alfa use in CKD due to its superiority over epoetin alfa in
hemoglobin control, 202, 203dosing efficacy, 204-206 and cost efficacy207 claimed in many reports
since the approval of darbepoetin alfa in 2001.208
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Differences in the characteristics of users of epoetin alfa and darbepoetin alfa were also
observed in our sample. Greater proportion of patients older than 65 years of age used epoetin
alfa compared to darbepoetin alfa (59.4% vs. 52.8%). It is possible that physicians were more
comfortable prescribing epoetin alfa which has been in the market longer to the older and frailer
patients. Greater proportion of Medicare patients used darbepoetin alfa compared to epoetin alfa
(65.7% vs. 58.5%). This was likely due to the fact that darbepoetin alfa was used extensively in
the population with CKD usually covered by Medicare in our sample. Greater proportion of
patient admitted as emergency or urgent cases used epoetin alfa rather than darbepoetin alfa
(emergency+urgent: 83.9% epoetin alfa vs. 75.2% darbepoetin alfa). Lastly, more patients who
used darbepoetin alfa were prescribed by specialists while the use of epoetin alfa was to a greater
extent, initiated by non-specialists. We believe that this finding was also due to familiarity of the
two ESA drugs. The study by Patkar et al, 2007, reported that almost all of the ESAs used in the
hospitals from 2002 to 2004 were epoetin alfa.15 Specialists, especially nephrologists, are likely
to be more familiar with the newer darbepoetin alfa compared to the non-specialists who might
be more familiar with epoetin alfa since it has been in the market since 1989. It is important to
note that the findings on certain variables such as primary payer, admission type, and physician
specialty may be tempered because as many as 50% of the hospitals did not report such
information.
Descriptive statistics, bar chart, and graphs were used to understand the prevalence of
ESA therapy for on-label, off-label supported, and off-label unsupported indications among
patients seen in the inpatient settings. The results of this study revealed that off-label prescribing
of ESAs constituted more than half of the utilization of the drugs in the hospitals. The use of
epoetin alfa and darbepoetin alfa for off-label treatment (both supported and unsupported) was
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52.6% and 47.2%, respectively, between 2005 and 2011. Our findings were consistent with
previous study investigating off-label use of ESAs in the hospital settings between 2002 and
2004.15
However, in contrary to the similar study which found the majority of the off-label use to
be supported with evidence, our results indicated that as high as 83% of the off-label use in our
sample was for indications unsupported by strong scientific evidence. These OFU use included
chronic anemia and neoplastic diseases without concurrent chemotherapy. This high level of offlabel unsupported use was however consistent with the study assessing off-label drug use in the
physician’s office which found that most off-label drug mentions in 2001 (73%) had little or no
scientific support.190 It is possible that contradicting results between Patkar’s finding and ours
were due to the differences in the inclusion of patient population and the identification of the onlabel and off-label use with ICD-9-CM codes. First, we only included adult patients in this study
while they included the pediatric population. The study then found that off-label use was highly
prevalent in pediatric population. Second, in addition to ICD-9-CM diagnoses codes, we
identified additional patients underwent major surgery with ICD-9-CM procedures codes. We
also strictly classified ESA use as for chemotherapy-induced anemia (on-label) only if a patient
presented with cancer had procedures codes or drug records indicated the use of
chemotherapeutic agents during that visits. Patients who had cancer diagnoses but did not
receive concurrent chemotherapy were categorized into the off-label unsupported group. We
believe that our on-label and off-label classification was a conservation approach that accurately
captured all patients.
Differences in characteristics of ESA users for the on-label, off-label supported, and offlabel unsupported indications were observed in our sample. Patients who used ESAs for OFS
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indications were oldest compared to than patients in the ONS or OFU groups. There were a
greater proportion of patients in the OFS group who expired in the hospitals. This was likely due
to the high prevalence of acute renal failure (ARF) which contributed the highest off-label
supported use of ESAs in very old hospitalized patients.209, 210 In addition to the high
prevalence, death rates among hospitalized patients with ARF was reported to be as high as 25 to
>70%.211 Chronic kidney disease, on the other hand, began relatively earlier in life, progressed
slowly, and rarely the main cause of inpatient death.2 Lastly, OFU patients appeared to be the
“least sick” patients among the three users groups with comorbidity index of 0.29 compared to
that of the ONS (2.72) and OFS (2.00). With such low level of clinical complexity, it is possible
that OFU use seen in our study truly reflected inappropriate use of ESAs in patients who may not
need the drug. However, it was also possible these patients were identified as OFU only because
of the inadequate records of their diagnoses.

Specific Aim 2

Segmented ordinary regression with interrupted time-series technique was used to
quantify the impacts of safety interventions. Our initial hypothesis was that we could detect the
impacts of black box warning, national coverage determination, and REMS as a decline in the
proportion of visits that a patient was prescribed ESAs for on-label, off-label supported, and offlabel unsupported indications. However, this hypothesis was proven to be partially correct.
When the use of epoetin alfa and darbepoetin alfa was analyzed collectively as ESAs, we found
only two significant immediate drop related to the safety interventions. These significant
impacts of the interventions included a significant immediate 1.2% drop in ONS use in the
month after the implementation of black box warning, and a 0.3% drop in ESA OFS use after
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NCD. The decrease in the proportion of visits with ESA use on-label was consistent with the
study by Vadhan-Raj et al, 2010 that found a 26% reduction in the use of ESAs in cancer
patients concurrently on chemotherapy in 2007 from that in 2006.183
Despite the downward trends in ONS, OFS, and OFU use, the decline after the
interventions did not reach a statistically significant level. After the analysis of ESAs was
broken down by specific drugs, we found that only epoetin alfa OFS use was only affected by
NCD (0.3% decrease). The use of darbepoetin alfa on-label, on the other hand, was sensitive to
several safety interventions. We found that black box warning led to a 0.6% rise in darbepoetin
alfa ONS use. NCD and REMS were associated with 0.4% and 0.5% drop in darbepoetin alfa
ONS use, respectively. Finally, REMS reduced darbepoetin alfa OFU use by 0.5%.
Contradictorily to our hypotheses, we found that darbepoetin alfa OFS and OFU use increased
immediately after the release of black box warning and NCD, though slight decreasing trends
were observed after such interventions took place. It is possible that some of these spurious
results were due to the delay in the effect of the interventions that would be discussed in the
section below.
Our aggregate time-series technique used a small number of data points to detect changes
in the proportion of ESA use at the time point which an intervention started; these time points
were specified a priori. As a results, our findings were sensitive to noises, impact of other
possible intervention unspecified in our time-series models, and time lags in the change in the
utilization patterns. These confounding factors may have created spurious statistical results.
Therefore, the following discussion was based on the actual graphical representation of the
proportion of visits with ESA use rather the results from the specified time-series models. The
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graphical representations of ESA, epoetin alfa, and darbepoetin alfa utilization patterns are
shown in Figure 4.12, 4.13, and 4.14, respectively.
The use of epoetin alfa in our sample hospitals increased from 2005 to October 2006,
after which drug utilization started to decline. The only exception was found in the OFS use of
epoetin alfa that showed a decreasing trend throughout study period. The increase in epoetin alfa
use on-label (ONS) and off-label unsupported (OFU) before 2007 was consistent with many
studies.182, 183 Since the time of approval, ESAs had been promoted rigorously by their
manufacturers as an alternative to blood transfusion. No safety warning attempts were present
before the release of negative clinical trial results that led to a release of public health advisory in
November 2006.28 The results of the clinical trials published in late 2006 later revealed the
increased risk of mortality in cancer patients who use ESAs.19-23
As a result of these published trials, declining trends in epoetin alfa use were observed
even before the release of a black box warning. The decline in the proportion of visits with
epoetin alfa use after the release of negative results from the clinical trials and public health
advisory in November 2006 was confirmed in a separate time-series analysis (data not shown).
In that analysis, we specified the first intervention as the negative results from the clinical trials
and public health advisory in November 2006 as the first intervention, instead of a black box
warning in March 2007. We found a significant immediate drop of 0.8% in the proportion of
visits with on-label epoetin alfa use. This drop was followed by a non-significant decreasing
trend in epoetin alfa ONS use after the intervention.
Since declining trends in epoetin alfa use existed even before the institution of a black
warning, no significant reduction in utilization was detected at the release of the FDA black box
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warning or NCD though non-significant declining slopes were observed. However, a noticeable
drop in the proportion of visits which epoetin alfa was used for on-label and off-label was seen in
December 2008 (month 48). This sharp decline coincided with the FDA revision of epoetin alfa
label in August 2008 (month 44) to strengthen the safety information for healthcare
professionals. Changes in the labeling included a statement that ESAs were not indicated for
patients receiving myelosuppressive therapy when the anticipated outcome is cure.212 The FDA
later approved the use a Medication Guide and Patient Instruction for Use in place of the old
patient package insert in November 2008. The Medication Guide which was created to disclose
possible side effects of ESAs were to be distributed to all patients who were dispensed ESAs.
This medication guide, alone with physician’s judgment, can affect patients’ decision to use the
drug. At the same time, Amgen and J&J Ortho Biotech, the manufacturers of epoetin alfa and
darbepoetin alfa released a Dear Health Care Professional Letter to emphasize the content of the
labeling change. 213 In addition to the labeling revision in August 2008, several published
clinical trials started reporting negative results of epoetin alfa could have led to a reduction in
epoetin alfa use at the end of 2008. One of the largest impacts could have resulted from the
German Stroke Study. In September 2008, results from a large German trial investigating
effectiveness of ESAs as an aid to improve the ability of patients to care for themselves after
their strokes. Results of the trial revealed the increased risk of death in post-stroke patients
receiving high dose epoetin alfa. Among 522 post-stroke patients involved in the trial, 16
percent of the patients who received epoetin alfa 40,000 units daily for 3 days died, compared to
only 9 percent of patients in the placebo group.214
Interestingly, we found a slow rebound in the level of epoetin alfa use one year after the
decline. This gradual increase in ESA use was likely to be due to prescribers being comfortable
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with ESAs again after a long period of the absence of alerts since there were no published alerts
in the FDA website that year. This increase in the epoetin alfa use continued from August 2009
to February 2010, after which we observed a non-statistically significant decline in epoetin alfa
on-label and off-label use. This decline coincided with the implementation of REMS in March
2010. Despite it being officially implemented on March 24, 2010, the creation of REMS was
announced by the FDA on February 16, 2010 to mitigate the risk of decreased survival in
patients with cancer. REMS restricted prescribing of ESAs in cancer patients only to physicians
who underwent a manufacturer-created risk management and training program which
emphasized the FDA-approved indications and the increased risks of using the drugs off-label.
We believe that this decline was a true reduction in inappropriate use of epoetin alfa related to
REMS restriction. However, because our ONS, OFS, and OFU cohorts did not consist entirely
of cancer patients, but instead a mixture of cancer patients and other conditions which were not
directly affected by REMS, the reduction was not sufficient to reach a statistically significant
level.
Similar to epoetin alfa, the use of darbepoetin alfa on-label and off-label grew rapidly
from 2005 to the beginning of the last quarter of 2006. However, unlike epoetin alfa where an
immediate drop was observed after the release of negative results trials and the first public health
advisory in November 2006 November 2006, the use of darbepoetin continued to grow, but at a
decreasing rate. This slow increase in the use of darbepoetin alfa despite the warning may due to
Amgen’s illegal promotion of Aranesp® off-label. From 2001 to 2007, Amgen was found guilty
of promoting off-label use of darbepoetin alfa by marketing dosing information not approved by
the FDA as being an advantage to that of epoetin alfa. 215
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According to the actual use of darbepoetin alfa shown Figure 4.14, the addition of a black
box warning onto the label significantly reduced the proportion of visits which darbepoetin alfa
was use on-label and off-label. ESA labeling was revised in March 2007 to include a black box
warning which highlighted the negative results several completed cancer trials. Though the
warning applies to all products in this drug class: darbepoetin alfa, Aranesp®, Amgen, Inc) and
epoetin alfa (Epogen® and Procrit®, Amgen), the fact the most of trials were based on the use of
darbepoetin alfa and the possibility that physicians were less comfortable with using the newer
darbepoetin alfa in cancer patients, a stronger impact of the black box warning on darbepoetin
alfa compared to epoetin alfa was observed.
The strongest reduction in darbepoetin alfa use was observed after the change in
Medicare reimbursement policy. NCD was announced effective in July 2007 and officially
implemented in April 2008 to restrict payment of Medicare to only on-label use of ESAs. With
NCD, use of ESAs for unapproved indications to Medicare beneficiaries seen in the outpatient
settings were no longer reimbursed under Medicare Part B. Previous studies showed strong
impact of NCD on ESA prescribing patterns in both Medicare and non-Medicare patients in the
outpatient settings.187 Strictly speaking, NCD did not financially affect payment of Medicare to
ESA use in the hospitals because charges for inpatient drug use were bundled as total hospital
charges and were covered under Medicare Part A. Our study was the first to show its significant
impact in the inpatient settings which NCD was not directly applied. Such strong impact that
was observed in both on-label and off-label ESA utilization merits further investigation. We
believe that the coverage change sent out a strong message about inappropriate use of ESAs to
prescribers tending all patients in all settings. A decline in use may also due to the fact that
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physicians who worked in the hospitals also worked concurrently in the outpatient settings and
were familiar with the coverage change.
Lastly we observed a significant reduction in the proportion of visits with darbepoetin
alfa on-label and off-label use after the implementation of REMS in March 2010. This was a
similar reduction was observed with epoetin alfa use that did not reach a statistically significant
level. It was likely to be due to the true effect of REMS.

Specific Aim 3

Binary logistic regression using generalized estimating equations (GEE), clustered by
hospitals was used to identify the impacts of safety interventions on the odds of receiving ESA
therapy. Studies highlighting changes in prescribing patterns were important to measure the
relative impact of various safety communications put in place to promote safe drug use. The use
of patient-level information in the logistic regression allowed for the inclusion of demographic,
clinical condition, physician and hospital characteristics, all of which had been proposed to
influence prescribing patterns. This inclusion adjusted for the confounding effects these
covariates may have imposed onto the effect of safety interventions on ESA utilization patterns.
The use of GEE model therefore offered superiority to the aggregated time-series technique.
Our results indicated that black box warning had low impact on all three ESA use
categories. These findings were consistent with previous literature investigating the impact of
black box warning on ESA therapy for CKD and cancer patients in the outpatient settings.182, 183
Interestingly, we again found strong impact of national coverage determination (NCD) on ESA
use, both on-label and off-label, despite the fact that this coverage change did not directly apply
to our population. As mentioned earlier, NCD implemented in April 2008 restricted
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reimbursement only to on-label use of ESAs for patients covered under Medicare Part B seen the
outpatient settings. Our results highlight such strong safety messages sent from payers that could
be seen in the care settings not financially affected. Finally, we did not observe any significant
impact of REMS in our sample. It is possible that oncologists have adjusted to ESA guidelines
after the black box warning and NCD that no change was observed after the implementation of
REMS.
Using the same logistic regression models with GEE to assess associations between
patient, clinical, hospital, and physician characteristics, we observed apparent differences in
patient, clinical, hospital, and physician characteristics between the users and non-users of ESAs
for all the three use categories. Characteristics of ESA on-label and off-label supported recipient
were found to be similar, but very different from those of the off-label unsupported group.
Among patients with ONS, and OFS conditions, the odds of receiving the drugs increased
with age. The relationship was flipped when a patient was in oldest age group; the oldest old
patients were less likely to receive ESAs. This age relationship may also be due to the fact that
older patients were sicker and naturally needed ESAs more than the younger and healthier
patients. However, physicians may become more conscious to prescribe the drug the very
patients (85+). Interestingly, such age relationship was not found in the off-label unsupported
(OFU) ESA prescribing. We believe that because there was no consensus guidelines on the offlabel unsupported prescribing of ESAs, physicians would tend to prescribe the drugs to those
patients with very low Hb, regardless of their age. Additionally, we found that gender and racial
differences exists in ESA use. Female patients with ONS and OFS conditions were less likely to
use the drugs. On the other hand, female patients with OFU conditions were more likely to
receive ESAs. The associations of higher odds of female gender and ESA OFU prescribing
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shown in our study were uniform with the finding by Patkar et al.15 It is possible these female
patients with OFU conditions in our sample, despite having similar comorbidity scores, were
more anemic than their male counterparts. The very low Hb level of these patients could have
led physicians to be more inclined to prescribe ESAs. African-American were more likely to
receive ESAs for any indications. This finding contradicts many published studies of racial
disparities in prescription drug use.164, 165 Results of our study led us to believe that there were
differences in prescribing behaviors between the inpatient and outpatient/office-based settings.
In the case of critical care like in the treatment of anemia, patient’s socioeconomic status, to a
lesser extent, influenced physician’s decision to prescribe. This might partially resulted from the
fact that, opposite to the outpatient care where patients were fully responsible for paying for their
medications, drug use in the hospitals was included as one charge. This mechanism could help
mask the price of the drugs from the ordering physicians. Also, the situation where charges were
paid off by the hospital as a charity care if patients were not able to pay for the services was not
at all uncommon. Lastly, our results indicated that financial resources were a key determinant of
ESA prescribing. Compared to Medicare patients, ONS and OFS patients with other type of
payment were less likely to use ESAs. The findings were unsurprising as Medicare pledged to
pay for the health care of the patients with end-stage renal disease (ESRD) - the conditions which
ESAs were approved for use. Moreover, Medicare was the largest payer of ESAs with
approximately three billion ESA spending in 2011.216 However, this relationship was not
observed in the OFU group. We believe that this finding reflects in part from Medicare’s strict
off-label reimbursement policy after 2008. Nonetheless, other results indicated that for all three
use categories, self-pay patients were the least likely to use the drugs. This is truly intuitive
since listed price of one dose of 10,000 IU of epoetin alfa could cost a patient over $100.217
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Other predictors of ESA ONS and OFS use were patient clinical conditions and hospital
size. The greater severity of illness as measured through combined comorbidity scores,
admission type, and discharge status, may have influenced physicians to prescribe ESAs.
Finally, consistent with our hypothesis, we found that patients admitted to larger hospitals were
more likely that any other patients to receive ESAs. This might due to the fact that larger
hospitals, to a greater extent, admitted more severely anemic patients. Physicians working the
larger hospitals should have seen more anemic patients and were more familiar with using ESAs
compared to those in the smaller hospitals.

Practical Implications

Our results confirm previous research of a strong impact of national coverage
determination and moderate impact of black box warning and REMS on ESA prescribing.
Despite extensive effort of risk communications, the FDA should be concerned as more than half
of ESAs was used for off-label purposes. Our findings indicate that as high as 43% of all ESA
use in the hospitals between January 2005 and June 2011 were for off-label unsupported
indications. The use of the drug off-label without strong supporting scientific evidence could
pose threats to patient’s health. Though no causal relationship could be established, it is
noteworthy to mention the distinguishably longer length of stay and high inpatient mortality in
patients who used the drug for off-label label unsupported indications compared to patients in
other groups.
Results of our study highlight the importance of different means of communicating drug
risks to the health care community. Off-label drug use can have serious safety implications. The
FDA needs to regulate prescribing of high-risk drugs more strictly. Patient characteristics
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associated with ESA off-label drug use identified in this study show that physicians were more
likely to administer the drugs to the sicker patients. Another area of intervention could be in
large hospitals with more than 200 beds where ESAs were prescribed significantly to a greater
extent. Efforts from the safety regulatory authority should be emphasized on the sickest
population of admitted patients, and in large hospitals to promote appropriate use of ESAs.
This research adds incremental knowledge to ESA off-label prescribing and Cerner
hospital database of electronic health records. The Cerner database is a rich source of
information on patient characteristics, diagnoses and procedures codes, drug administration, and
clinical outcomes new to most researchers. The use of electronic health records in observational
study can offer insight into clinical conditions, detailed drug administration, and timing of the
treatments unavailable in surveyed, publicly-available, or government-provided database such as
National Ambulatory Medical Care Survey (NAMCS) and Medicare Provider and Analysis
Review (MedPAR) Files. Additionally, Cerner data has a good mix of teaching and nonteaching hospitals as well as small and large sized hospitals across different geographic regions
in the United States.
We developed a novel systematic algorithm to identify two types of off-label drug use
from the domain of strength of evidence, level of recommendation, and efficacy provided in a
reputable compendium, DRUGDEX. Furthermore, we extensively provide all possible ICD-9CM diagnoses and procedures codes that could be used to identify on-label, off-label supported,
and off-label unsupported use of ESAs from any electronic health records. This knowledge can
be useful to any researcher interested in assessing ESA off-label use.
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Limitations

Our study offers insights into the impacts safety interventions had on the on-label and
off-label use of ESAs, but limitations of the study must be noted. The first limitation was the
possibility of other interventions not being captured in our study. Our study design did not allow
for the determination of the impacts of any other interventions that may have occurred during the
same period as the interventions of interest such as news articles, and publication of large clinical
trials. In this study, those external factors were considered as a part of the respective
intervention of interest. In addition, we were not able to separate the effect of the updated black
box warning in March 2008 from the implementation of NCD in April 2008. Nonetheless, the
implementation of NCD is chosen as an intervention instead of the black box warning update
because we believed that the reimbursement change would have a greater impact on prescribing
pattern than updating the already-exist black box warning.
One of the possible limitations of the study included threats to internal validity relating to
any longitudinal study designs that did not include the use of a control group. Instrumental
threat refer to the fact that aspects of the record keeping procedures in the database may have
changed at the same time as the intervention and thus any changes observed could not be
concluded whether they were related to the intervention. 218 Moreover, this study relied heavily
on the ICD-9-CM classification system; coding misclassification may lead to false estimations of
the effects. However, ICD-9-CM classification has been use in the use in studies identifying offlabel prescribing including ESAs.15 The use of ICD-9-CM classification for various health
conditions in hospital data has also been validated. 219-222
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Even though we were able to identify the off-label use of ESAs for indications other than
the ones approved by the FDA using ICD-9-CM codes, their doses and use in targeting a
hemoglobin level exceeding the suggested level could not be readily determined from the
database. This was because the dosing information could only was provided by Cerner with a
low level of confidence. Utilizing the dosing information in our case would therefore add errors
into the analyses and should be avoided. As a result of this data issue, identification of the ESA
off-label usage in terms of dose and target hemoglobin level was not undertaken in this study.
This may lead to an underestimation of the off-label usage in our study findings.
Another limitation was that physicians may be more inclined to prescribe ESAs to
patients who have had encounters with the medications even though it was for the indication
lacking supporting evidence. Since patient medication history in the non-participating outpatient
and inpatient hospitals were not captured in our data, it could have posed a potential confounding
effect on the off-label ESA use in the analysis. It was also important to note that the physician
specialties information included in the GEE models was based specifically to attending
physicians and not ordering physicians. For example, a patient with CKD could be admitted by a
generalist, developed anemia during his stay, referred to a nephrologist within the same hospital
who prescribed him with an ESA. In this specific case, a generalist was recorded under
physician specialty and not nephrologist.
Only inpatients of participating Cerner hospitals were included for analyses. Thus, any
changes in prescribing trends found in this study may not be generalized to patients in the
outpatient setting or patients hospitalized at other hospitals. However, we believe that there is
good external validity of our findings. This was a multi-hospital study that included 128
hospitals of various sizes from different geographical regions across the nation. As mentioned
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earlier, Cerner database was a rich source of information on patient characteristics, diagnoses
and procedures codes, drug records, and clinical outcomes. More importantly, their electric
health records accurately captured dates and times of admission, discharge, and drug
administration most crucial in this study. Hence, in spite of some limitations of existing database
and retrospective analysis, Cerner database served as a very insightful resource in studying
impacts of safety interventions on ESA utilization patterns in the inpatients settings.
Last but not least we recognized that there could have been errors created from the way
we dealt with outliers in our data. We were certain that spurious data points observed in the third
and fourth quarter of 2007, and the last two quarters of our study period in 2011 were due to data
recording system that could not be corrected on our end. We used a conservative method of
forecasting missing values from the continual trends in utilization if the intervention has not
occurred. We were confident that our data manipulation method produced accurate predictions
of values that could be used in place of the outliers.

Future Research

Our study methods, database, and results provide basis to future research in off-label drug
use. We developed a categorization scheme of ESA off-label use with drug records, and
diagnoses, and procedures codes of patients admitted to the Cerner Health System inpatient
settings rarely known exists to researchers. We found that while REMS had little to no impact
on the on-label and off-label utilization patterns of ESAs in our sample hospitals, black box
warning could potentially have affected off-label unsupported use of epoetin alfa, and both offlabel supported and unsupported use of darbepoetin alfa. Interestingly, we found that a
significant decline in the on-label, off-label supported, and off-label unsupported use of ESAs
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after the month Medicare national coverage determination was implemented. This impact of
NCD was similar for both epoetin alfa and darbepoetin alfa prescribing patterns.
Despite the exciting findings, this study focused mainly on the impacts of the safety
interventions on the likelihood of receiving ESAs, without looking into other aspect of treatment
such as ESA doses and days of therapy. Moreover, patient clinical outcomes such as length-ofstay, inpatient mortality, and blood transfusion were beyond the scope of this investigation.
Further analysis of such outcomes can provide insight into the impacts of different risk
communication tools attempted to reduce inappropriate drug use.
We quantified relatively few ESA users in our Cerner database. There were on average
130 patients who used ESAs per hospital in 2010 who used ESAs. Future study should consider
using larger database such as Marketscan® commercially provided by Thompson Reuters. With
a larger sample size, future study could focus on individual indications of ESA use instead of a
collective on-label, off-label supported, or off-label unsupported use to determine which
conditions was the main driver of the change in ESA utilization. Additionally, with sufficient
sample size, future study can focus on assessing the impact of REMS on ESA prescribing and
utilization among the target cancer population. Finally, pharmaceutical marketing efforts in
counteracting the decline in the prescribing of ESAs resulted from these warning messages merit
further exploration.
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Conclusions

This study was the first to determine the impacts of safety interventions on ESA on-label
and off-label utilization patterns in the inpatient settings using Cerner database. In this study we
attempted to quantify the impacts of the three types of safety interventions: black box warning,
national coverage determination, and risk evaluation and mitigation strategy (REMS) program on
ESA prescribing and utilization patterns. Analysis of data collected from 128 hospitals from
2005 to 2011 highlights the decreasing trend in ESA on-label use after the last quarter of 2006,
increasing trend in ESA use for unsupported indications, and overall very low and decreasing
prevalence of off-label supported use of ESAs (8.6%). From 2005 to 2010, the proportion of
visits with ESA ONS and OFS use decreased 53.2% and 81.9%, while ESA OFU increased
112.6%. The trends were similar for both epoetin alfa and darbepoetin alfa. ESAs were used to
the greatest extent to treat anemia in patients with chronic kidney disease (41.1%). Almost all of
ESA use classified as off-label supported (60.4% OFS) in our sample were for non-chronic
kidney disease patients. Lastly, a total of 42.7% of ESA use in our sample was for the
unsupported indications. The greatest unsupported use of ESAs was for the treatment of chronic
anemia (31.8%).
Differences in the impacts of risk communication techniques were observed in the ESA
inpatient prescribing patterns. Black box warning and REMS appeared to have little effect on
physician’s prescribing patterns compared to Medicare national coverage determination. Despite
the intention of reducing inappropriate (off-label unsupported use of ESAs), we found that these
three risk communication techniques were as likely to affect appropriate on-label and off-label
supported use of the drug rather the potentially inappropriate off-label unsupported use.
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Results from binary logistic regression using GEE model showed that REMS had no
impact on the odds of receiving ESAs among patients with on-label and off-label conditions.
Black box warning reduced the odds of being prescribed with epoetin alfa in patients with offlabel unsupported conditions by 40%. It was also associated with 4% and 15% per month
reduction in the odds of using darbepoetin alfa in patients with off-label supported and
unsupported conditions. Finally, we found a significant decline in the on-label, off-label
supported, and off-label unsupported use of ESAs after the month Medicare national coverage
determination was implemented. The impact of NCD ranged from 20% reduction in odds of offlabel supported use, to 37% in the on-label use. Patient demographic, clinical condition, and
hospital and physician characteristics associated with ESA on-label and off-label drug use
included age, gender, race, source of payment, admission type, clinical complexity, discharge
disposition, and hospital size.
We demonstrated lag time between these interventions and the observed change in
clinical practice and also the relative impacts the three types of safety interventions had on the
on-label and off-label ESA use in the hospital settings. The indirect impacts of NCD may have
unintended consequences of reducing ESA use in patients with indicated conditions that could
have otherwise benefited from the drugs. Policymakers should keep in mind of the lag time
between the intervention and changes in clinical practice, their relative effectiveness, and
potential unintended consequences of these safety interventions.
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